<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     form10-k.htm     <text>      <title>      </title>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Rule-Page -->      <div style="width: 100%">       <div style="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         UNITEDSTATES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         SECURITIESAND EXCHANGE COMMISSION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">        <b>         WASHINGTOND.C. 20549        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         FORM10-K        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         (MarkOne)        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            [X]           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 99%; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            ANNUAL    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe fiscal year ended December 31, 2020       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OR        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            [  ]           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 99%; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            TRANSITION    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         COMMISSIONFILE NUMBER: 001-35731        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         InspireMD,Inc.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Exactname of registrant as specified in its charter)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Delaware           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            26-2123838           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (State    or other jurisdiction of           <br/>           incorporation or organization)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (I.R.S.    Employer           <br/>           Identification Number)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             4        Menorat Hamaor St.            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Tel        Aviv, Israel            </b>           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            6744832           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Address    of principal executive offices)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Zip    Code)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Registrant’stelephone number, including area code:        <b>         (888) 776-6804        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Securitiesregistered pursuant to Section 12(b) of the Act:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Title    of each class           </b>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Trading    Symbol(s)           </b>          </font>         </td>         <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Name    of each exchange on which registered           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Common    Stock, par value $0.0001 per share          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NSPR          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NYSE    American          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Warrants,    exercisable for one share of Common Stock          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NSPR.WS          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NYSE    American          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Series    B Warrants, exercisable for one share of Common Stock          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NSPR.WSB          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NYSE    American          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Securitiesregistered pursuant to Section 12(g) of the Act: none       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [  ]No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [  ]No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes [X] No [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Large    accelerated filer [  ]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Accelerated    filer [  ]          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Non-accelerated    filer [X]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Smaller    reporting company [X]          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Emerging    growth company [  ]          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report. [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act). Yes [  ] No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaggregate market value of the voting and non-voting stock held by non-affiliates of the registrant as of June 30, 2020, basedon the price at which the common equity was last sold on the NYSE American on such date, was $15,616,214. For purposes of thiscomputation only, all officers, directors and 10% or greater stockholders of the registrant are deemed to be affiliates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicatethe number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Class           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Outstanding    at March 8, 2021           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Common    Stock, $0.0001 par value          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           117,832,226          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Documentsincorporated by reference:        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Rule-Page -->      <div style="width: 100%">       <div style="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <!-- Field: Page; Sequence: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         TABLEOF CONTENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Page           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; unicode-bidi: embed">          <a href="#a_001">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PART I           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    1.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_002">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Business.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    1A.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_003">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Risk Factors.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           29          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    1B.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_004">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Unresolved Staff Comments.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           53          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    2.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_005">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Properties.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           53          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    3.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_006">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Legal Proceedings.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           54          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    4.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_007">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mine Safety Disclosures.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           54          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; unicode-bidi: embed">          <a href="#a_008">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PART II           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           54          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    5.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_009">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           54          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    6.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_010">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Selected Financial Data.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           55          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    7.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_011">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Management’s Discussion and Analysis of Financial Condition and Results of Operations.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           55          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    7A.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_012">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Quantitative and Qualitative Disclosures About Market Risk.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           63          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    8.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_013">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Financial Statements and Supplementary Data.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           63          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    9.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_014">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           63          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    9A.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_015">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Controls and Procedures.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           64          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    9B.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_016">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other Information.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           64          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; unicode-bidi: embed">          <a href="#a_017">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PART III           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           64          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    10.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_018">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Directors, Executive Officers and Corporate Governance.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           64          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    11.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_019">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Executive Compensation.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           67          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    12.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_020">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           74          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    13.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_021">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certain Relationships and Related Transactions, and Director Independence.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           77          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    14.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_022">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Principal Accounting Fees and Services.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           77          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; unicode-bidi: embed">          <a href="#a_023">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PART IV           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           78          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    15.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <a href="#a_024">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exhibits and Financial Statement Schedules.           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           78          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           2           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <u>         <a name="a_001">         </a>         PARTI        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthis Annual Report on Form 10-K, unless the context requires otherwise, the terms “we,” “our,” “us,”or “the Company” refer to InspireMD, Inc., a Delaware corporation, and its subsidiaries, including InspireMD Ltd.,taken as a whole.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_002">         </a>         Item1. Business.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Overview        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare a medical device company focusing on the development and commercialization of our proprietary MicroNet™ stent platformtechnology for the treatment of complex vascular and coronary disease. A stent is an expandable “scaffold-like” device,usually constructed of a metallic material, that is inserted into an artery to expand the inside passage and improve blood flow.Our MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurCGuard™ carotid embolic prevention system (“CGuard EPS”) combines MicroNet and a self-expandable nitinol stentin a single device for use in carotid artery applications. Our CGuard EPS received CE mark approval in the European Union in March2013 and was fully launched in Europe in September 2015. Subsequently, we launched CGuard EPS in Russia and certain countriesin Latin America and Asia, including India. In September 2020, we launched CGuard EPS in Brazil after receiving regulatory approvalin July 2020 and, as discussed below, on February 3, 2021 we executed a distribution agreement with Chinese partners for the purposeof expanding our presence in China. Currently, we are seeking strategic partners for a potential launch of CGuard EPS in Japan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 8, 2020, we received approval from the U.S. Food and Drug Administration (“FDA”) of our Investigation DeviceExemption (“IDE”), thereby allowing us to proceed with a pivotal study of our CGuard™ Carotid Stent System,CARENET-III, for prevention of stroke in patients in the United States. CARENET-lll is a prospective, multicenter, single-arm,pivotal study to evaluate the safety and efficacy of the CGuard™ Carotid Stent System when used to treat symptomatic andasymptomatic carotid artery stenosis in patients undergoing carotid artery stenting. The trial will enroll approximately 315 subjectsin a maximum of 40 study sites located in the United States. Additional sites in Europe may also participate in the study, contributinga maximum of ~50% of the total enrollees. The primary endpoint of the study will be the composite of the following: incidenceof the following major adverse events: death (all- cause mortality), all stroke, and myocardial infarction (DSMI) through 30-dayspost-index procedure, based on the clinical events committee (CEC) adjudication or ipsilateral stroke from 31-365 day follow-up,based on Clinical Events Committee (CEC) adjudication.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we intend to continue to invest in current and future potential product and manufacturing enhancements for CGuard EPS that areexpected to reduce cost of goods and/or provide the best-in-class performing delivery system. In furtherance of our strategy thatfocuses on establishing CGuard EPS as a viable alternative to vascular surgery, we are exploring adding new delivery systems andaccessory solutions for procedural protection to our portfolio.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconsider the addressable market for our CGuard EPS to be individuals with diagnosed, symptomatic high-grade carotid artery stenosis(HGCS, ≥70% occlusion) for whom intervention is preferable to medical (drug) therapy. This group includes not only carotidartery stenting patients but also individuals undergoing carotid endarterectomy, as the two approaches compete for the same patientpopulation. Assuming full penetration of the intervention caseload by CGuard EPS, we estimate that the addressable market forCGuard EPS was approximately $1.0 billion in 2017 (source: Health Research International 2017 Results of Update Report on GlobalCarotid Stenting Procedures and Markets by Major Geography and Addressable Markets).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurMGuard™ Prime™ embolic protection system (“MGuard Prime EPS”) is marketed for use in patients with acutecoronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypasssurgery). MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent. MGuard Prime EPS received CE markapproval in the European Union in October 2010 for improving luminal diameter and providing embolic protection. However, as aresult of a shift in industry preferences away from bare-metal stents in favor of drug-eluting (drug-coated) stents, in 2014 wedecided to curtail further development of this product in order to focus on the development of a drug-eluting stent product, MGuardDES™. Due to limited resources, however, our efforts have been limited to testing drug-eluting stents manufactured by potentialpartners for compatibility with MicroNet and seeking to incorporate MicroNet onto a drug-eluting stent manufactured by a potentialpartner. The FDA has clarified that the primary mode of action for drug-eluting cardiovascular stents, which are regulated ascombination products, is that of the device component and has assigned the FDA Center for Devices and Radiological Health (CDRH)primary responsibility for premarket review and regulation, providing some clarity about what to expect regarding the regulatoryframework related to the development of MGuard DES™.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wealso intend to develop a pipeline of other products and additional applications by leveraging our MicroNet technology to new applicationsto improve peripheral vascular and neurovascular procedures, such as the treatment of the superficial femoral artery disease,vascular disease below the knee and neurovascular stenting to seal aneurysms in the brain.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Presently,none of our products may be sold or marketed in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wewere organized in the State of Delaware on February 29, 2008.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RecentDevelopments        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         PublicOffering        </i>        s       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 8, 2021, we closed an underwritten public offering of 29,032,258 units, with each such unit being comprised of one shareof our common stock, par value $0.0001 per share, and one Series G Warrant to purchase one-half of one share of common stock (the“February 2021 Offering”). The offering price to the public was $0.62 per unit. The Series G Warrants were immediatelyexercisable at a price of $0.682 per share, subject to adjustment in certain circumstances, and expire five years from the dateof issuance. We also granted the underwriter of the offering an option to purchase an additional 4,354,838 shares of common stockand Series G Warrants to purchase 2,177,419 shares of common stock, which the underwriter exercised in full. , In connection withthe offering we granted to the underwriter a compensation warrant to purchase up to 1,669,355 shares of common stock with an exerciseprice of $0.682 per share and which are exercisable for five years from February 3, 2021. Our net proceeds from the offering,after giving effect to the exercise of the underwriter’s over-allotment option, were approximately $18.9 million, afterdeducting underwriting discounts and commissions and payment of other expenses associated with the offering, but excluding theproceeds, if any, from the exercise of Series G Warrants sold in the offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 3; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           3           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJune 5, 2020, we closed an underwritten public offering of (i) 7,635,800 Units, with each Unit being comprised of one share ofour common stock, par value $0.0001 per share, and one Series F warrant to purchase one share of common stock, and (ii) 14,586,400Pre-Funded Units, with each Pre-Funded Unit being comprised of one Pre-Funded Warrant to purchase one share of common stock andone Series F Warrant. In connection with this public offering, the underwriter exercised the option practically in full, for 3,333,300shares of common stock and 3,333,300 Series F Warrants. The offering price to the public was $0.45 per Unit and $0.449 per Pre-FundedUnit. Our net proceeds from the offering and the exercise of the underwriter’s over-allotment option were approximately$10.7 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated withthe offering, but excluding the proceeds, if any, from the exercise of Series F Warrants and the Pre-Funded Warrants sold in theoffering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Distributionand Purchase Agreement with Chinese Partners        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 3, 2021, we entered into a Distribution Agreement with three China-based partners, pursuant to which the Chinese partnerswill be responsible for conducting the necessary registration trials for commercial approval of our products in China, followedby an eight-year exclusive distribution right to sell our products in China with the term of the agreement continuing on a year-to-yearbasis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations.The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatoryapprovals or for other material breaches.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, and on the same day, we entered into an investment transaction with QIDI, which included (i) an SPA, pursuant to whichQIDI agreed to invest $900,000 in exchange for shares of our common stock at a purchase price of $0.6708 per share, and (ii) anIRA, whereby QIDI was provided certain customary registration rights, including a commitment by us to file a registration statementwith the SEC on Form S-1 or Form S-3 and have such registration statement become effective not later than 150 days following theclosing of the transactions under the SPA.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetransactions closed on February 5, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         SixthAmendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Effectiveas of August 31, 2020, our stockholders approved the Sixth Amendment to the Plan and, accordingly, increased the number of sharesof common stock available for issuance pursuant to awards under such Plan by 6,500,000 shares, to a total of 7,178,395 sharesof common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RegainedCompliance with New York Stock Exchange        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 7, 2019, we received a notification from the NYSE American that we did not meet the continued listing standards of theNYSE American as set forth in Part 10 of the Company Guide. Specifically, we were not in compliance with Section 1003(a)(iii)of the Company Guide because we reported stockholders’ equity of less than $6 million as of September 30, 2019, and netlosses in our five most recent fiscal years ended December 31, 2018. As a result, we became subject to the procedures and requirementsof Section 1009 of the Company Guide. On October 11, 2019, the NYSE American accepted our plan to regain compliance with Section1003(a)(iii) of the Company Guide by August 7, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 7, 2020, following our submission to the NYSE American of our plan for regaining compliance, the NYSE American approvedsuch plan and, accordingly and as of such date, we are compliant with all of the NYSE American LLC continued listing standardsset forth in Part 10 of the NYSE American Company Guide. In particular, we regained compliance with the continued listing requirementunder NYSE American Company Guide Section 1003(a)(iii). The return to compliance was achieved as a result of our recently-consummatedpublic offering, in which we raised approximately $10.7 million of net proceeds from the sale of units and pre-funded units.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 4; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           4           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         FDAApproval of IDE        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 8, 2020, we received approval from the FDA of our IDE, thereby allowing us to proceed with a pivotal study of our CGuard™Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ATMOffering        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 28, 2020, we entered into a Sales Agreement with A.G.P. pursuant to which we may offer and sell, from time to time, at ouroption, through or to A.G.P., up to an aggregate of approximately $9,300,000 of shares of common stock (the “ATM Facility”).Any shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to the Company’s RegistrationStatement on Form S-3 (File No. 333-223130), filed with the SEC on February 21, 2018 and the prospectus supplement thereto filedwith the SEC on July 28, 2020, by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgatedunder the Securities Act of 1933, as amended, or if specified by us, by any other method permitted by law. On January 11, 2021,we increased the aggregate amount of our shares of common stock that may be sold under the Sales Agreement from $9,300,000 to$10,382,954, and, as a result, utilized and sold the maximum amount allowable under the ATM Facility, which resulted in an aggregateamount of $10,381,958.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RegistrationClearance for CGuard™ MicroNet         <sup>          ®         </sup>         in Brazil        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 23, 2020, we announced that we obtained registration from the Brazilian registration authority, Agéncia Nacional deVigiláncia Sanitária (ANVISA), for our CGuard MicroNet covered stent, clearing it for sale and distribution in Brazil.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         NewTrial Results for CGuard EPS        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJune 10, 2020, we reported the publication of the results of our PARADIGM trial in the        <i>         EuroIntervention        </i>        journal. In thattrial, 101 unselected consecutive real-life patients were treated with our CGuard MicroNET covered stent for carotid stenosisand were monitored for postprocedural neurologic events for a period of 12 months. The results displayed sustained protectionagainst any such neurologic events. At 30 days, only one adverse event occurred (a minor transient stroke with no other strokes,myocardial infarctions, or deaths). Furthermore, those study results showed that no strokes occurred between 30 days and twelvemonths.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJune 25, 2020, we reported the results from an investigator-initiated SIBERIA randomized clinical trial of our CGuard EPS, whichevaluated 30-day silent brain infarcts associated with the use of the Acculink™ conventional open-cell nitinol stent vs.our CGuard Micronet-covered stent. Those results displayed that CGuard had a statistically significant (greater than three-fold)reduction in the procedure-generated mean cerebral lesion volume relative to Acculink. At 30 days, there were zero new cerebrallessons in the CGuard arm, compared to six in the Acculink arm, also statistically significant.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 3, 2020 we reported the award for Best ESC Congress Poster for the presentation of updated data from the large, long-termPARADIGM-EXTEND study of the CGuard™ Embolic Prevention System (EPS), as part of the European Society of Cardiology 2020Carotid Update e-presentation at the European Society of Cardiology (ESC) Congress 2020. PARADIGM/EXTEND is an investigator-drivenon-going study performed with CGuard Carotid stent for primary and secondary stroke prevention in a large, consecutive all-comerspopulation, with 5 years (60 months) follow-up. The results for 480 patients of the expected total of 550 that completed the 30-dayfollow-up were presented were no peri-procedural major strokes or death. The total death/stroke /myocardial incidence at 30 dayswas 1.04% (5/480) due to two minor strokes, one myocardial infarction and two stent-unrelated deaths. In the study, 354/480 patientscompleted the 12-month follow-up with only 1 patient experiencing in-stent restenosis, 0.28% (1/354). At the 12-month follow-upthere were no other device-related adverse clinical events. Finally, 46/480 patients completed the 60-month follow-up period withone more case of in-stent restenosis and no additional cases of device-related stroke.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Appointmentof Dr. Gary Roubin, M.D. to our Board of Directors        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 12, 2020, our board of directors, or the Board, appointed Dr. Gary S. Roubin as a Class I member of the Board, effectiveas of that date, with a term expiring at the Company’s 2021 annual meeting of stockholders. Dr. Roubin is an internationallyrenowned interventional cardiologist recognized for his pioneering work in carotid stenting and embolic and protection devices.He is also acknowledged for the development of coronary stenting and the first FDA-approved coronary stent. In connection withhis appointment, Dr. Roubin was granted options to purchase 79,650 shares of common stock and 238,950 shares of restricted stock.Shortly after his appointment as a director, and on October 16, 2020, Dr. Roubin invested $100,000 in the Company in exchangefor 222,223 units consisting of (i) one share of common stock and (ii) one warrant to purchase our common stock with an exerciseprice of $0.495. For additional biographical information about Dr. Roubin, please see “Management” herein.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 5; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           5           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         COVID-19Developments        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inan effort to contain and mitigate the spread of COVID-19, which the World Health Organization, or WHO, declared to be a pandemicon March 12, 2020, many countries have imposed unprecedented restrictions on travel, quarantines and other public health safetymeasures. As of the beginning of the second quarter of 2020, we began to experience a significant COVID-19 related impact on ourfinancial condition and results of operations, which we primarily attribute to the postponement of CGuard EPS procedures (non-emergencyprocedures), as hospitals shifted resources to patients affected by COVID-19. To our knowledge, most European countries in whichwe operate are slowly reinstating elective procedures, but we do not know when the hospitals will resume to normal pre-pandemiclevels with such procedures in light of recent increases in COVID-19 cases in the territories we sell into. We anticipate thatthe continuation of the pandemic and related restrictions and safety measures would likely result in continued fluctuations insales of our products for the upcoming periods. For more discussion on our risks related to COVID-19, please see risk factorsincluded under “Item 1A. Risk Factors” herein.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inresponse to significant market volatility and uncertainties relating to COVID-19, the fees and salaries of our Board, managementand most of our employees were reduced in order to alleviate corporate operating expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EffectiveApril 1, 2020, the Board approved a 50% decrease in the annual cash compensation for non-employee directors from an aggregateamount of $154,000 to $77,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnApril 21, 2020, Marvin Slosman, our President, Chief Executive Officer and Director, signed a waiver reducing his monthly basesalary from $33,333 to $16,666 for the period beginning April 1, 2020 and ending on such date as Mr. Slosman was to determine,and Craig Shore, our Chief Financial Officer, Chief Administrative Officer, Secretary and Treasurer, signed a waiver reducinghis monthly base salary from NIS 80,125 to NIS 40,063 for the period beginning April 1, 2020 and ending on such date as Mr. Shorewas to determine.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EffectiveApril 1, 2020, we reduced the annual salaries of most of our employees by 20% to 30% until further notice.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Basedon a determination made by each of Mr. Slosman and Mr. Shore on June 10, 2020, following the closing of our underwritten publicoffering in June 2020, as described above, each of Mr. Slosman’s and Mr. Shore’s monthly base salaries were reinstatedto $33,333 and NIS 80,125, respectively, effective as of June 1, 2020. Each of the salaries for the remaining officers, directorsand employees was similarly reinstated by no later than June 30, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asa result of the reduction of those fees and salaries during the second quarter of 2020, our operating expenses were reduced byapproximately $235,000 in the second quarter of 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Releasefrom Former Underwriter        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theterms of our engagement of the underwriter for our September 2019 financing contained a purported 12 month right of first refusalin favor of such underwriter with respect to future financings. Due to, among other things, difficulties in the relationship withthat prior underwriter and our need to raise additional funds to finance our ongoing operations, we engaged A.G.P./Alliance GlobalPartners in May 2020 as underwriter for our June 2020 public offering, and again in July 2020 for an ATM Facility.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 28, 2020, we entered into a settlement agreement and release with that prior underwriter, under which it provided us a final,unconditional release from any further obligations arising out of or related to the engagement agreements, underwriting agreementsand placement agency agreements which we had been party to with it and with respect to any services which it had provided to us.We, in turn, provided the prior underwriter a final, unconditional release from any further obligations arising out of or relatedto the prior agreements and services.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 6; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           6           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asconsideration for the final release provided to us, we paid to the prior underwriter $400,000 in cash and reduced, to $0.495,the exercise price per share of warrants to purchase 274,029 shares of our common stock that had been issued by us to the priorunderwriter in various offerings that took place between March 2018 and September 2019. That reduced exercise price representsthe exercise price for the Series F Warrants that we issued in our June 2020 public offering. The warrants that were repricedhad existing exercise prices per share ranging from $187.50 to $2.25 and a weighted average exercise price per share of $7.32.All other terms of those warrants remained unchanged. The related increase in expenses of $400,000 was recorded during the threemonths ended June 30, 2020 to “General and Administrative expense” within the Consolidated Statements of Operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OurIndustry        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Carotid         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Carotidarteries are located on each side of the neck and provide the primary blood supply to the brain. Carotid artery disease, alsocalled carotid artery stenosis, is a type of atherosclerosis (hardening of the arteries) that is one of the major risk factorsfor ischemic stroke. In carotid artery disease, plaque accumulates in the artery walls, narrowing the artery and disrupting theblood supply to the brain. This disruption in blood supply, together with plaque debris breaking off the artery walls and travelingto the brain, are the primary causes of stroke. According to the World Health Organization (https://www.who.int/cardiovascular_diseases/resources/atlas/en/)every year, 15 million people worldwide suffer a stroke, and nearly six million die and another five million are left permanentlydisabled. According to the same source, stroke is the second leading cause of disability, after dementia.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        In2017, 2.2 million people were diagnosed with carotid artery disease, of which, approximately 600,000 patients had high grade carotidstenosis requiring intervention for carotid artery disease        <i>         (2017 Health Research International Market Report        </i>        ). Carotidartery stenting is a minimally invasive treatment option for carotid artery disease and an alternative to carotid endarterectomy,where a surgeon accesses the blocked carotid artery though an incision in the neck, and then surgically removes the plaque. Endovasculartechniques using stents and carotid embolic prevention system protect against plaque and debris traveling downstream, blockingoff the vessel and disrupting blood flow. We believe that the use of a stent with an embolic protection system should increasethe number of patients being treated since it would avoid the need for complex surgery.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Coronary         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Physiciansand patients may select from a variety of treatments to address coronary artery disease, including pharmaceutical therapy, balloonangioplasty, stenting with bare metal or drug-eluting stents, and coronary artery bypass graft procedures, with the selectionoften depending upon the stage of the disease.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theglobal market for coronary stents is estimated at $5.5 billion and projected to grow to $8 billion by 2025. (Global Market Insights,Inc. Nov 06, 2019). Growth will be driven by a continued increases in incidence (Coronary heart disease burden is projected torise from around 47 million DALYs globally in 1990 to 82 million DALYs (Disability Adjusted Life Year)in 2020 – WHO GlobalBurden of Coronary Heart Disease) – especially in developing countries). However, this market is dominated by drug elutingstents (DES) which limits the opportunity for MGuard.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Neurovascular         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theneurovascular market focuses on catheter-delivered products used to treat strokes that already happened or unruptured brain aneurysmsthat could lead to strokes. In the latter case, coils are wound into blood vessel bulges to block blood flow entering the aneurysmsto prevent the aneurysms from rupturing. Endovascular treatment of arterial aneurysm has evolved substantially over the past twodecades, transitioning from an investigational therapy into routine clinical practice and ultimately emerging as the treatmentof choice for many lesions        <i>         (source: Medtech Ventures 2009, Aneurysm Flow Modulating Device Market).        </i>        We believe that themarket for aneurysm flow modulating devices is still in the embryonic stage with windows of opportunities for early entrance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theneurovascular market includes over-the-wire, flow-guided microcatheters, guiding catheters, coil and liquid embolics, neurovascularstents and flow diversion stents. According to iData Research, the market is expected to be driven by the conversion from surgicalprocedures to endovascular techniques in the treatment of aneurysms and arteriovenous malformations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 7; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           7           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Peripheral         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Peripheralvascular diseases (“PVD”) are caused by the formation of atherosclerotic plaques in arteries, which carry blood toorgans, limbs and head. It is also known as peripheral artery occlusive disease or peripheral artery disease. It comprises diseasespertaining to both peripheral veins and peripheral arteries, affecting the peripheral and cardiac circulation in the body. PVDincludes diseases outside of the heart and brain, but most times refers to the leg and foot.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Peripheralstents are more often used in combination with balloon angioplasty to open the veins, so that blood can flow through the blockedveins in the body.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thegrowing prevalence of PVD is expected to cause increased demand for treatment options. PVD is age related and its prevalence increasesmarkedly with advancing age. In addition PVD is more prevalent in lower and medium income countries than in higher income countries(https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30255-4)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OurProducts        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Belowis a summary of our current products and products under development, and their intended applications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          MicroNet         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        MicroNetis our proprietary circular knitted mesh which wraps around a stent to protect patients from plaque debris flowing downstreamupon deployment. MicroNet is made of a single fiber from a biocompatible polymer widely used in medical implantations. The size,or aperture, of the current MicroNet ‘pore’ is only 150-180 microns in order to maximize protection against the potentiallydangerous plaque and thrombus.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CGuard– Carotid Applications         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurCGuard EPS combines our MicroNet mesh and a self-expandable nitinol stent (a stent that expands without balloon dilation pressureor need of an inflation balloon) in a single device for use in carotid artery applications. MicroNet is placed over and attachedto an open cell nitinol metal stent platform which is designed to trap debris and emboli that can dislodge from the diseased carotidartery and potentially travel to the brain and cause a stroke. This danger is one of the greatest limitations of carotid arterystenting with conventional carotid stents and stenting methods. The CGuard EPS technology is a highly flexible stent system thatconforms to the carotid anatomy.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webelieve that our CGuard EPS design provides advantages over existing therapies in treating carotid artery stenosis, such as conventionalcarotid stenting and surgical endarterectomy, given the superior embolic protection characteristics provided by the MicroNet.We believe the MicroNet will provide acute embolic protection at the time of the procedure, but more importantly, we believe thatCGuard EPS will provide post-procedure protection against embolic dislodgement, which can occur up to 48 hours post-procedure.It is in this post-procedure time frame that embolization is the source of post-procedural strokes in the brain. Schofer, et al.(“Late cerebral embolization after emboli-protected carotid artery stenting assessed by sequential diffusion-weighted magneticresonance imaging,”        <i>         Journal of American College of Cardiology Cardiovascular Interventions        </i>        , Volume 1, 2008) haveshown that the majority of the incidents of embolic showers associated with carotid stenting occur post-procedure.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurCGuard EPS with over-the-wire delivery system received CE mark approval in the European Union in March 2013. In October 2014,we initiated a limited market release of CGuard EPS with over-the-wire delivery system for use in carotid artery applicationsin Germany, Poland and Italy.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InSeptember 2014, we reported the results of the CGuard CARENET trial at the Transcatheter Cardiovascular Therapeutics (“TCT”)conference in Washington D.C. In the CARENET trial, the CGuard EPS system demonstrated better results over historical data usingconventional commercially available carotid stents. In the third quarter of 2015 the results of the CGuard CARENET trial werepublished in the Journal of the American College of Cardiology. In November 2015, positive twelve-month follow-up data from theCGuard CARENET trial was presented at the 42nd Annual Symposium on Vascular and Endovascular Issues, documenting the benefitsof the CGuard MicroNet technology as well as the patency benefits (maintaining the artery open) of the internal and external carotidarteries at twelve months.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 8; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           8           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe first quarter of 2015, we introduced CGuard RX, the new rapid exchange delivery system for CGuard EPS. The rapid exchangedelivery system has a guidewire that passes through the delivery system, running through the guiding catheter. It has one port,and thus, can be operated by one operator, while an over-the-wire-delivery system has two lumens and ports and requires two operatorsto perform the procedure. Our rapid exchange delivery system received CE mark approval in January 2015. We launched our CGuardEPS in Europe with the rapid exchange delivery system in multiple medical specialties that perform carotid artery stenting. Thesecustomers include interventional cardiologists, vascular surgeons, interventional neuroradiologists and interventional radiologists.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InSeptember 2015, we announced full market launch of CGuard EPS in Europe. Subsequently, we launched CGuard EPS in Russia and certaincountries in Latin America and Asia, including India. In September, 2020, we launched CGuard EPS in Brazil after receiving regulatoryapproval in July 2020, and we are seeking strategic partners for a potential launch of CGuard EPS in Japan and China.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InApril 2017, we had a pre-IDE submission meeting with the FDA regarding CGuard EPS where we presented materials that we believedwould support a formal IDE submission seeking approval to conduct a human clinical trial in the United States which included ourdraft synopsis for the clinical trial design. The FDA agreed to our pre-clinical test plan and clinical trial design. On July26, 2019, we submitted an IDE application for CGuard EPS. In connection with such application, on August 23, 2019, we receiveda request for additional information from the FDA in support of our application. On September 8, 2020, we received IDE approvalfor CGuard™ Carotid Stent System, CARENET-III.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we intend to continue to evaluate potential product enhancements and manufacturing enhancements for CGuard EPS expected to reducecost of goods and/or provide the best-in-class performing delivery system. We cannot give any assurance that we will receive sufficient(or any) proceeds from future financings or the timing of such financings, if ever for potential product enhancements and manufacturingenhancements. In addition, such additional financings may be costly or difficult to complete. Even if we receive sufficient proceedsfrom future financings, there is no assurance that we will be able to timely apply for CE mark approval following our receiptof such proceeds. We believe these improvements may allow us to reduce cost of goods and increase penetration in our existinggeographies and better position us for entry into new markets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          MGuardProducts– Coronary Applications         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Bare-MetalStent MGuard Product.         </i>        </b>        Our MGuard Prime EPS coronary product is comprised of MicroNet wrapped around a cobalt-chromiumbased bare-metal stent. In comparison to a conventional bare-metal stent, we believe our MGuard Prime EPS coronary product withMicroNet mesh provides protection from dangerous embolic showers in patients experiencing ST-segment elevation myocardial infarction,the most severe form of a heart attack, referred to as STEMI. Standard stents were not engineered for heart attack patients. Rather,they were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attackpatient. In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causingdownstream blockages in a significant portion of heart attack patients. Our MGuard Prime EPS is integrated with a precisely engineeredmicro net mesh that is designed to prevent the unstable arterial plaque and thrombus that caused the heart attack blockage frombreaking off.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          NGuard— Neurovascular Applications         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webegan developing a neurovascular flow diverter, which we refer to as NGuard, which is an endovascular device that diverts bloodflow away from cerebral aneurysms and ultimately seals the aneurysms. We have tested early flow diverter prototypes in initialpre-clinical testing in both simulated aneurysm bench models using various MicroNet configurations with varying aperture sizes,as well as in standard in vivo pre-clinical models, in which we observed aneurysm sealing and also wide open side branch vesselsacross which the device was placed. We have suspended all further development activity of NGuard until we obtain sufficient fundingfor such purpose.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 9; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           9           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          PVGuard— Peripheral Vascular Applications         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weintend to develop our MicroNet mesh sleeve and a self-expandable stent for use in peripheral vascular applications, to which werefer to as PVGuard. PVDs are usually characterized by the accumulation of plaque in arteries in the legs. This accumulation canlead to the need for amputation or even death, when untreated. PVD is treated either by trying to clear the artery of the blockage,or by implanting a stent in the affected area to push the blockage out of the way of normal blood flow.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asin carotid procedures, peripheral procedures are characterized by the necessity of controlling embolic showers both during andpost-procedure. Controlling embolic showers is so important in these indications that physicians often use fully covered stents,at the risk of blocking branching vessels, to ensure that emboli do not fall into the bloodstream and move to the brain. We believethat our MicroNet design will provide substantial advantages over existing therapies in treating peripheral artery stenosis.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        However,as we plan to focus our resources on the further expansion of our sales and marketing activities for CGuard EPS and, providedthat we have sufficient resources, potential product enhancements and manufacturing enhancements for CGuard EPS expected to reducecost of goods and/or provide the best-in-class performing delivery system and its submission for CE mark approval, we do not intendto pursue the development of PVGuard in the near future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CompletedClinical Trials for CGuard EPS         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CARENET         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCARENET trial was the first multi-center study of CGuard EPS following the receipt of CE mark of this device in March 2013. TheCARENET trial was designed to evaluate feasibility and safety of CGuard EPS in treatment of carotid lesions in consecutive patientssuitable for coronary artery stenting (“CAS”) in a multi-operator, real-life setting. The acute, 30 day, magneticresonance imaging (“MRI”), ultrasound and six month clinical event results were presented at the LINC conference inLeipzig, Germany in February, 2015. In the third quarter of 2015, the results of the CGuard CARENET trial were published in theJournal of the American College of Cardiology. In November 2015, positive twelve month follow-up data from the CGuard CARENETtrial was presented at the 42nd Annual Symposium on Vascular and Endovascular Issues, documenting the benefits of the CGuard MicroNettechnology as well as the patency benefits (maintaining the artery open) of the internal and external carotid arteries at twelvemonths.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        MACCE(myocardial infarction (“MI”), stroke or death) rate was 0.0% at 30 days. At six months, there was one death, whichwas not device or procedure-related but did result in a MACCE rate of 3.6% at six months. At twelve months there were two additionaldeaths, which were not device or procedure-related resulting in a MACCE rate of 10.7% at one year.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt; text-align: center">         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          <p style="text-align: center; margin-top: 0; margin-bottom: 0">           <font style="font-size: 10pt">            <b>             30 days            </b>           </font>          </p>          <p style="text-align: center; margin-top: 0; margin-bottom: 0">           <font style="font-size: 10pt">            <b>             (n=30)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          <p style="text-align: center; margin-top: 0; margin-bottom: 0">           <font style="font-size: 10pt">            <b>             6 months            </b>           </font>          </p>          <p style="text-align: center; margin-top: 0; margin-bottom: 0">           <font style="font-size: 10pt">            <b>             (n=28)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          <p style="text-align: center; margin-top: 0; margin-bottom: 0">           <font style="font-size: 10pt">            <b>             12 months            </b>           </font>          </p>          <p style="text-align: center; margin-top: 0; margin-bottom: 0">           <font style="font-size: 10pt">            <b>             (n=28)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 52%; text-align: left">          MACCE (MI, stroke, death)         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="width: 1%; text-align: left">          %         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          <font style="font-size: 10pt">           (1) 3.6          </font>         </td>         <td style="width: 1%; text-align: left">          %         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          <font style="font-size: 10pt">           (3) 10.7          </font>         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          MI         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          stroke         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (          <font style="font-size: 10pt">           0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          death         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (0) 0.0          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (1) 3.6          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-size: 10pt">           (3) 10.7          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        CAScarries the risk of cerebral embolization during and following the procedure, leading to life-threatening complications, mainlycerebral ischemic events. Diffusion-weighted magnetic resonance imaging (DW-MRI) is a sensitive tool used to identify cerebralemboli during CAS by measuring “lesions” within the brain which are areas that are ischemic and do not receive oxygenatedblood due to cerebral emboli. In the CARENET trial, 37.0% of patients treated with CGuard EPS had new ischemic lesions at 48 hoursafter the procedure, with an average volume of 0.039 cm3. Of these lesions, there was only one that remained at 30 days followingthe procedure and all others had resolved. Complete details appear in the following table. Where there is a second number shownbelow after a ± symbol, it indicates the potential error in the measurement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             48 hours            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             n=27            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             30 days            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             n=26            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          Subjects with new Acute Ischemic Lesions (“AIL”)         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          10         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          1         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Incidence of new lesions         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          37.0         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4.0         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Total number new AIL         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          83         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Avg. number new AIL per patient         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.19 ± 10.33          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0.04 ± 0.20          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Average lesion volume (cm           <sup>            3           </sup>           )          </font>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0.039 ± 0.08          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0.08 ± 0.00          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Maximum lesion volume (cm           <sup>            3           </sup>           )          </font>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.445         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.116         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Permanent AIL at 30 days         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          —         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 10; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           10           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thehealing process of the tissue and in-stent restenosis can be measured by a non-invasive form of ultrasound called duplex ultrasound.This type of ultrasound measures the velocity of the blood that flows within the carotid arteries, which increases exponentiallyas the lumen of the internal carotid artery narrows and the percent stenosis increases. One of the measurements is called PSV(peak systolic volume) and is known to be highly correlated to the degree of in-stent restenosis; PSV values higher than 300 cm/secare indicative of &gt;70% stenosis, while PSV values lower than 104 cm/sec are indicative of &lt;30% restenosis and healthy healing.In the CARENET trial, duplex ultrasound measurements done at 30 days, 6 months and 12 months following the stenting procedureall attest to healthy normal healing without restenosis concerns, as the PSV values were 60.96 cm/sec ± 22.31, 85.24 cm/sec± 39.56, and 90.22 cm/sec ± 37.72 respectively. The internal carotid artery was patent in all patients (100%).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theconclusions of the CARENET trial were:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    CARENET trial demonstrated safety of the CGuard EPS stent, with a 30 day MACCE rate of 0%.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Incidence    of new ipsilateral lesions (percent of patients with new lesions on the ipsilateral side (same side where the stent was employed))    at 48 hours was reduced by almost half compared to published data, and volume was reduced almost tenfold.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           All    but one lesion had resolved completely by 30 days.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Twelve    month data showed no stroke or stroke-related deaths, and no cardiac adverse events.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           CGuard    EPS offers enhanced benefits for patients undergoing CAS with unprecedented safety.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Physician-SponsoredClinical Trials for CGuard—PARADIGM-101 Study         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        PARADIGM-101(        <b>         <u>          P         </u>        </b>        rospective evaluation of        <b>         <u>          A         </u>        </b>        ll-comer pe        <b>         <u>          R         </u>        </b>        cutaneous c        <b>         <u>          A         </u>        </b>        roti        <b>         <u>          D         </u>        </b>        revascularization        <b>         <u>          I         </u>        </b>        n symptomatic and increased-risk asymptomatic carotid artery stenosis, using C        <b>         <u>          G         </u>        </b>        uard™        <b>         <u>          M         </u>        </b>        esh-covered embolic prevention stent system-101) was an investigator-led, single center study with the objectiveof evaluating feasibility and outcome of routine use of CGuard EPS in 101 consecutive unselected all-comer patients referred forcarotid revascularization, initiated in 2015. In May 2016, the 30-day results were presented at the EuroPCR 2016 Late-BreakingClinical Trial Session in Paris, and in the Journal of EuroIntervention.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Keyfindings from the PARADIGM-101 study and the follow-up data are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           CGuard    EPS delivery success was 99.1%. The clinical evaluation also found no device foreshortening or elongation;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Angiographic    diameter stenosis or vessel narrowing was reduced from 83±9% to only 6.7±5% (p&lt;0.001);          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Periprocedural    death/major stroke/ myocardial infarction (“MI”) rates were 0%;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           One    event was adjudicated by the Clinical Events Committee as a minor stroke (0.9%), with no change in NIH Stroke Scale or modified    Ranking scale;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theresults of the PARADIGM-101 study demonstrated that CGuard EPS can safely be used in a high risk, all-comer population of patientswith carotid artery stenosis and indicated that routine use of CGuard EPS may prevent cerebral events, such as strokes, by holdingplaque against the vessel wall, preventing emboli from being released into the blood stream. The PARADIGM-101 study found thatCGuard EPS is applicable in up to 90% of all-comer patients with carotid stenosis.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 11; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           11           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          ClinicalResults and Mechanical Properties of the Carotid CGUARD Double-Layered Embolic Prevention Stent Study         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        “ClinicalResults and Mechanical Properties of the Carotid CGUARD Double-Layered Embolic Prevention Stent Study” was an investigator-led,prospective single-center study which evaluated CGuard EPS in 30 consecutive patients with internal carotid artery stenosis diseasewith the objective of reporting early clinical outcomes with a novel MicroNet covered stent for the internal carotid artery andthe in vitro investigation of the device’s mechanical properties. In October 2016, the 30-day positive results were publishedonline-ahead-of-print in the Journal of Endovascular Therapy.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Keyfindings from the study are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           100%    success in implanting CGuard EPS without residual stenosis;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           No    peri- or post-procedural complications;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           No    deaths, major adverse events, minor or major strokes, or new neurologic symptoms during the six months following the procedure;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Modified    Rankin Scale improved for the symptomatic patients from 1.56 prior to the procedure to 0 afterwards;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           All    vessels treated with CGuard EPS remained patent (open) at six months; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           DW-MRI    performed in 19 of 30 patients found no new ipsilateral lesions after 30 days and after six months compared with the baseline    DW-MRI studies.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,based on engineering evaluations, the study concluded that CGuard EPS provides a high radial force and strong support in stenoticlesions. The stent is easy to use and safe to implant because it does not foreshorten and its structure adapts well to changesin diameter and direction of tortuous vascular anatomies. The MicroNet mesh of CGuard did not cause any changes to specific mechanicalparameters of the underlying stent.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CGUARDMesh-Covered Stent in Real World: The IRON-Guard Registry         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        “CGUARDMesh-Covered Stent in Real World: The IRON-Guard Registry using CGuard EPS” was a physician initiated prospective multi-centerregistry that included 200 patients from 12 medical centers in Italy. The objective of the study was to report 30-day outcomes(including MACCE) in a prospective series of patients who were treated with CGuard EPS between April 2015 and June 2016. In January2017, 30-day results were presented at the Leipzig Interventional Course (LINC) 2017 and published in the Journal of EuroInterventionin May 2017. The 12 month follow-up was published in the Journal of EuroIntevention in October 2018.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Key30-day results presented were:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           100%    success in implanting CGuard EPS;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           No    MI, major stroke or death at 30 days;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           There    were two transient ischemic attacks and five periprocedural minor strokes, including one thrombosis solved by surgery.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Total    elimination of post-procedural neurologic complications by 30 days;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           DW-MRI    performed pre-procedure and between 24 and 72 hours post-procedure in 61 patients, indicated that 12 patients had new micro    emboli (19%).          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           At    12 months, there were no new major neurological adverse events, thrombosis or external carotid occlusion recorded;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           One    myocardial infarction occurred at 12 months.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 12; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           12           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Peri-proceduralbrain lesions prevention in CAS (3PCAS): Randomized trial comparing CGuard stent vs. WallStent™ Study         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        3PCASstudy was an independent investigator-led single center randomized clinical trial, comparing CGuard EPS vs. WallStent™,intended to evaluate the incidence of peri-procedural diffusion-weighted-magnetic-resonance-imaging (DW-MRI) new brain lesionsafter carotid artery stenting. Sixty-one consecutive patients referred for carotid revascularization (between January 2015 andOctober 2016) were eligible for the study. The results of the 3PCAS study was published in the International Journal of Cardiologyin September 2018. The discussion distinguished between peri-procedural (from procedure to 48h -72h) and post-procedural periods(72h to 30 days) where the CGuard EPS demonstrated a reduction in the post-procedural embolic effect during the carotid plaquehealing period. In contrast, there was no difference between the two stent groups during the peri-procedural stage because of,according to the published article, the presence of bilateral/contralateral lesions (lesions resulting from the contralateralartery from the non-treated carotid) which suggest that the peri-procedural neurological damage may have originated from extra-carotidsources (outside of the artery which was treated and outside the stent itself).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          InitialClinical Study of the New CGuard EPS MicroNet Covered Carotid Stent: “One Size Fits All”         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        “InitialClinical Study of the New CGuard EPS MicroNet Covered Carotid Stent: ‘One Size Fits All’” was an investigator-led,single-center study, which evaluated CGuard EPS in 30 consecutive patients with symptomatic stenosis of the internal carotid arterywith the objective of evaluating the CGuard EPS MicroNet covered stent for its ability to adjust to different vessel diameters.The results of the study were published in the Journal of Endovascular Therapy in May 2019. The conclusion of the study as reportedwas that CGuard EPS has high conformability combined with an almost equivalent outward radial force at expansion diameters rangingfrom 5.5 to 9.0 mm. The first clinical results demonstrate the “One Size Fits All” stent can be implanted in internalcarotid arteries with reference diameters within this range.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Keyfindings from the study were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           100%    technical success in implanting CGuard EPS;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           No    neurological events within 30 days;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    chronic outward force normalized by stent length demonstrated a near-equivalent radial force outcome; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    stent displayed only a minor difference between the minimal radial force at 9.0 mm (0.195 N/mm) and the maximal radial force    at 5.5 mm (0.330 N/mm).          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          PreliminaryResults from a Prospective Real-World Multicenter Clinical Practice of Carotid Artery Stenting Using the CGuard Embolic PreventionSystem: The IRONGUARD 2 Study         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        “PreliminaryResults From a Prospective Real-World Multicenter Clinical Practice of Carotid Artery Stenting Using the CGuard Embolic PreventionSystem: The IRONGUARD 2 Study” is a physician initiated prospective multi-center registry enrolling 733 patients from 20medical centers in Italy, from January 2017 to June 2019. The objective of the study is to evaluate periprocedural (24 hours),post-procedural (up to 30 days), and 12-month outcomes in a largest, prospective, multicenter series of patients submitted forprotected carotid artery stenting with the CGuard Embolic Prevention System. The 24-hour, 30-day and 12-month preliminary results(data available on 726 patients out of the 733 treated) were presented at the Leipzig Interventional Course (LINC) in January2021. The study’s preliminary results from the IRONGUAURD 2 study suggested in a real-world evaluation of carotid arterystenting, Cguard EPS can be safely used for treatment of extracranial carotid artery stenosis, allowing a low rate of post proceduraladverse events by 12 months.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Keyfindings from the study are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           100%%    procedural success in implanting CGuard EPS;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1    death from hemorrhagic stroke (patient was admitted for immediate treatment of CAS due to stroke), 2 minor strokes, 6 TIAs    and one nonfatal AMI at 24 hours;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1    minor stroke, 2 TIAs, three AMIs, no deaths and no stent thrombosis/occlusions between 24 hours and 30 days; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1    minor stroke, 4 TIAs, 2 AMIs and 8 deaths (the 2 mentioned AMIs, 4 malignancies, 1 suicide and 1 undefined complication in    Guillain-Barré Syndrome) between 30 days and 1 year.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 13; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           13           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          TheSIBERIA Trial for Carotid Artery Stenosis: A Randomized Controlled Trial of Conventional Versus Micronet™-Covered StentUse in Percutaneous Neuroprotected Carotid Artery Revascularization: Peri-procedural and 30-day Diffusion-Weighted Magnetic ResonanceImaging and Clinical Outcomes         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        “TheSIBERIA Trial for Carotid Artery Stenosis: A Randomized Controlled Trial of Conventional Versus Micronet™-Covered StentUse in Percutaneous Neuroprotected Carotid Artery Revascularization: Peri-procedural and 30-day Diffusion-Weighted Magnetic ResonanceImaging and Clinical Outcomes” was an investigator-initiated randomized clinical trial, single-center study, which evaluatedone hundred patients who qualified for carotid revascularization with high risk for surgery and were randomized 1:1 to eitherCGuard EPS or Acculink        <sup>         TM        </sup>        . The primary endpoints were incidence and volume of new cerebral embolic post-procedural lesions(24-48 hours) as determined by diffusion weighted magnetic resonance imaging (DW-MRI). The principal secondary endpoints includedincidence of periprocedural or postprocedural stroke, myocardial infarction and death at 30 days. The results of the study werepresented in a late-breaking session at the EuroPCR in June 2020. The conclusion of the study was that the CGuard™ Micronet™-coveredstent use in consecutive unselected patients subjected to neuroprotected carotid artery stenting was associated with a greaterthan three-fold reduction in the procedure-generated mean cerebral lesion volume, and with zero post-procedural cerebral embolismsobserved.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Keyfindings from the study are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Post    Procedure (24-48 hours), the CGuard™ arm was observed to have a 78% reduction in the average volume of new cerebral    lesions (157 mm3 vs. 700 mm3), a statistically significant improvement (p=0.007;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           At    30 days, DW-MRI showed zero new cerebral lessons in the CGuard™ arm versus six in the Acculink™ arm (p=0.03);          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           At    30 days, there were zero strokes, myocardia infarctions or deaths in the CGuard arm and three events the Acculink™ arm    (two strokes and one myocardial infarction).          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CompletedClinical Trials for MGuard Bare-Metal Coronary Products         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave completed eight clinical trials with respect to our first generation stainless steel-based MGuard coronary device and ourcobalt-chromium based MGuard Prime EPS stent. Our first generation MGuard stent combining the MicroNet with a stainless steelstent received CE mark approval for the treatment of coronary artery disease in the European Union in October 2007. We subsequentlyreplaced the stainless steel stent with a more advanced cobalt-chromium based stent for MGuard Prime EPS.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFirst in Men (FIM) study conducted in Germany from the fourth quarter of 2006 through the second quarter of 2008 focused on patientswith occlusion in their stent graft. This group is considered to be in “high risk” for complications during and shortlyafter the procedure due to the substantial risk of occurrence of a thromboembolic event. The study demonstrated MGuard’ssafety in this high risk group. This study was followed by the GUARD study in Brazil in 2007 with a similar patient populationwhich reinforced the safety profile of MGuard in patients prone to procedural complications. The MAGICAL study was a pilot studyin STEMI patients conducted in Poland from 2008 through 2012 which demonstrated safety, measured by MACE rates at 30 days followingthe procedure, as well as efficacy results, measured by the ability of MGuard to reestablish blood flow into the infarcted areaof the muscle. Furthermore, we conducted three registries (iMOS, IMR and iMOS Prime) that confirmed the feasibility of MGuardand MGuard Prime EPS for the treatment of STEMI patients and the safety of MGuard and MGuard Prime EPS in the STEMI patient group.Safety was repeatedly demonstrated in these trials and registries by the low mortality rate in the first month after the procedure.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe second calendar quarter of 2011, we began the MGuard for Acute ST Elevation Reperfusion Trial (which we refer to as our “MASTERI trial”), a prospective, randomized study, which demonstrated that among patients with acute STEMI undergoing emergencyPCI, patients treated with MGuard had superior rates of epicardial coronary flow (blood flow within the vessels that run alongthe outer surface of the heart) and complete ST-segment resolution, or restoration of blood flow to the heart muscle after a heartattack, compared to those treated with commercially-approved bare metal or drug-eluting stents. The results of this trial aresummarized in greater detail below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 14; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           14           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Finally,the MASTER II trial, which we initially initiated as part of our efforts to seek approval of our MGuard Prime EPS by the FDA,was discontinued at our election in its current form in light of market conditions moving toward the use of drug-eluting stentsover bare-metal stents. Analysis of the patients already enrolled in the MASTER II trial prior to its suspension, however, reconfirmedthe MASTER I safety results due to a continued low mortality rate.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          MASTERI Trial         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe second calendar quarter of 2011, we began the MASTER I trial, a prospective, randomized study in Europe, South America andIsrael to compare the MGuard with commercially-approved bare metal and drug-eluting stents in achieving superior myocardial reperfusion(the restoration of blood flow) in primary angioplasty for the treatment of acute STEMI, the most severe form of heart attack.The MASTER I trial enrolled 433 subjects, 50% of whom were treated with MGuard and 50% of whom were treated with a commercially-approvedbare metal or drug-eluting stents. The detailed acute and 30 days results from the trial were presented at the TCT conferenceon October 24, 2012 and published (Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh–CoveredStent (MGuard) in ST-Segment Elevation Myocardial Infarction, Stone et. al,        <i>         JACC        </i>        , 60; 2012). The results were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    primary endpoint of post-procedure complete ST-segment resolution (restoration of blood flow to the heart muscle after a heart    attack) was statistically significantly improved in patients randomized to the MGuard compared to patients receiving a commercially-approved    bare metal or drug-eluting stent (57.8% vs. 44.7%).          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Patients    receiving MGuard exhibited superior rates of thrombolysis in myocardial infarction (TIMI) 3 flow, which evidences normal coronary    blood flow that fills the distal coronary bed completely, as compared to patients receiving a commercially-approved bare metal    or drug-eluting stent (91.7% vs. 82.9%), with comparable rates of myocardial blush grade 2 or 3 (83.9% vs. 84.7%) and corrected    TIMI frame count (cTFC) (17.0 vs. 18.1          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Angiographic    success rates (attainment of &lt;50% final residual stenosis of the target lesion and final TIMI 3 flow) were higher in the    MGuard group compared to commercially-approved bare metal or drug-eluting stents (91.7% vs 82.4%).          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mortality    (0% vs. 1.9%) and major adverse cardiac events (1.8% vs. 2.3%) at 30 days post procedure were not statistically significantly    different between patients randomized to MGuard as opposed to patients randomized to commercially-approved bare metal or drug-eluting    stents. All other major adverse cardiac event components, as well as stent thrombosis, were comparable between the MGuard    and commercially-approved bare metal or drug-eluting stents.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesix month results from the MASTER I trial were presented at the 2013 EuroPCR Meeting, the official annual meeting of the EuropeanAssociation for Percutaneous Cardiovascular Interventions, on May 23, 2013 in Paris, France. The results were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mortality    (0.5% vs. 2.8%) and major adverse cardiac events (5.2% vs. 3.4%) at 6 months post procedure were not statistically significantly    different between patients randomized to the MGuard as compared to patients randomized to commercially-approved bare metal    or drug-eluting stents. All other major adverse cardiac event components, as well as stent thrombosis, were comparable between    patients treated with MGuard and those treated with commercially-approved bare metal or drug-eluting stents.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetwelve month results from the MASTER I trial were presented at the TCT conference on October 29, 2013 and published (Mesh-CoveredEmbolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction Final 1-Year Clinical and AngiographicResults From the MGUARD for Acute ST Elevation Reperfusion Trial, Dudek et. al,        <i>         Coronary Interventions        </i>        , 2014). The resultswere as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mortality    (1.0% vs. 3.3%) and major adverse cardiac events (9.1% vs. 3.3%) at 12 months post procedure were not statistically significantly    different between patients randomized to the MGuard as opposed to those randomized to commercially-approved bare metal or    drug-eluting stents. All other major adverse cardiac events, as well as stent thrombosis, were comparable between the MGuard    and commercially-approved bare metal or drug-eluting stents.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 15; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           15           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Insummary, the MASTER I trial demonstrated that among patients with acute STEMI undergoing emergency PCI patients treated with MGuardhad superior rates of epicardial coronary flow (blood flow within the vessels that run along the outer surface of the heart) andcomplete ST-segment resolution compared to those treated with commercially-approved bare metal or drug-eluting stents. In addition,patients treated with MGuard showed a slightly lower mortality rate and a slightly higher major adverse cardiac event rate ascompared to patients treated with commercially-approved bare metal or drug-eluting stents six and twelve months post procedure.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Adetailed table with the results from the MASTER I trial is set forth below. The “p-Value” refers to the probabilityof obtaining a given test result. Any p value less than 0.05 is considered statistically significant.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          MGuard         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Bare Metal Stents/Drug            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Eluting Stents            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          p-Value         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 46%; text-align: left">          Number of Patients         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 14%; text-align: right">          217         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 14%; text-align: right">          216         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 14%; text-align: right">          —         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          TIMI 0-1         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.8         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5.6         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.01         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          TIMI 3         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          91.7         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          82.9         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.006         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Myocardial blush grade 0-1         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          16.1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          14.8         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.71         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Myocardial blush grade 3         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          74.2         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          72.1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.62         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          ST segment resolution &gt;70         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          57.8         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          44.7         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.008         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          30 day major adverse cardiac event         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.8         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2.3         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.75         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          6 month major adverse cardiac event         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5.2         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3.4         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.34         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          12 month major adverse cardiac event         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9.1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3.3         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.02         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FutureClinical Trials for CGuard EPS and MGuard Prime EPS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Post-marketingclinical trials (outside the United States) could be conducted to further evaluate the safety and efficacy of CGuard EPS in specificindications. These trials would be designed to facilitate market acceptance and expand the use of the product. We expect to beable to rely upon CE mark approval of the product and other supporting clinical data to obtain local approvals.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedo not anticipate conducting additional post-marketing clinical trials for our bare-metal MGuard coronary products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         GrowthStrategy        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourprimary business objective is to utilize our proprietary MicroNet technology and products to become the industry standard fortreatment of stroke, complex vascular and coronary disease and to provide a superior solution to the common acute problems causedby current stenting procedures, such as restenosis, embolic showers and late thrombosis. We are pursuing the following businessstrategies to achieve this objective.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Widen    the adoption of CGuard EPS           </b>           . We are seeking to expand the population of CGuard EPS patients in those countries in which    CGuard EPS is commercially available. In particular, our focus is on establishing CGuard EPS as a viable alternative (in appropriate    cases) to conventional carotid stents and vascular surgery within the applicable medical communities. We intend to accomplish    this goal by continuing to publish and present our clinical data, support investigator-initiated clinical registries and exploring    addition of a procedural protection device to our portfolio incorporating the principal of reverse flow of the carotid artery    as an adjuctive alternative to femoral access. We have partnered and will continue to seek out partnerships with organizations    focused on the treatment of stroke. We will also continue to engage advisory boards and to develop a network of key opinion    leaders to assist us in our efforts to widen the adoption of CGuard EPS.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Grow    our presence in existing and new markets for CGuard EPS.           </b>           We have launched CGuard EPS in most European and Latin American    countries through a comprehensive distributor sales organizations network. We are continuing to focus on larger growing markets    through this network by supporting our distributors with a comprehensive marketing and clinical education programs. In November    2018, we obtained approval for reimbursement and commercial sale for CGuard EPS in Australia and immediately launched the    product. We are also pursuing additional product registrations and distribution contracts with local distributors in other    countries in Europe, Asia and Latin America.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 16; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           16           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Continue    to leverage our MicroNet technology to develop additional applications for interventional cardiologists and vascular surgeons.           </b>           In addition to the applications described above, we believe that we will eventually be able to utilize our proprietary    MicroNet technology to address imminent market needs for new product innovations to significantly improve patients’    care. We continue to broadly develop and protect intellectual property using our mesh technology. Examples of some areas include    peripheral vascular disease, neurovascular disease, renal artery disease and bifurcation disease.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Establish    relationships with collaborative and development partners to fully develop and market our existing and future products.           </b>           We    are seeking strategic partners for collaborative research, development, marketing, distribution, or other agreements, which    could assist with our development and commercialization efforts for CGuard EPS and MGuard DES, and other potential products    that are based on our MicroNet technology.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Resume    development and successfully commercialize MGuard DES.           </b>           While we have limited the focus of product development to our carotid    products, if we resume development of our coronary products, we plan to evaluate opportunities to further develop MGuard DES.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Portfolio    expansion and pipeline development           </b>           We will continue to invest in advancing our portfolio with new delivery system alternatives    to facilitate the use of CGuard by all physicians. Our delivery systems will enable all endovascular access points including    accessory devices for Arterial Venous (AV) shunting           <b>            .           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Competition        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themarkets in which we compete are highly competitive, subject to change and impacted by new product introductions and other activitiesof industry participants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Carotid         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecarotid stent markets in the United States and Europe are dominated by Abbott Laboratories, Boston Scientific Corporation, CovidienLtd. (currently part of Medtronic, Inc.), and Cordis Corporation (currently part of Cardinal Health, Inc.). Gore Medical and TerumoMedical Corporation produce a polytetrafluoroethylene mesh-covered stent and a double layer metal stent, respectively. All ofthese larger companies have substantially greater capital resources, larger customer bases, broader product lines, larger salesforces, greater marketing and management resources, larger research and development staffs and larger facilities than ours andhave established reputations and relationships with our target customers, as well as worldwide distribution methods that are moreeffective than ours. However, we believe that the European market is somewhat fragmented, and, in our opinion, smaller competitorsmay be able to gain market share with greater flexibility.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Coronary         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thebare-metal stent and the drug-eluting stent markets in the United States and Europe are dominated by Abbott Laboratories, BostonScientific Corporation, and Medtronic, Inc. In Europe, the market is now almost exclusively dominated by drug eluding stents andis rapidly becoming so in the rest of the world. (Catheter Cardiovasc Interv. 2018 Oct 1;(92(4):E262-E270. doi: 10.1002/ccd.27375.Epub 2017 Oct 13.        <u>         https://www.ncbi.nlm.nih.gov/pubmed/29027735        </u>        ). We believe physicians look to next-generation stent technologyto compete with existing therapies. Such next-generation technologies include bio-absorbable stents, stents that focus on treatingbifurcated lesions, and stents with superior polymer and drug coatings, and many industry participants are working to improvestenting procedures as the portfolio of available stent technologies rapidly increases.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Accordingto the MEDTECH OUTLOOK, the three major players (Abbott Laboratories, Boston Scientific Corporation and Medtronic, Inc.) in theworldwide coronary stent market have a combined total market share of approximately 92%. To date, our sales are not significantenough to register in market share. As such, one of the challenges we face to further our product growth is the competition fromnumerous pharmaceutical and biotechnology companies in the therapeutics area, as well as competition from academic institutions,government agencies and research institutions. Most of our current and potential competitors, including but not limited to thoselisted above, have, and will continue to have, substantially greater financial, technological, research and development, regulatoryand clinical, manufacturing, marketing and sales, distribution and personnel resources than we do. Due to ongoing consolidationin the industry, there are high barriers to entry for small manufacturers in the European and the U.S. markets and the rest ofthe world.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 17; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           17           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Neurovascular         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Leadingindustry players in the global neurovascular devices market include Medtronic, Stryker, Terumo and Johnson &amp; Johnson. Acquisitionsand mergers are increasingly used as a strategy for product portfolio expansion and to grow footprint. (Global Market Insights,Inc. - Devices Market Share 2018-2024 Industry Size Report.        <u>         https://www.gminsights.com/industry-analysis/neurovascular-devices-market)        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Salesand Marketing        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Salesand Marketing         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Basedon the positive CGuard EPS clinical data, we initiated the commercial launch of CGuard EPS in CE marked countries in early 2015.In September 2015, we announced full market launch of CGuard EPS in Europe.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        In2017, we decided to shift our commercial strategy to focus on sales of our products through local distribution partners and ourown internal sales initiatives to gain greater reach into all the relevant clinical specialties and to expand our geographic coverage.Our current strategy seeks to broaden our sales efforts to transition vascular surgeons from carotid endarterectomy proceduresto carotid stenting with CGuard EPS, which we believe can greatly expand our customer base. We have focused and we plan to continueto focus our marketing efforts primarily on key growth markets and to evaluate opportunities in new territories if and when theybecome available. In addition, we are using international trade shows and industry conferences to gain market exposure and brandrecognition. We continue to work with leading physicians to enhance our marketing effort and are developing relationships withnew key opinion leaders to champion our technology and work with us in clinical studies       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Currently,we are actively selling our MGuard coronary products with a bio-stable MicroNet through local distributors in Europe, Latin America,the Middle East and Asia.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          ProductPositioning         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whentreating carotid artery disease, we believe that there is an opportunity to enter the market with bare-metal stent platform andto become a competitive player without a drug-eluting stent platform. Therefore, we believe that CGuard EPS is poised for commercialgrowth in 2020 as more and more positive clinical data is presented.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we intend to continue to evaluate potential product enhancements and manufacturing enhancements for CGuard EPS expected to reducecost of goods or provide the best-in-class performing delivery system. We believe these improvements may allow us to reduce costof goods and increase penetration in our existing geographies and better position us for entry into new markets. Finally, we donot expect that it would be crucial to use a drug-eluting stent platform to compete in certain new markets such as the neurovascularmarket, and hence, we plan to continue to explore this area of opportunity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheMGuard coronary products have initially penetrated the market by entering segments with indications that present high risks ofembolic dislodgement, notably acute MI and saphenous vein graft coronary interventions. Even though MGuard technology has demonstratedits advantages with clinical data, it is based on a bare-metal platform while the market demand has shifted away from bare-metalstents in favor of drug-eluting stents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         InsuranceReimbursement        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inmost countries, a significant portion of a patient’s medical expenses is covered by third-party payors. Third-party payorscan include both government funded insurance programs and private insurance programs. While each payor develops and maintainsits own coverage and reimbursement policies, payors, in many instances, have similarly established policies, and in the U.S.,for example, coverage policies and reimbursement rates of private payors are often influenced by those established by the U.S.Department of Health and Human Services Centers for Medicare and Medicaid Services (CMS). The CGuard products and MGuard coronaryproducts sold to-date in applicable foreign countries have been designed and labeled to facilitate the utilization of existingreimbursement codes for such countries, and we intend to continue to design and label our present and future products in a mannerconsistent with this goal.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 18; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           18           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whilemost countries have established reimbursement codes for stenting procedures, certain countries may require additional clinicaldata before recognizing coverage and/or to obtain a certain level of reimbursement for one or more of our products. In these situations,we intend to complete the required clinical studies to obtain reimbursement approval in countries where it makes economic senseto do so.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         IntellectualProperty        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Patents         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave 52 issued patents, including 14 patents issued in the U.S., and seven pending patent applications, four of which are pendingin the United States. Many of these patents and applications cover aspects of our CGuard and MGuard technology. Patents outsidethe U.S. have been filed in Canada, China, Europe, Israel, India, Japan, Australia, and South Africa. The patents and applicationsfall into a number of patent families, as listed below:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Base    Title of Patent Family           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 13%">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Pending        patent             <br/>             applications            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Countries)            </b>           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Issued        patents            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Country        and Patent No.)            </b>           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Issue    Date           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Bifurcated    Stent Assemblies          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           US    8,961,586           <br/>           China ZL200780046676.2          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           02/24/2015           <br/>           9/26/2012          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Deformable    Tip for Stent Delivery and Methods of Use          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           US    10,258,491           <br/>           Israel 260,945          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4/16/2019           <br/>           07/01/2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Visualization    of blood flow in a venous/arterial shunting system          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           US          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           In    Vivo Filter Assembly          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           US    9,132,261          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           09/15/2015          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Filter    Assemblies          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Israel    198,189          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2/1/2014          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Knitted    Stent Jackets          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Canada    2,666,728           <br/>           Canada 2,887,189           <br/>           China ZL200780046697.4           <br/>           China ZL201210320950.3           <br/>           Israel 198,190           <br/>           EP 2076212           <br/>           (Germany, France, &amp; UK)           <br/>           US 10,137,015          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           6/23/2015           <br/>           5/1/2018           <br/>           10/10/2012           <br/>           12/2/2015           <br/>           2/1/2014           <br/>           3/29/2017           <br/>           <br/>           11/27/2018          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           India    323792          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10/28/2019          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Optimized    Stent Jacket          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Canada           <br/>           EPO           <br/>           US          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Canada    2,670,724           <br/>           China ZL201210454357.8           <br/>           China ZL200780043259.2           <br/>           India 297,257           <br/>           Israel 230,922           <br/>           US 9,132,003           <br/>           US 9,526,644           <br/>           US 9,782,281           <br/>           US 10,070,976           <br/>           US 10,406,006           <br/>           US 10,406,008           <br/>           EP 2088962           <br/>           (validated in 9 countries: BE, CH, DE, FR, UK, IT, IE, LX, NL)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           12/11/2018           <br/>           12/9/2015           <br/>           1/2/2013           <br/>           5/30/2018           <br/>           10/01/2020           <br/>           9/15/2015           <br/>           12/27/2016           <br/>           10/10/2017           <br/>           9/11/2018           <br/>           9/10/2019           <br/>           9/10/2019           <br/>           10/11/2017          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Stent    Apparatuses for Treatment Via Body Lumens and Methods of Use          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           US           <br/>           EPO          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           South    Africa 2007/10751           <br/>           Canada 2,609,687           <br/>           Canada 2,843,097           <br/>           EP 1885281           <br/>           (CH, DE, FR, GB, IE, IT)           <br/>           US 10,058,440           <br/>           US 10,070,977          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10/27/2010           <br/>           4/22/2015           <br/>           10/27/2015           <br/>           2/13/2019           <br/>           3/1/2017           <br/>           8/28/2018           <br/>           9/11/2018          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Stent    Thermoforming Apparatus and Methods          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           JP    6553178           <br/>           US 9,527,234           <br/>           US 10,376,393           <br/>           Australia 2015326517           <br/>           Canada 2962713          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           7/12/2019           <br/>           12/27/2016           <br/>           8/13/2019           <br/>           05/21/2020           <br/>           02/19/2019          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Methods    or using a self-adjusting stent assembly and kits including the same          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           US           <br/>           PCT          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 19; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           19           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepatents and patent applications listed above cover various aspects of our products, specifically focusing on the mesh sleeve coveringour stents, as well as methods for production and delivery mechanisms of the stents. We believe that our patents, in particularthose covering the use of a knitted micron-level mesh sleeve over a stent for various indications, as well as our pending patentapplications (if issued as patents with claims substantially in their present form), create a significant barrier against othercompanies seeking to use similar technology. We believe these patents and patent applications collectively cover all our existingproducts and may be useful in protecting our future technological developments. We intend to aggressively continue patenting newtechnologies and to actively pursue any infringement of our key patents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          TradeSecrets         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wealso rely on trade secret protection to protect our interests in proprietary know-how and/or for processes for which patents aredifficult to obtain or enforce. As part of our trade secret policy, we rely on non-disclosure and confidentiality agreements withemployees, consultants and other parties to protect trade secrets and other proprietary technology.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Trademarks         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave registered or applied to register the following trademarks, which we use in connection with our products:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           InspireMD           <sup>            ®           </sup>           (US, European Union, and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           MGuard           <sup>            ®           </sup>           (European Union, and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           CGuard           <sup>            ®           </sup>           (US, European Union, and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           MGuard    Prime           <sup>            ®           </sup>           (US, European Union, and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           NGuard           <sup>            ®           </sup>           US, European Union)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           PVGuard®    (US, European Union, and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Micronet®    )US(          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           MNP    Micronet Protection logo )European Union and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Carenet®    )European Union and UK)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           SmartFit™    (US)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetrademarks are renewable indefinitely, so long as we continue using the marks and make the appropriate filings when required.We also use and may have common-law rights to various trademarks, trade names, and service marks.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         GovernmentRegulation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themanufacture and sale of our products are subject to regulation by numerous governmental authorities, principally the EuropeanUnion CE mark and other corresponding foreign agencies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 20; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           20           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Salesof medical devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country.These laws and regulations range from simple product registration requirements in some countries to complex approval process,clinical trials and production controls in others. As a result, the processes and time periods required to obtain foreign marketingapproval may be longer or shorter than those necessary to obtain FDA market authorization. These differences may affect the timelinessof international market introduction of our products. For the European Union nations, medical devices must obtain a CE mark beforethey may be placed on the market. In order to obtain and maintain the CE mark, we must comply with the Medical Device Directive93/42/EEC (“MDD”) by presenting comprehensive technical files for our products demonstrating safety and efficacy ofthe product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standardby an European Notified Body. We have obtained ISO 13485 quality system certification and the products we currently distributeinto the European Union display the required CE mark. In order to maintain certification, we are required to pass an annual surveillanceaudit conducted by Notified Body auditors. The European Union replaced the MDD with the new European Medical Devices Regulation,or MDR (MDR 2017/745). The MDR will apply after a transitional period of three years ending on May 26, 2020, which is expectedto change several aspects of the existing regulatory framework in Europe. Manufacturers have the duration of the transition periodto update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. After May 26,2020, medical devices can still be placed on the market under the provision of the MDD until May 27, 2024; provided the CE Markwas issued prior to this date and the manufacturer continues to comply with this directive. By May 27, 2024, all medical devicesentering the EU will need to have a CE Mark under the MDR, even if they have been on the market previously under the MDD. In ourcase, CGuard and MGuard can continue to be marketed under the MDD until November 12, 2022. Specifically, the EU MDR will requirechanges in the clinical evidence required for medical devices, post-market clinical follow-up evidence, annual reporting of safetyinformation for Class III products, Unique Device Identification (“UDI”) for all products, submission of core dataelements to a European UDI database prior to placement of a device on the market, and multiple other labeling changes. Approvalsfor certain of our currently-marketed products could be curtailed or withdrawn as a result of the implementation and recertificationprocess of the EU MDR and acquiring approvals for new products could be more challenging, time consuming and costly.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; text-indent: 20pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asnoted below, we have or had regulatory approval and made sales of CGuard EPS, MGuard Prime EPS or both products either throughdistributors pursuant to distribution agreements or directly, in the following countries: Argentina, Australia, Austria, Belarus,Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Estonia, Finland, France, Germany,Hong Kong, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Netherlands, New Zealand,Norway, Peru, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland,Turkey Vietnam and the United Kingdom In addition, we are awaiting regulatory approval to sell our products in Taiwan. While eachof the European Union member countries accepts the CE mark as its sole requirement for marketing approval, some of these countriesstill require us to take additional steps in order to gain reimbursement rights for our products. Furthermore, while we believethat certain of the above-listed countries that are not members of the European Union accept the CE mark as a primary requirementfor marketing approval, each such country requires additional regulatory requirements for final marketing approval of our products.Furthermore, we are currently targeting additional countries in Europe, Asia, and Latin America, however, even if all governmentalregulatory requirements are satisfied in each such country, we anticipate that obtaining marketing approval in each country couldtake as few as three months or as many as twelve months or more, due to the nature of the approval process in each individualcountry, including typical wait times for application processing and review, as discussed in greater detail below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InOctober 2007, our first generation MGuard stent combining the MicroNet with a stainless steel stent received CE mark approvalfor the treatment of coronary artery disease in the European Union. We subsequently replaced the first generation MGuard productwith MGuard Prime EPS, which uses a more advanced cobalt-chromium based stent. Our MGuard Prime EPS received CE mark approvalin the European Union in October 2010 and marketing approval in those countries listed in the table below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCGuard EPS received CE mark approval in the European Union on March 14, 2013 and marketing approval in the countries listed inthe table below. We are currently seeking marketing approval for CGuard EPS in, South Korea and Taiwan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pleaserefer to the table below setting forth the approvals and sales made for CGuard EPS and the MGuard Prime EPS on a country-by-countrybasis       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 21; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           21           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <u>          Approvalsand Sales of MGuard Prime EPS and CGuard EPS on a Country-by-Country Basis         </u>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Countries           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            CGuard    EPS Approval           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>           </b>          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            CGuard    EPS Sales           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            MGuard    Prime            <br/>            EPS Approval           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            MGuard    Prime EPS Sales           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Argentina          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Australia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Austria          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Belarus          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Belgium          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Brazil          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Bulgaria          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chile          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (2)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Colombia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Croatia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Cyprus          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Czech    Republic          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Denmark          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Dominican    Republic          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Ecuador          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Estonia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Finland          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           France          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Germany          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Greece          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Netherlands          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Hong    Kong          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Hungary          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Iceland          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           India          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Ireland          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Israel          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Italy          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Latvia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Lithuania          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Liechtenstein          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Luxembourg          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Malaysia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Malta          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mexico          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Montenegro          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           New    Zealand          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Norway          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Peru          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Poland          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Portugal          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Romania          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Russia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Saudi    Arabia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (4)          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Serbia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Slovakia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Slovenia          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           South    Africa          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (5)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Spain          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Sweden          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Switzerland          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Turkey          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Venezuela          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Vietnam          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Ukraine          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           N          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           United    Kingdom          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Y          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    approval expired and per management decision it was decided not to renew it.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chile    is a non-regulated market, the health system in Chile only relies on CE mark or FDA certificates.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    approval expired and per management decision it was decided not to renew it.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (4)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    approval expired in November 2017. We have not had sales of MGuard Prime EPS in Saudi Arabia since 2014.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (5)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    certificate evidencing regulatory approval for MGuard Prime EPS in South Africa was held by our former distributor in South    Africa, and we cannot guarantee that it is in full force and effect. Our distribution agreement with the distributor in South    Africa expired pursuant to the terms of such distribution agreement on February 1, 2015, and we have not had sales of MGuard    Prime EPS in South Africa since 2015          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 22; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           22           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          FDAGovernment Regulation of Medical Devices for Human Subjects         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Manyof our activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Actand regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing, andexport of medical devices.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          FDAApproval/Clearance Requirements         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe United States, Class II or III medical devices must be cleared or approved by the FDA prior to commercialization. Unless anexemption applies, each medical device that we market or wish to market in the United States must receive 510(k) clearance orpremarket approval. Medical devices that receive 510(k) clearance are “cleared” by the FDA to market, distribute,and sell in the United States. Medical devices that obtain a premarket approval by the FDA are “approved” to market,distribute, and sell in the United States. We anticipate filing a premarket approval application in the future and do not anticipatefiling a 510(k) premarket notification. Even though we do not anticipate filing a 510(k), we cannot be certain that the FDA willfind it more appropriate for us to file a 510(k) premarket notification instead of a premarket approval application. Further,we cannot be sure that we will ever obtain premarket approval. Descriptions of the premarket approval and 510(k) clearance processesare provided below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ClassI        </i>        devices are those for which safety and effectiveness can be assured by adherence to the FDA’s general regulatory controlsfor medical devices, or the General Controls, which include compliance with the applicable portions of the FDA’s qualitysystem regulations, facility registration and product listing, reporting of adverse medical events, and appropriate, truthfuland non-misleading labeling, advertising, and promotional materials. Some Class I devices also require premarket clearance bythe FDA through the 510(k) process described below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ClassII        </i>        devices are subject to the FDA’s General Controls, and any other special controls as deemed necessary by the FDAto ensure the safety and effectiveness of the device. Premarket review and clearance by the FDA for Class II devices is accomplishedthrough the 510(k) process. Pursuant to the Medical Device User Fee and Modernization Act of 2002 (MDUFMA), as of October 2002,unless a specific exemption applies, 510(k) submissions are subject to user fees. Certain Class II devices are exempt from thispremarket review process. The FDA has recently indicated that it intends to modernize the 510(k) process and has issued new guidancedocuments that may change the way that devices are cleared by the FDA.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ClassIII        </i>        includes devices with the greatest risk. Devices in this class must meet all of the requirements in Classes I and II.In addition, Class III devices cannot generally be marketed until they receive a premarket approval. The safety and effectivenessof Class III devices cannot be assured solely by the General Controls and the other requirements described above. These devicesrequire formal clinical studies to demonstrate safety and effectiveness. Under MDFUMA, premarket approval applications (and supplementalpremarket approval applications) are subject to significantly higher user fees than 510(k) applications, and they also requireconsiderably more time and resources.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA decides whether a device line must undergo either the 510(k) clearance or premarket approval based on statutory criteria thatutilize a risk-based classification system. Premarket approval is the FDA process of scientific and regulatory review to evaluatethe safety and effectiveness of Class III medical devices and, in many cases, Class II medical devices. Class III devices arethose that support or sustain human life, are of substantial importance in preventing impairment of human health, or which presenta potential, unreasonable risk of illness or injury. The FDA uses these criteria to decide whether a premarket approval or a 510(k)is appropriate, including the level of risk that the agency perceives is associated with the device and a determination by theagency of whether the product is a type of device that is similar to devices that are already legally marketed. Devices deemedto pose relatively less risk are placed in either Class I or II. In many cases, the FDA requires the manufacturer to submit a510(k) requesting clearance (also referred to as a premarket notification), unless an exemption applies. The 510(k) must demonstratethat the manufacturer’s proposed device is “substantially equivalent” in intended use and in safety and effectivenessto a legally marketed predicate device. A “predicate device” is a pre-existing medical device to which equivalencecan be drawn, that is either in Class I, Class II, or is a Class III device that was in commercial distribution before May 28,1976, for which the FDA has not yet called for submission of a premarket approval application.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 23; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           23           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect that unless an exemption applies, each medical device that we market or wish to market in the United States must receive510(k) clearance or premarket approval. Medical devices that receive 510(k) clearance are “cleared” by the FDA tomarket, distribute, and sell in the United States. Medical devices that obtain a premarket approval by the FDA are “approved”to market, distribute, and sell in the United States. We anticipate that each device that we wish to commercialize will be considereda Class III device by the FDA and therefore we anticipate filing a premarket approval application in the future and do not anticipatefiling a 510(k) premarket notification. Even though we do not anticipate filing a 510(k), we cannot be certain that the FDA willfind it more appropriate for us to file a 510(k) premarket notification instead of a premarket approval application or that applicationsof our technology may not be considered Class II devices. Further, we cannot be sure that we will ever obtain a premarket approval.Descriptions of the premarket approval and 510(k) clearance processes are provided below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          PremarketApproval Pathway         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect that current and future applications of our technology will result in medical devices that are considered Class III devicessubject to premarket approval. A premarket approval application must be submitted if a device cannot be cleared through the 510(k)process. A premarket approval application must be supported by extensive data including, but not limited to, analytical, preclinical,clinical trials, manufacturing, statutory preapproval inspections, and labeling to demonstrate to the FDA’s satisfactionthe safety and effectiveness of the device for its intended use. Before a premarket approval application is submitted, a manufacturermust apply for an IDE. If the device presents a “significant risk,” as defined by the FDA, to human health, the FDArequires the device sponsor to file an IDE application with the FDA and obtain IDE approval prior to initiation of enrollmentof human subjects for clinical trials. The IDE provides the manufacturer with a legal pathway to perform clinical trials on humansubjects where without the IDE, only approved medical devices may be used on human subjects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheIDE application must be supported by appropriate data, such as analytical, animal and laboratory testing results, manufacturinginformation, and an Investigational Review Board (IRB) approved protocol showing that it is safe to test the device in humansand that the testing protocol is scientifically sound. If the clinical trial design is deemed to have “non-significant risk,”the clinical trial may be eligible for “abbreviated” IDE requirements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Aclinical trial may be suspended by either the FDA or the IRB at any time for various reasons, including a belief that the risksto the study participants outweigh the benefits of participation in the study. Even if a study is completed, clinical testingresults may not demonstrate the safety and efficacy of the device, or they may be equivocal or otherwise insufficient to obtainapproval of the product being tested. After the clinical trials have been completed, if at all, and the clinical trial data andresults are collected and organized, a manufacturer may complete a premarket approval application.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Aftera premarket approval application is sufficiently complete, the FDA will accept the application and begin an in-depth review ofthe submitted information. By statute, the FDA has 180 days to review the “accepted application,” although, generally,review of the application can take between one and three years, but it may take significantly longer. During this review period,the FDA may request additional information or clarification of information already provided. Also, during the review period, anadvisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendationsto the FDA as to the approvability of the device. The preapproval inspections conducted by the FDA include an evaluation of themanufacturing facility to ensure compliance with the Quality Systems Regulations, as well as inspections of the clinical trialsites by the Bioresearch Monitoring group to evaluate compliance with good clinical practice and human subject protections. Newpremarket approval applications or premarket approval supplements are required for modifications that affect the safety or effectivenessof the device, including, for example, certain types of modifications to the device’s indication for use, manufacturingprocess, labeling and design. Significant changes to an approved premarket approval require a 180-day supplement, whereas lesssubstantive changes may utilize a 30-day notice, or a 135-day supplement. Premarket approval supplements often require submissionof the same type of information as a premarket approval application, except that the supplement is limited to information neededto support any changes from the device covered by the original premarket approval application, and it may not require as extensiveclinical data or the convening of an advisory panel.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 24; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           24           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          510(k)Clearance Pathway         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedo not currently market, distribute, or sell any products that have market clearance by the FDA under its 510(k) process. If,in the future, we develop products where 510(k) clearance is required, we would be required to submit a 510(k) demonstrating thatsuch proposed devices are substantially equivalent to a respective previously cleared 510(k) device or a device that was in commercialdistribution before May 28, 1976, for which the FDA has not yet called for the submission of 510(k). The FDA’s 510(k) clearancepathway usually takes from three to twelve months but could take longer. In some cases, the FDA may require additional information,including clinical data, to make a determination regarding substantial equivalence.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifa device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that wouldconstitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, apremarket approval. The FDA requires each device manufacturer to determine whether the proposed change requires submission ofa new 510(k) or a premarket approval, but the FDA can review any such decision and can disagree with a manufacturer’s determination.If the FDA disagrees with a manufacturer’s determination, the FDA can require the manufacturer to cease marketing and/orrecall the modified device until 510(k) clearance or premarket approval of the modified device is obtained.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Pervasiveand Continuing FDA Regulation         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ahost of regulatory requirements apply to our approved devices, including the quality system regulation (which requires manufacturersto follow elaborate design, testing, control, documentation and other quality assurance procedures), the Medical Device Reportingregulations (which require that manufacturers report to the FDA specified types of adverse events involving their products), labelingregulations, and the FDA’s general prohibition against promoting products for unapproved or “off-label” uses.Class II devices also can have special controls such as performance standards, post-market surveillance, patient registries, andFDA guidelines that do not apply to Class I devices.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anoncomprehensive list of the regulatory requirements that apply to our approved products classified as medical devices include:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           product    listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Quality    Systems Regulations, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing,    control, documentation and other quality assurance procedures during all aspects of the development and manufacturing process;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           labeling    regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           clearance    of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended    use of one of our cleared devices;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           approval    of product modifications that affect the safety or effectiveness of one of our cleared devices;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           medical    device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may    have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute    to a death or serious injury if the malfunction of the device or a similar device were to recur;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           post-approval    restrictions or conditions, including post-approval study commitments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           post-market    surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness    data for the device;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    FDA’s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the    market a product that is in violation of governing laws and regulations;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           regulations    pertaining to voluntary recalls; and,          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           notices    of corrections or removals.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 25; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           25           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedo not currently have a registered establishment with the FDA. If we are approved or cleared to manufacture, prepare, or processa device in the United States, we and any third-party manufacturers that we may use must will be required to register our establishmentswith the FDA. As such, we and our manufacturing facilities will be subject to FDA inspections for compliance with the FDA’sQuality System Regulation. Additionally, some of our subcontractors may also be subject to FDA announced and unannounced inspectionsfor compliance with the FDA’s Quality System Regulation. These regulations will require that we manufacture our productsand maintain our documents in a prescribed manner with respect to design, manufacturing, testing and quality control activities.As a medical device manufacturer, we will further be required to comply with FDA requirements regarding the reporting of adverseevents associated with the use of our medical devices, as well as product malfunctions that would likely cause or contribute todeath or serious injury if the malfunction were to recur. FDA regulations also govern product labeling and prohibit a manufacturerfrom marketing a medical device for unapproved applications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurCGuard EPS is classified as a Class III medical device by the FDA. Class III medical devices are generally the highest risk devicesand are therefore subject to the highest level of regulatory control by the FDA, since the FDA process of premarket approval involvesscientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices for the purpose(s) intended.The FDA will either approve or deny a premarket approval application and we cannot market a device unless or until the FDA approvesa premarket approval application.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect the approval process in the U.S. to take a significant amount of time, require the expenditure of significant resources,involve rigorous clinical investigations and testing, and potentially require changes to products. The approval process may resultin limitations on the indicated uses of the medical devices for which we are able to obtain approval (since the FDA can take actionagainst a company that promotes off-label uses) and will also require increased post-market surveillance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          U.S.Healthcare Laws and Regulations         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to the FDA regulations, there are a variety of other healthcare laws and regulations to which we may be subject if anyof our products are marketed, sold, distributed, and/or utilized in the United States. Of specific note are federal and statefraud and abuse laws, which prohibit the payment or receipt of kickbacks, bribes or other remuneration, including the offer orsolicitation of such payment, intended to induce or reward the purchase, recommendation or generation of business involving healthcareproducts any item or service payable by a health-care program. Other provisions of federal and state laws prohibit presenting,or causing to be presented, to third party payors (including, government program, such as Medicare and Medicaid) for reimbursement,claims that are false or fraudulent, or which are for items or services that were not provided as claimed. In addition, otherhealthcare laws and regulations may apply, such as transparency and reporting requirements, and privacy and security requirements.Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and statehealthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicableto manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutionalor individual providers that may refer or purchase such products. The healthcare laws that may be applicable to our business oroperations include, but are not limited to:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The    federal Anti-Kickback Statute, which prohibits the offer, payment, solicitation or receipt of any form of remuneration in    return for referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing    of, items or services payable by Medicare, Medicaid or any other federal healthcare program;           </font>          </td>         </tr>        </tbody>       </table>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 26; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           26           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Federal    false claims laws and civil monetary penalty laws, including the False Claims Act, that prohibit, among other things, individuals    or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government    healthcare programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation    to pay money to the federal government;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which includes provisions that    prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or    obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or    under the custody or control of, any healthcare benefit program, and for knowingly and willfully falsifying, concealing or    covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare    benefits, items or services;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           HIPAA,    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations,    also imposes obligations and requirements on healthcare providers, health plans, and healthcare clearinghouses as well as    their respective business associates that perform certain services for them that involve the use or disclosure of individually    identifiable health information, with respect to safeguarding the privacy and security of certain individually identifiable    health information;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    federal transparency requirements under the Affordable Care Act, including the provision commonly referred to as the Physician    Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable    under Medicare, Medicaid or Children’s Health Insurance Program to report annually to Centers for Medicare and Medicaid    Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals, and ownership    and investment interests held by physicians and their immediate family members; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Analogous    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and    apply to referrals and items or services reimbursed by both governmental and non-governmental third-party payors, including    private insurers, many of which differ from each other in significant ways and often are not preempted by federal law, thus    complicating compliance efforts.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Customers        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcustomer base is varied. We began shipping our product to customers in Europe in January 2008 and have since expanded our globaldistribution network to Southeast Asia, India, Latin America and Israel. We currently have distribution agreements for our CEmark-approved MGuard Prime EPS and/or CGuard EPS with medical product distributors based in Europe, the Middle East, Asia Pacificand Latin America. We are currently in discussions with additional distribution companies in Europe, Asia, and Latin America.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Mostof our current agreements with our distributors stipulate that, and we expect our future agreements with our distributors to stipulatethat, while we shall assist in training by providing training materials, marketing guidance, marketing materials, and technicalguidance, each distributor will be responsible for carrying out local registration, sales and marketing activities. In addition,in most cases, all sales costs, including sales representatives, incentive programs, and marketing trials, will be borne by thedistributor. Under current agreements, distributors purchase stents from us at a fixed price. Our current agreements with distributorsare generally for a term of two to three years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Manufacturingand Suppliers        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepolymer fiber for MicroNet is supplied by Biogeneral, Inc., a San Diego, California-based specialty polymer manufacturer for medicaland engineering applications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NatecMedical Ltd. supplies us with catheters that help create the base for our CGuard EPS stents. Our agreement with Natec MedicalLtd., as amended, may be terminated by us upon eight months’ notice. On August 1, 2017, we amended the agreement with NatecMedical Ltd., so that we are responsible for purchasing and handling inventory of CGuard EPS delivery system, and Natec MedicalLtd.is responsible for the manufacturing process.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NatecMedical Ltd. supplies us with catheters that help create the base for our MGuard Prime EPS. Our agreement with Natec Medical Ltd.,which may be terminated by either party upon six months’ notice, calls for non-binding minimum orders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 27; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           27           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecobalt-chromium stent for our MGuard Prime EPS was designed by Svelte Medical Systems Inc. We have an agreement with Svelte MedicalSystems Inc., as amended, that grants us a non-exclusive, worldwide license for production and use of the MGuard Prime cobalt-chromiumstent for the life of the stent’s patent, subject to the earlier termination of the agreement upon the bankruptcy of eitherparty or the uncured default by either party under any material provision of the agreement. Our royalty payments to Svelte MedicalSystems Inc. are determined by the sales volume of MGuard Prime EPS. Currently, the royalty rate is 2.9% of all net sales.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemanufacture our CGuard EPS and MGuard Prime EPS at our own facility. The bare-metal cobalt-chromium stents for our MGuard PrimeEPS and the self-expanding bare-metal stents for our CGuard EPS are being manufactured and supplied by MeKo Laserstrahl-Materialbearbeitung.Our agreement with MeKo Laserstrahl-Materialbearbeitung for the production of electro polished L605 bare-metal stents for MGuardPrime EPS and CGuard EPS is priced on a per-stent basis, subject to the quantity of stents ordered. The complete assembly processfor MGuard Prime EPS and CGuard EPS, including knitting and securing the sleeve to the stent and the crimping of the sleeve stenton to a delivery catheter, is done at our Israel manufacturing site. Once MGuard Prime EPS and CGuard EPS have been assembled,they are sent for sterilization in a third-party facility in Israel, and then back to our facility for final packaging and distribution.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe quarter ended March 31, 2019, our former third-party sterilizer’s equipment failures resulted in significant interruptionin sterilized product supply for the majority of the quarter. As a result of this interruption in the delivery of sterilized productsand our limited inventory levels on hand prior to this interruption, we were unable to fulfill a significant portion of the ordersreceived during the three months ended March 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EachMGuard stent is manufactured from two main components, the stent and the mesh polymer. The stent is made out of cobalt chromium.This material is readily available, and we acquire it in the open market. The mesh is made from polyethylene terephthalate (polyester).This material is readily available in the market as well, because it is used for many medical applications. In the event thatour supplier can no longer supply this material in fiber form, we would need to qualify another supplier, which could take severalmonths. In addition, in order to retain the approval of the CE mark, we are required to perform periodic audits of the qualitycontrol systems of our key suppliers in order to insure that their products meet our predetermined specifications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ACGuard EPS consists of a CGuard stent and the delivery system. Each CGuard stent is manufactured from two main components, a self-expendingnickel-titanium stent and the mesh polymer. This material is readily available and we acquire it in the open market. The meshis made from polyethylene terephthalate (polyester). We have pending patent rights that cover the proposed CGuard stent with mesh.This material is readily available in the market as well, because it is used for many medical applications. In the event thatour supplier can no longer supply this material in fiber form, we would need to qualify another supplier, which could take severalmonths. The delivery system for CGuard is made out of polymer tubes we acquire from an original equipment manufacturer. In theevent that our supplier can no longer supply this material, we would need to qualify another supplier, which could take severalmonths. In addition, in order to retain the approval of the CE mark, we are required to perform periodic audits of the qualitycontrol systems of our key suppliers in order to insure that their products meet our predetermined specifications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Properties        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourheadquarters are located in Tel Aviv, Israel, where we lease a 1,000 square meter office and manufacturing facility that has thecapacity to manufacture and assemble 1,200 stents per month, based upon the production schedule of one shift per day. We believethat our current facility is sufficient to meet anticipated future demand by adding additional shifts to our current productionschedule.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         LegalProceedings        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Fromtime to time, we may be involved in litigation that arises through the normal course of business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 28; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           28           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 10, 2019, Bosti Trading Ltd., a former distributor in Russia (“Bosti”), filed suit with the Tel Aviv-Jaffa DistrictCourt in Israel, or the Complaint, against InspireMD Ltd., claiming damages for alleged breaches by InspireMD Ltd. under the DistributionAgreement, dated May 26, 2011, between Bosti and InspireMD Ltd., in connection with the voluntary field corrective action of ourMGuard Prime EPS we initiated in 2014. Bosti claimed that Bosti and its Russian subsidiary returned 1,830 units of MGuard PrimeEPS to InspireMD Ltd. upon initiation of the voluntary filed action, and, since the Russian Ministry of Health prohibited distributionof MGuard Prime EPS on August 28, 2014, and did not approve distribution MGuard Prime EPS until September 20, 2016, Bosti wasentitled to recover from InspireMD Ltd. €1,830,000 (which is approximately $2 million), the amount Bosti was due to receivefrom its Russian subsidiary, or alternatively, €1,024,000 (which is approximately $1.1 million), the amount Bosti paid toInspireMD Ltd., for the MGuard Prime EPS returned to InspireMD Ltd. On January 31, 2020, InspireMD Ltd. filed with court its letterof defense in which it contested this matter vigorously. On January 21, 2021, we executed a Mediation Agreement with Bosti andInspireMD Ltd., pursuant to which Bosti agreed to release the Company from all claims stated in the Complaint in exchange fora payment of $580,000, which we paid on January 25, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof the date of this filing, we are not aware of any other material legal proceedings to which we or any of our subsidiaries isa party or to which any of our property is subject, nor are we aware of any such threatened or pending litigation or any suchproceedings known to be contemplated by governmental authorities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare not aware of any material proceedings in which any of our directors, officers or affiliates or any registered or beneficialstockholder of more than 5% of our common stock, or any associate of any of the foregoing, is a party adverse to or has a materialinterest adverse to, us or any of our subsidiaries.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         HumanCapital Management        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, we had 48 employees 45 full-time and 3 part-time, consisting of two in executive management, five in researchand development, four in quality assurance and compliance, five in finance and accounting, 18 in operations/production, 11 insales, marketing and clinical, and three in all other miscellaneous roles, including business development, information technologyservices, and administration. Except for four of our employees in Europe, our employees are not party to any collective bargainingagreements. We do not expect the collective bargaining agreements to which our employees are party to have a material effect onour business or results of operations. We also employ two independent contractors in Poland.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webelieve that our future success will depend, in part, on our continued ability to attract, hire and retain qualified personnel.In particular, we depend on the skills, experience and performance of our senior management and research personnel. We competefor qualified personnel with other medical device, biotechnology, pharmaceutical and healthcare companies, as well as universitiesand non-profit research institutions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weprovide competitive compensation and benefits programs to help meet the needs of our employees. In addition to salaries, theseprograms (which vary by country/region and employment classification) include incentive compensation plan, pension, healthcareand insurance benefits, paid time off, family leave, and on-site services, among others. We also use targeted equity-based grantswith vesting conditions to facilitate retention of personnel, particularly for our key employees.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesuccess of our business is fundamentally connected to the well-being of our people. Accordingly, we are committed to the healthand safety of our employees. In response to the COVID-19 pandemic, we implemented significant changes that we determined werein the best interest of our employees, as well as the communities in which we operate, and which comply with government regulations.This includes having employees work from home, while implementing additional safety measures for employees continuing criticalon-site work.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconsider our relations with our employees to be good.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_003">         </a>         Item1A. Risk Factors.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Thereare numerous and varied risks, known and unknown, that may prevent us from achieving our goals. You should carefully considerthe risks described below and the other information included in this Annual Report on Form 10-K, including the consolidated financialstatements and related notes. If any of the following risks, or any other risks not described below, actually occur, it is likelythat our business, financial condition, and/or operating results could be materially adversely affected. The risks and uncertaintiesdescribed below include forward-looking statements and our actual results may differ from those discussed in these forward-lookingstatements.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 29; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           29           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         SummaryRisk Factors        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourbusiness is subject to numerous risks and uncertainties, including those highlighted in the section titled “Risk Factors”immediately following this prospectus summary. These risks include, among others, the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="width: 0.25in">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </p>          <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    COVID-19 pandemic has caused interruptions or delays of our business plan and may have a significant adverse effect on our    business;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    have a history of net losses and may experience future losses;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly    or difficult to obtain and could dilute our stockholders’ ownership interests;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    may become subject to claims by much larger and better capitalized competitors enforcing their intellectual property rights    against us or seeking to invalidate our intellectual property or our rights thereto;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           there    are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           clinical    trials necessary to support a pre-market approval application will be lengthy and expensive and will require the enrollment    of a large number of patients, and suitable patients may be difficult to identify and recruit. Any such delay or failure of    clinical trials could prevent us from commercializing our stent products, which would materially and adversely affect our    results of operations and the value of our business;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    products may in the future be subject to product notifications, recalls, or voluntary market withdrawals that could harm our    reputation, business and financial results;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           completing    clinical trials for CGuard EPS in the United States require meeting a number of regulatory requirements and must be conducted    in compliance with the FDA’s IDE regulations. Failure to maintain compliance with IDE regulations could have a material    adverse effect on our business;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           though    necessary to pursue FDA premarket approval, pre-clinical and clinical trials are inherently lengthy and expensive and subject    to any number of regulatory and/or clinical difficulties that can cause further delays, additional costs, and/or rejection    by the FDA, and any such delay, added cost, or failure in connection with any future clinical trials could prevent us from    commercializing our MicroNet products in the United States, which would materially and adversely affect our results of operations    and the value of our business;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    may be subject, directly or indirectly, to applicable U.S. federal and state anti-kickback, false claims laws, physician payment    transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, which could expose us to    criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    may be exposed to product liability claims and insurance may not be sufficient to cover these claims;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           even    if one or more of our products are approved by the FDA, we may fail to obtain an adequate level of reimbursement for our products    by third party payors, such that there may be no commercially viable markets for our products or the markets may be much smaller    than expected;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           in    the United States and European Union, our business could be significantly and adversely affected by healthcare reform initiatives    and/or other legislation or judicial interpretations of existing or future healthcare laws and/or regulations;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           if    we are unable to obtain and maintain intellectual property protection covering our products, others may be able to make, use    or sell our products, which would adversely affect our revenue;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 30; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           30           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    are an international business, and we are exposed to various global and local risks that could have a material adverse effect    on our financial condition and results of operations venue;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    market prices of our common stock and our publicly traded warrants are subject to fluctuation and have been and may continue    to be volatile, which could result in substantial losses for investors;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    common stock could be delisted from the NYSE American if we fail to meet the NYSE American’s stockholders’ equity    continued listing standards. Our ability to publicly or privately sell equity securities and the liquidity of our common stock    could be adversely affected if we are delisted from the NYSE American;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           a    low trading price could lead the NYSE American to take actions toward delisting our common stock, including immediately suspending    trading in our common stock;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td colspan="3" style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           offers    or availability for sale of a substantial number of shares of our common stock may cause the price of our publicly traded    securities to decline;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues    will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           if    there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have    a material adverse effect on our business relationships and profitability;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           it    may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors    or officers;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Our Business        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          TheCOVID-19 pandemic has caused interruptions or delays of our business plan and may have a significant adverse effect on our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inan effort to contain and mitigate the spread of COVID-19, a strain of coronavirus which the World Health Organization, or WHO,declared to be a pandemic on March 12, 2020, many countries have imposed unprecedented restrictions on travel, quarantines andother public health safety measures. At this point, the extent to which COVID-19 may impact our business cannot be estimated;however, procedures with CGuard EPS, which are generally scheduled or non-emergency procedures, have mostly been postponed ashospitals shift resources to patients affected by COVID-19, and it is highly plausible that this trend will continue. We anticipatethat the continuation of the pandemic and related restrictions and safety measures would likely result in continued fluctuationsin sales of our products for the upcoming periods.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Certaincomponent parts of our delivery system are sourced from countries that have been impacted by COVID-19, and the continued pandemicand spreading of COVID-19 may adversely impact our suppliers and in turn our manufacture of CGuard EPS. Although the manufacturingof our products in Israel has not been materially impacted by COVID-19 as of February 2021, we cannot guarantee that we will continueto manufacture at full capacity in the event that pandemic persists and further restrictions are imposed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theextent to which COVID-19 will impact our results will depend on future developments, which are highly uncertain and cannot bepredicted, including new information which may emerge concerning the severity of the coronavirus. The actions to contain COVID-19or treat its impact, the efficacy and scale of the various vaccines currently deployed across the world, among others. Moreover,COVID-19 has had indeterminable adverse effects on general commercial activity and the world economy, and our business and resultsof operations could be adversely affected to the extent that COVID-19 or any other epidemic continues to harm the global economygenerally.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave a history of net losses and may experience future losses.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave yet to establish any history of profitable operations. We reported a net loss of $10.5 million for the fiscal year endedDecember 31, 2020, and had a net loss of approximately $10 million during the fiscal year ended December 31, 2019. As of December31, 2020, we had an accumulated deficit of $168 million. We expect to incur additional operating losses for the foreseeable future.There can be no assurance that we will be able to achieve sufficient revenues throughout the year or be profitable in the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 31; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           31           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wewill need to raise additional capital to meet our business requirements in the future, and such capital raising may be costlyor difficult to obtain and could dilute our stockholders’ ownership interests.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inorder for us to pursue our business objectives without materially curtailing our operations, we will need to raise additionalcapital, which additional capital may not be available on reasonable terms or at all. For instance, we will need to raise additionalfunds to accomplish the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           furthering    our efforts to ultimately seek the FDA approval for commercial sales of CGuard EPS in the United States;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           development    of our current and future products, including CGuard EPS enhancements;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           pursuing    growth opportunities, including more rapid expansion and funding regional distribution systems;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           making    capital improvements to improve our infrastructure;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           hiring    and retaining qualified management and key employees;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           responding    to competitive pressures;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           complying    with regulatory requirements such as licensing and registration; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           maintaining    compliance with applicable laws.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anyadditional capital raised through the sale of equity or equity-backed securities may dilute our stockholders’ ownershippercentages and could also result in a decrease in the market value of our equity securities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theterms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences,superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect onthe holders of any of our securities then outstanding.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees,accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required torecognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which mayadversely impact our financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weoperate in an intensely competitive and rapidly changing business environment, and there is a substantial risk our products couldbecome obsolete or uncompetitive.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themedical device market is highly competitive. We compete with many medical device companies globally in connection with our currentproducts and products under development. We face intense competition from numerous pharmaceutical and biotechnology companiesin the therapeutics area, as well as competition from academic institutions, government agencies and research institutions. AbbottLaboratories, Boston Scientific Corporation, Medtronic, Inc., and Johnson and Johnson, Gore Medical and Terumo Medical Corporationproduce a polytetrafluoroethylene mesh-covered stent and a double layer metal stent, respectively. Most of our current and potentialcompetitors, including but not limited to those listed above, have, and will continue to have, substantially greater financial,technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnelresources than we do. There can be no assurance that we will have sufficient resources to successfully commercialize our products,if and when they are approved for sale. The worldwide market for stent products is characterized by intensive development effortsand rapidly advancing technology. Our future success will depend largely upon our ability to anticipate and keep pace with thosedevelopments and advances. Current or future competitors could develop alternative technologies, products or materials that aremore effective, easier to use or more economical than what we or any potential licensee develop. If our technologies or productsbecome obsolete or uncompetitive, our related product sales and licensing revenue would decrease. This would have a material adverseeffect on our business, financial condition and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 32; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           32           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay become subject to claims by much larger and better capitalized competitors enforcing their intellectual property rights againstus or seeking to invalidate our intellectual property or our rights thereto.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Basedon the prolific litigation that has occurred in the stent industry and the fact that we may pose a competitive threat to somelarge and well-capitalized companies that own or control patents relating to stents and their use, manufacture and delivery, webelieve that it is possible that one or more third parties will assert a patent infringement claim against the manufacture, useor sale of our stents based on one or more of these patents. These companies also own patents relating to the use of drugs totreat restenosis, stent architecture, catheters to deliver stents, and stent manufacturing and coating processes and compositions,as well as general delivery mechanism patents like rapid exchange, which might be alleged to cover one or more of our products.In addition, it is possible that a lawsuit of which we are not aware asserting patent infringement, misappropriation of intellectualproperty, or related claims may have already been filed against us. As the number of competitors in the stent market grows andas the geographies in which we commercially market grow in number and scope, the possibility of patent infringement by us, and/ora patent infringement or misappropriation claim against us, increases.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcompetitors have maintained their positions in the market by, among other things, establishing intellectual property rights relatingto their products and enforcing these rights aggressively against their competitors and new entrants into the market. All themajor companies in the field of stents and related markets, including Boston Scientific Corporation, C.R. Bard, Inc., W.L. Gore&amp; Associates, Inc. and Medtronic, Inc., have been repeatedly involved in patent litigation relating to stents since at least1997. The field of stents and related markets have experienced rapid technological change and obsolescence in the past, and ourcompetitors have strong incentives to stop or delay the introduction of new products and technologies. We may pose a competitivethreat to many of the companies in these markets. Accordingly, these companies will have a strong incentive to take steps, throughpatent litigation or otherwise, to prevent us from distributing our products. Such litigation or claims would divert attentionand resources away from the development and/or commercialization of our products and could result in an adverse court judgmentthat would make it impossible or impractical to sell our products in one or more territories.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe fail to maintain or establish satisfactory agreements or arrangements with suppliers or if we experience an interruption ofthe supply of materials from suppliers, we may not be able to obtain materials that are necessary to develop our products.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedepend on outside suppliers for certain raw materials. These raw materials or components may not always be available at our standardsor on acceptable terms, if at all, and we may be unable to locate alternative suppliers or produce necessary materials or componentson our own.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Someof the components of our products are currently provided by only one vendor, or a single-source supplier. For CGuard EPS and MGuardPrime EPS, we depend on MeKo Laserstrahl-Materialbearbeitung for the laser cutting of the stent, Natec Medical Ltd. for the supplyof catheters, and Biogeneral Inc. for the fiber. We may have difficulty obtaining similar components from other suppliers thatare acceptable to the FDA or foreign regulatory authorities if it becomes necessary.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe have to switch to a replacement supplier, we will face additional regulatory delays and the interruption of the manufactureand delivery of our stents for an extended period of time, which would delay completion of our clinical trials or commercializationof our products. In addition, we will be required to obtain prior regulatory approval from the FDA or foreign regulatory authoritiesto use different suppliers or components that may not be as safe or as effective. As a result, regulatory approval of our productsmay not be received on a timely basis or at all.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 33; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           33           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we rely on a third-party vendor to perform the sterilization process. A third-party vendor’s failure to properlysterilize a component may cause delays or disruptions in our manufacturing process. During the fiscal year ended December 31,2019, our third-party sterilizer’s equipment failures resulted in significant interruption in sterilized product supplyfor the majority of the first quarter. As a result of this interruption in the delivery of sterilized products and our limitedinventory levels on hand prior to this interruption, we were unable to fulfill a significant portion of the orders received duringthe fiscal year ended December 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare subject to financial reporting and other requirements that place significant demands on our resources.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirementsof Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectivenessof our internal controls over financial reporting. These reporting and other obligations place significant demands on our management,administrative, operational, internal audit and accounting resources. Any failure to maintain effective internal controls couldhave a material adverse effect on our business, operating results and stock price. Moreover, effective internal control is necessaryfor us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud,we may not be able to manage our business as effectively as we would if an effective control environment existed, and our businessand reputation with investors may be harmed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thereare inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theongoing internal control provisions of Section 404 of the Sarbanes-Oxley Act of 2002 require us to identify material weaknessesin internal control over financial reporting, which is a process to provide reasonable assurance regarding the reliability offinancial reporting for external purposes in accordance with accounting principles generally accepted in the United States. Ourmanagement, including our chief executive officer and chief financial officer, does not expect that our internal controls anddisclosure controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provideonly reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the design of a controlsystem must reflect the fact that there are resource constraints and the benefit of controls must be relative to their costs.Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that allcontrol issues and instances of fraud, if any, in our company have been detected. These inherent limitations include the realitiesthat judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Further, controlscan be circumvented by individual acts of some persons, by collusion of two or more persons, or by management override of thecontrols. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events,and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.Over time, a control may be inadequate because of changes in conditions, such as growth of the company or increased transactionvolume, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effectivecontrol system, misstatements due to error or fraud may occur and not be detected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, discovery and disclosure of a material weakness, by definition, could have a material adverse impact on our financialstatements. Such an occurrence could discourage certain customers or suppliers from doing business with us and adversely affecthow our stock trades. This could in turn negatively affect our ability to access equity markets for capital.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to our Products, Clinical Trials and Regulatory Matters        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Clinicaltrials necessary to support a pre-market approval application will be lengthy and expensive and will require the enrollment ofa large number of patients, and suitable patients may be difficult to identify and recruit. Any such delay or failure of clinicaltrials could prevent us from commercializing our stent products, which would materially and adversely affect our results of operationsand the value of our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Clinicaltrials necessary to support a pre-market approval application to the FDA for our CGuard EPS stent will be expensive and will requirethe enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit, which may causea delay in the development and commercialization of our product candidates. Patient enrollment in clinical trials and the abilityto successfully complete patient follow-up depends on many factors, including the size of the patient population, the nature ofthe trial protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial and patient compliance.For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergoextensive post-treatment procedures or follow-up to assess the safety and efficacy of our products, or they may be persuaded toparticipate in contemporaneous clinical trials of competitive products. In addition, patients participating in our clinical trialsmay die before completion of the trial or suffer adverse medical events unrelated to or related to our products. Delays in patientenrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays orresult in the failure of the clinical trial.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 34; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           34           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, the length of time required to complete clinical trials for pharmaceutical and medical device products varies substantiallyaccording to the degree of regulation and the type, complexity, novelty and intended use of a product, and can continue for severalyears and cost millions of dollars. The commencement and completion of clinical trials for our products under development maybe delayed by many factors, including governmental or regulatory delays and changes in regulatory requirements, policy and guidelinesor our inability or the inability of any potential licensee to manufacture or obtain from third parties materials sufficient foruse in preclinical studies and clinical trials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourproducts may in the future be subject to product notifications, recalls, or voluntary market withdrawals that could harm our reputation,business and financial results.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themanufacturing and marketing of medical devices involves an inherent risk that our products may prove to be defective and causea health risk even after regulatory clearances have been obtained. Medical devices may also be modified after regulatory clearanceis obtained to such an extent that additional regulatory clearance is necessary before the device can be further marketed. Inthese events, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe European Economic Area, we must comply with the EU Medical Device Vigilance System. Under this system, manufacturers are requiredto take Field Safety Corrective Actions (“FSCAs”) to reduce a risk of death or serious deterioration in the stateof health associated with the use of a medical device that is already placed on the market. A FSCA may include the recall, modification,exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representativeto its customers and/or to the end users of the device through Field Safety Notices.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anyadverse event involving our products could result in other future voluntary corrective actions, such as recalls or customer notifications,or agency action, such as inspection or enforcement action. Adverse events have been reported to us in the past, and we cannotguarantee that they will not occur in the future. Any corrective action, whether voluntary or involuntary, as well as defendingourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our businessand could harm our reputation and financial results.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weexpect to derive our revenue from sales of our CGuard EPS and MGuard Prime EPS stent products and other products we may develop,such as CGuard EPS with enhancements. If we fail to generate revenue from these sources, our results of operations and the valueof our business would be materially and adversely affected.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect our revenue to be generated from sales of our CGuard EPS and MGuard Prime EPS stent products and other products we maydevelop. Future sales of CGuard EPS will be subject to the receipt of regulatory approvals and commercial and market uncertaintiesthat may be outside our control. In addition, sales of MGuard Prime EPS have been hampered by weakened demand for bare metal stents,which may never improve, and we may not be successful in developing a drug-eluting stent product. In addition, there may be insufficientdemand for other products we are seeking to develop, such as CGuard EPS with enhancements. If we fail to generate expected revenuesfrom these products, our results of operations and the value of our business and securities would be materially and adverselyaffected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifour manufacturing facilities are unable to provide an adequate supply of products, our growth could be limited and our businesscould be harmed.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wecurrently manufacture our CGuard EPS and MGuard Prime EPS products at our facility in Tel Aviv, Israel. If there were a disruptionto our existing manufacturing facility, we would have no other means of manufacturing our CGuard EPS or MGuard Prime EPS stentsuntil we were able to restore the manufacturing capability at our facility or develop alternative manufacturing facilities. Ifwe were unable to produce sufficient quantities of our CGuard EPS or MGuard Prime EPS stents to meet market demand or for usein our current and planned clinical trials, or if our manufacturing process yields substandard stents, our development and commercializationefforts would be delayed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 35; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           35           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,any damage to or destruction of our Tel Aviv facility or its equipment, prolonged power outage or contamination at our facilitywould significantly impair our ability to produce either CGuard EPS or MGuard Prime EPS stents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Finally,the production of our stents must occur in a highly controlled, clean environment to minimize particles and other yield and quality-limitingcontaminants. In spite of stringent quality controls, weaknesses in process control or minute impurities in materials may causea substantial percentage of defective products in a lot. If we are unable to maintain stringent quality controls, or if contaminationproblems arise, our clinical development and commercialization efforts could be delayed, which would harm our business and resultsof operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Completingclinical trials for CGuard EPS in the United States require meeting a number of regulatory requirements and must be conductedin compliance with the FDA’s IDE regulations. Failure to maintain compliance with IDE regulations could have a materialadverse effect on our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Clinicaltrials involve use of a medical device candidate (or drug, biological, or other product candidate, as applicable) on human subjectsunder the supervision of qualified investigators in accordance with current Good Clinical Practices, including the requirementthat all research subjects provide informed consent for their participation in the clinical study. The FDA classifies medicaldevice candidates into “significant risk” and “non-significant risk” devices. Significant risk devicespresent a potential for serious risk to the health, safety, or welfare of a subject. Examples may include implants, devices thatsupport or sustain human life, and devices that are substantially important in diagnosing, curing, mitigating, or treating diseaseor in preventing impairment to human health. If a medical device candidate presents a significant risk, an IDE application mustbe submitted and approved prior to commencing any human clinical trials in the United States in connection with such device. TheFDA may approve, conditionally approve, or deny an IDE or it may require further information and, thus, delay approval. On September8, 2020, we received IDE approval for CGuard™ Carotid Stent System, CARENET-III.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to our recent IDE approval for CGuard™ Carotid Stent System, CARENET-III, we must apply for and obtain IRB approvalof the proposed CGuard EPS clinical study in connection with each clinical site before commencing any study activities. A writtenprotocol with predefined end points, an appropriate sample size, and pre-determined patient inclusion and exclusion criteria,is also required before we may initiate or conduct the CGuard EPS trial. If we obtain IDE approval, IRB approval, and meet allof the other applicable requirements that must be met before beginning clinical trials in the United States, we will, then, beable to lawfully initiate the clinical investigation of the safety and effectiveness of CGuard EPS in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Importantly,the CGuard EPS clinical trial and any others that we may conduct in the future, must be conducted in accordance with the FDA’sIDE regulations, which, among other things, establish requirements for investigational device labeling, prohibit pre-approvalpromotion of a device candidate, and specify recordkeeping, reporting, and monitoring responsibilities of study sponsors and studyinvestigators.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay not be able to obtain IRB approval to undertake clinical trials in the United States for CGuard EPS or any new devices weintend to market in the United States in the future. If we do obtain such approvals, we may not be able to conduct studies whichcomply with the IDE and other regulations governing clinical investigations or the data from any such trials may not support clearanceor approval of the investigational device. Failure to obtain such approvals or to comply with such regulations could have a materialadverse effect on our business, financial condition and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Relatedly,certainty that clinical trials will meet desired endpoints, produce meaningful or useful data, and be free of unexpected adverseeffects, or that the FDA will accept the validity of foreign clinical study data, as applicable, cannot be guaranteed, and suchuncertainty could preclude or delay regulatory approvals and commercialization, resulting in significant financial costs and reducedrevenue. Moreover, the timing of the commencement, continuation, and completion of any future clinical trial may be subject tosignificant delays attributable to various causes, including, but not limited to, scheduling conflicts with participating cliniciansand clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria, failure ofpatients to complete the clinical trial, delay in or failure to meet regulatory and/or IRB requirements to conduct a clinicaltrial at a one or more prospective sites, and shortages of supply in the investigational device.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 36; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           36           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thoughnecessary to pursue FDA’s premarket approval, pre-clinical and clinical trials are inherently lengthy and expensive andsubject to any number of regulatory and/or clinical difficulties that can cause further delays, additional costs, and/or rejectionby the FDA, and any such delay, added cost, or failure in connection with any future clinical trials could prevent us from commercializingour MicroNet products in the United States, which would materially and adversely affect our results of operations and the valueof our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Aspart of the regulatory process, we must conduct clinical trials for each product candidate to demonstrate safety and efficacyto the satisfaction of the regulatory authorities, including, if we seek in the future to sell our products in the United States,the FDA. Clinical trials are subject to rigorous regulatory requirements and are expensive and time-consuming to design and implement.They require the enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit, whichmay cause a delay in the development and commercialization of our product candidates. In some trials, a greater number of patientsand a longer follow-up period may be required. Patient enrollment in clinical trials and the ability to successfully completepatient follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, theproximity of patients to clinical sites, the eligibility criteria for the clinical trial and patient compliance. For example,patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatmentprocedures or follow-up to assess the safety and efficacy of our products, or they may be persuaded to participate in contemporaneousclinical trials of competitive products. In addition, patients participating in our clinical trials may die before completionof the trial or suffer adverse medical events unrelated to or related to our products. Delays in patient enrollment or failureof patients to continue to participate in a clinical trial may cause an increase in costs and delays or result in the failureof the clinical trial.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, the length of time required to complete clinical trials for pharmaceutical and medical device products varies substantiallyaccording to the degree of regulation and the type, complexity, novelty and intended use of a product, and can continue for severalyears and cost millions of dollars. The commencement and completion of clinical trials for our existing products and those underdevelopment may be delayed by many factors, including governmental or regulatory delays and changes in regulatory requirements,policy and guidelines or our inability or the inability of any potential licensee to manufacture or obtain from third partiesmaterials sufficient for use in preclinical studies and clinical trials. In addition, market demand may change for products beingtested due to the length of time needed to complete requisite clinical trials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Physiciansmay not widely adopt our products unless they determine, based on experience, long-term clinical data and published peer reviewedjournal articles, among other standard-of-care considerations, that the use of our stents provides a safe and effective alternativeto other existing treatments for coronary artery disease and carotid artery disease.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webelieve that physicians will not widely adopt our products unless they determine, based on experience, long-term clinical data,published peer reviewed journal articles and payor coverage policies, among other factors, that the use of our products providea safe and effective alternative to other existing treatments for the conditions we are seeking to address.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe fail to demonstrate safety and efficacy that is at least comparable to existing and future therapies available on the market,our ability to successfully market our products will be significantly limited. Even if the data collected from clinical studiesor clinical experience indicate positive results, each physician’s actual experience with our products will vary. Clinicaltrials conducted with our products may involve procedures performed by physicians who are technically proficient and are high-volumestent users of such products. Consequently, both short-term and long-term results reported in these clinical trials may be significantlymore favorable than typical results of practicing physicians, which could negatively affect rates of adoptions of our products.We also believe that published peer-reviewed journal articles and recommendations and support by influential physicians regardingour products will be important for market acceptance and adoption, and we cannot assure you that we will receive these recommendationsand support, or that supportive articles will be published.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Physicianscurrently consider drug-eluting stents to be the industry standard for treatment of coronary artery disease. MGuard Prime EPS,our current coronary product, is not drug-eluting, and this may adversely affect our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourability to attract customers depends to a large extent on our ability to provide goods that meet the customers’ and themarket’s demands and expectations. If we do not have a product that is expected by the market, we may lose customers. Themarket demand has shifted away from bare metal stents in favor of drug-eluting stents for coronary artery disease. Our MGuardPrime EPS is a bare-metal stent product and has experienced no growth in sales over the past five years. Such sales may nevergrow and we do not currently have the resources to develop a drug-eluting stent product. Our failure to provide industry standarddevices could adversely affect our business, financial condition and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 37; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           37           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave only limited experience in regulatory affairs, which may affect our ability or the time required to navigate complex regulatoryrequirements and obtain necessary regulatory approvals, if such approvals are received at all. Regulatory delays or denials mayincrease our costs, cause us to lose revenue and materially and adversely affect our results of operations and the value of ourbusiness.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Becauselong-term success measures have not been completely validated for our products, especially CGuard EPS, regulatory agencies maytake a significant amount of time in evaluating product approval applications. Treatments may exhibit a favorable measure usingone metric and an unfavorable measure using another metric. Any change in accepted metrics may result in reconfiguration of, anddelays in, our clinical trials. Additionally, we have only limited experience in filing and prosecuting the applications necessaryto gain regulatory approvals, and our clinical, regulatory and quality assurance personnel are currently composed of only fiveemployees. As a result, we may experience delays in connection with obtaining regulatory approvals for our products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, the products we and any potential licensees license, develop, manufacture and market are subject to complex regulatoryrequirements, particularly in the United States, Europe and Asia, which can be costly and time-consuming. There can be no assurancethat such approvals will be granted on a timely basis, if at all. Furthermore, there can be no assurance of continued compliancewith all regulatory requirements necessary for the manufacture, marketing and sale of the products we will offer in each marketwhere such products are expected to be sold, or that products we have commercialized will continue to comply with applicable regulatoryrequirements. If a government regulatory agency were to conclude that we were not in compliance with applicable laws or regulations,the agency could institute proceedings to detain or seize our products, issue a recall, impose operating restrictions, enjoinfuture violations and assess civil and criminal penalties against us, our officers or employees and could recommend criminal prosecution.Furthermore, regulators may proceed to ban, or request the recall, repair, replacement or refund of the cost of, any device manufacturedor sold by us. Furthermore, there can be no assurance that all necessary regulatory approvals will be obtained for the manufacture,marketing and sale in any market of any new product developed or that any potential licensee will develop using our licensed technology.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Evenif our products are approved by regulatory authorities, if we or our suppliers fail to comply with ongoing regulatory requirements,or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal fromthe market.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anyregulatory approvals that we receive for our products will require surveillance to monitor the safety and efficacy of the productand may require us to conduct post-approval clinical studies. In addition, if a regulatory authority approves our products, themanufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import,export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Moreover,if we obtain regulatory approval for any of our products, we will only be permitted to market our products for the indicationapproved by the regulatory authority, and such approval may involve limitations on the indicated uses or promotional claims wemay make for our products. In addition, later discovery of previously unknown problems with our products, including adverse eventsof unanticipated severity or frequency, or with our suppliers or manufacturing processes, or failure to comply with regulatoryrequirements, may result in, among other things:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           restrictions    on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory    product recalls;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           fines,    warning letters, or untitled letters;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           holds    on clinical trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           refusal    by the regulatory authority to approve pending applications or supplements to approved applications filed by us or suspension    or revocation of license approvals;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           product    seizure or detention, or refusal to permit the import or export of our product candidates; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           injunctions,    the imposition of civil penalties or criminal prosecution.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 38; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           38           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA also requires that our sales and marketing efforts, as well as promotions, be consistent with various laws and regulations.Approved medical device promotions must be consistent with and not contrary to labeling, balanced, truthful and not false or misleading,adequately substantiated (when required), and include adequate directions for use. In addition to the requirements applicableto approved products, we may also be subject to enforcement action in connection with any promotion of an investigational newdevice. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, may not represent in a promotionalcontext that an investigational new device is safe or effective for the purposes for which it is under investigation or otherwisepromote the device.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifthe FDA investigates our marketing and promotional materials or other communications and finds that any of our investigationaldevices, or future commercial products, if any, are being marketed or promoted in violation of the applicable regulatory restrictions,we could be subject to the enforcement actions listed above, among others. Any enforcement action (or related lawsuit, which couldfollow such action) brought against us in connection with alleged violations of applicable device promotion requirements, or prohibitions,could harm our business and our reputation, as well as the reputation of any devices that may be approved for marketing in theU.S. in the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theapplicable regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent,limit or delay regulatory approval of our products. We cannot predict the likelihood, nature or extent of government regulationthat may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unableto adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintainregulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Failureto obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products in such jurisdictions.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemarket our products in international markets. In order to market our products in other foreign jurisdictions, we must obtain separateregulatory approvals from the appropriate governing body in each applicable country. The approval processes vary among countriesand can involve additional testing, and the time required to obtain approval may differ from that required to obtain CE mark orFDA approval. Foreign regulatory approval processes may include all of the risks associated with obtaining CE mark or FDA approvalin addition to other risks. We may not obtain foreign regulatory approvals on a timely basis, if at all. CE mark approval or anyfuture FDA approval does not ensure approval by regulatory authorities in other countries. We may not be able to file for regulatoryapprovals and may not receive necessary approvals to commercialize our products in certain markets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare, or may be, subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to suchhealthcare laws and regulations could adversely affect our business and results of operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inboth the United States and certain foreign jurisdictions, there are laws and regulations specific to the healthcare industry whichmay affect all aspects of our business, including development, testing, marketing, sales, pricing, and reimbursement. Additionally,there have been a number of legislative and regulatory proposals in recent years to change the healthcare system in ways thatcould impact our ability to sell our products. If we are found to be in violation of any of these laws or any other federal orstate regulations, we may be subject to administrative, civil and/or criminal penalties, damages, fines, individual imprisonment,exclusion from federal healthcare programs and the restructuring of our operations. Any of these could have a material adverseeffect on our business and financial results. Since many of these laws have not been fully interpreted by the courts, there isan increased risk that we may be found in violation of one or more of their provisions. Any action against us for violation ofthese laws, even if we ultimately are successful in our defense, will cause us to incur significant legal expenses and divertour management’s attention away from the operation of our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 39; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           39           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be subject, directly or indirectly, to applicable U.S. federal and state anti-kickback, false claims laws, physician paymenttransparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, which could expose us to criminalsanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Healthcareproviders, physicians and others will play a primary role in the recommendation, ordering and utilization of any products forwhich we obtain regulatory approval. If we obtain U.S. Food &amp; Drug Administration approval for any of our products and begincommercializing those products in the United States, our operations may be subject to various federal and state fraud and abuselaws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician payment sunshinelaws and regulations. These laws may impact, among other things, our potential sales, marketing and education programs. In addition,we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business.The laws that may affect our ability to operate include:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offeringor paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash orin kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation ofany good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, suchas the Medicare and Medicaid programs;       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which may be pursuedthrough civil whistleblower or qui tam actions, impose criminal and civil penalties against individuals or entities for knowinglypresenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or otherthird-party payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to paymoney to the federal government;       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●federal criminal statutes created through the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”),which prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit programor obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, orunder the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowinglyand willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statementsin connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their respective implementingregulations, which imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses aswell as their respective business associates that perform services for them that involve the use, or disclosure of, individuallyidentifiable health information, relating to the privacy, security and transmission of individually identifiable health information;       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●the federal transparency requirements under The Patient Protection and Affordable Care Act and the Health Care and Education ReconciliationAct, enacted into law in the United States in March 2010 (known collectively as the “Affordable Care Act”), includingthe provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devicesand medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Programto report annually to the U.S. Department of Health and Human Services information related to payments or other transfers of valuemade to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediatefamily members; and       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●state and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activitiesthat potentially harm consumers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we may be subject to state and non-U.S. equivalents of each of the healthcare laws described above, among others, some of whichmay be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-KickbackStatute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmentalpayors, including private insurers. Several states impose marketing restrictions or require medical device companies to make marketingor price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements, and ifwe fail to comply with an applicable state law requirement we could be subject to penalties.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 40; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           40           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Becauseof the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that someof our future business activities could be subject to challenge under one or more of such laws. In addition, healthcare reformlegislation has strengthened these laws. For example, the Affordable Care Act, among other things, amended the intent requirementof the federal Anti-Kickback and criminal healthcare fraud statutes. As a result of such amendment, a person or entity no longerneeds to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. Moreover,the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violationof the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Violationsof fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspensionfrom federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government.In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the False Claims Actas well, as under the false claims laws of several states.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Effortsto ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involvesubstantial costs. It is possible that governmental authorities will conclude that our existing or future business practices donot comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare lawsand regulations. Any such actions instituted against us could have a significant adverse impact on our business, including theimposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participationin Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and futureearnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our resultsof operations. Even if we are successful in defending against such actions, we may nonetheless be subject to substantial costs,reputational harm and adverse effects on our ability to operate our business. In addition, the approval and commercializationof any of our products outside the United States will also likely subject us to non-U.S. equivalents of the healthcare laws mentionedabove, among other non-U.S. laws.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifany of our employees, agents, or the physicians or other providers or entities with whom we expect to do business are found tohave violated applicable laws, we may be subject to criminal, civil or administrative sanctions, including exclusions from governmentfunded healthcare programs, or, if we are not subject to such actions, we may suffer reputational harm for conducting businesswith persons or entities found, or accused of being, in violation of such laws. Any such events could adversely affect our abilityto operate our business and our results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be exposed to product liability claims and insurance may not be sufficient to cover these claims.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay be exposed to product liability claims based on the use of any of our products, or products incorporating our licensed technology,in the market or clinical trials. We may also be exposed to product liability claims based on the sale of any products under developmentfollowing the receipt of regulatory approval. Product liability claims could be asserted directly by consumers, health-care providersor others. We have obtained product liability insurance coverage; however such insurance may not provide full coverage for ourfuture clinical trials, products to be sold, and other aspects of our business. Insurance coverage is becoming increasingly expensiveand we may not be able to maintain current coverage, or expand our insurance coverage to include future clinical trials or thesale of new products or existing products in new territories, at a reasonable cost or in sufficient amounts to protect againstlosses due to product liability or at all. A successful product liability claim or series of claims brought against us could resultin judgments, fines, damages and liabilities that could have a material adverse effect on our business, financial condition andresults of operations. We may incur significant expense investigating and defending these claims, even if they do not result inliability. Moreover, even if no judgments, fines, damages or liabilities are imposed on us, our reputation could suffer, whichcould have a material adverse effect on our business, financial condition and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 41; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           41           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Evenif one or more of our products are approved by the FDA, we may fail to obtain an adequate level of reimbursement for our productsby third party payors, such that there may be no commercially viable markets for our products or the markets may be much smallerthan expected.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theavailability and levels of reimbursement by governmental and other third-party payors affect the market for our products. Theefficacy, safety, performance and cost-effectiveness of our products and of any competing products are factors that may impactthe availability and level of reimbursement. Reimbursement and healthcare payment systems in international markets vary significantlyby country and include both government sponsored healthcare and private insurance. To obtain reimbursement or pricing approvalin some countries, we may be required to produce clinical data, which may involve one or more clinical trials that compares thecost-effectiveness of our products to other available therapies. We may not obtain international reimbursement or pricing approvalsin a timely manner, if at all. Our failure to receive international reimbursement or pricing approvals would negatively impactmarket acceptance of our products in the international markets in which those approvals are sought.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webelieve that future reimbursement may be subject to increased restrictions both in the U.S. and in international markets. Thereis increasing pressure by governments worldwide to contain healthcare costs by limiting both the coverage and the level of reimbursementfor therapeutic products and by refusing, in some cases, to provide any coverage for products that have not been approved by therelevant regulatory agency. Future legislation, regulation or reimbursement policies of third party payors may adversely affectthe demand for our products and limit our ability to sell our products on a profitable basis. In addition, third party payorscontinually attempt to contain or reduce the costs of healthcare by challenging the prices charged for healthcare products andservices. If reimbursement for our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactorylevels, market acceptance of our products would be impaired, and future revenues, if any, would be adversely affected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Inthe United States and European Union, our business could be significantly and adversely affected by healthcare reform initiativesand/or other legislation or judicial interpretations of existing or future healthcare laws and/or regulations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheAffordable Care Act, signed into law in the United States in March 2010, contains certain provisions which are not yet fully implementedand for which it is unclear what the full impact will be from the legislation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thelegislation also focuses on a number of provisions aimed at improving quality, broadening access to health insurance, enhancingremedies for fraud and abuse, adding transparency requirements, and decreasing healthcare costs, among others. Uncertainties remainregarding what negative unintended consequences these provisions will have on patient access to new technologies, pricing andthe market for our products, and the healthcare industry in general. The Affordable Care Act includes provisions affecting theMedicare program, such as value-based payment programs, increased funding of comparative effectiveness research, reduced hospitalpayments for avoidable readmissions and hospital acquired conditions, and pilot programs to evaluate alternative payment methodologiesthat promote care coordination (such as bundled physician and hospital payments). Additionally, the provisions include a reductionin the annual rate of inflation for hospitals which started in 2011 and the establishment of an independent payment advisory boardto recommend ways of reducing the rate of growth in Medicare spending. Any reduction in reimbursement from Medicare or other governmentprograms may result in a similar reduction in payments from private payors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Someof the provisions of the Affordable Care Act have yet to be implemented, and there have been judicial and Congressional challengesto certain aspects of the Affordable Care Act, as well as recent efforts by the Trump presidential administration to repeal orreplace certain aspects of the Affordable Care Act. Since January 2017, the president has signed two executive orders and otherdirectives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent someof the requirements for health insurance mandated by the Affordable Care Act. Congress has considered legislation that would repealor repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation,two bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The TCJA includesa provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Acton certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred toas the “individual mandate.” Additionally, the 2020 federal spending package permanently eliminated, effective January1, 2020, the Affordable Care Act-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medicaldevice tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, among otherthings, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare plans, commonlyreferred to as the “donut hole.” In July 2018, the Centers for Medicare and Medicaid Services, or CMS, published afinal rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and healthinsurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigationregarding the method CMS uses to determine this risk adjustment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 42; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           42           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheTrump administration has also taken executive actions to undermine or delay implementation of the Affordable Care Act. Since January2017, the President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the AffordableCare Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. One ExecutiveOrder directs federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptionsfrom, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal or regulatory burdenon states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The secondExecutive Order terminates the cost-sharing subsidies that reimburse insurers under the Affordable Care Act. Several state AttorneysGeneral filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was deniedby a federal judge in California on October 25, 2017. In addition, CMS has recently proposed regulations that would give statesgreater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effectof relaxing the essential health benefits required under the Affordable Care Act for plans sold through such marketplaces. Further,on June 14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay morethan $12 billion in Affordable Care Act risk corridor payments to third-party payors who argued such payments were owed to them,which the U.S. Supreme Court is reviewing during its current term. The effects of this gap in reimbursement on third-party payors,the viability of the Affordable Care Act marketplace, providers, and potentially our business, are not yet known.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wecannot predict the impact that such actions against the Affordable Care Act will have on our business, and there is uncertaintyas to what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the United States,or the effect of any future legislation or regulation. Furthermore, we cannot predict what actions the Biden administration willimplement in connection with the Affordable Care Act. However, it is possible that such initiatives could have an adverse effecton our ability to obtain approval and/or successfully commercialize products in the United States in the future. For example,any changes that reduce, or impede the ability to obtain, reimbursement for the type of products we intend to commercialize inthe United States (or our products more specifically, if approved) or reduce medical procedure volumes could adversely affectour business plan to introduce our products in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InMay 2017, the European parliament and the council of the European Union approved a new Medical Device Regulation (EU) 2017/745which has replaced the existing medical device directives (93/42/EEC). The new regulations will come into full application inMay 2020. The new Medical Device Regulation imposes stricter requirements on medical device manufacturers and strengthens thesupervising competences of the competent authorities of European Union member states, the notified bodies and the authorized representatives.As a result, the new legislation can prevent or delay the CE marking and certifications of our products under development or impactour ability to modify our currently CE marked products on a timely basis. If we fail to comply with the modified regulation andrequirements it can adversely affect our business, operating results and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         GeneralRisk Factors        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe are unable to obtain and maintain intellectual property protection covering our products, others may be able to make, use orsell our products, which would adversely affect our revenue.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourability to protect our products from unauthorized or infringing use by third parties depends substantially on our ability to obtainand maintain valid and enforceable patents. Similarly, the ability to protect our trademark rights might be important to preventthird party counterfeiters from selling poor quality goods using our designated trademarks, and trade names. Due to evolving legalstandards relating to the patentability, validity and enforceability of patents covering medical devices and pharmaceutical inventionsand the scope of claims made under these patents, our ability to enforce patents is uncertain and involves complex legal and factualquestions. Accordingly, rights under any of our pending patent applications and patents may not provide us with commercially meaningfulprotection for our products or may not afford a commercial advantage against our competitors or their competitive products orprocesses. In addition, patents may not be issued from any pending or future patent applications owned by or licensed to us, andmoreover, patents that may be issued to us now or in the future may later be found invalid or unenforceable. Further, even ifvalid and enforceable, our patents may not be sufficiently broad to prevent others from marketing products like ours, despiteour patent rights.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 43; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           43           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thevalidity of our patent claims depends, in part, on whether prior art references exist that describe or render obvious our inventionsas of the filing date of our patent applications. We may not have identified all prior art, such as U.S. and foreign patents orpublished applications or published scientific literature, that could adversely affect the patentability of our issued patentsand pending patent applications. For example, some material references may be in a foreign language and may not be uncovered duringexamination of our patent applications. Additionally, patent applications in the United States are maintained in confidence forup to 18 months after their filing. In some cases, however, patent applications remain confidential in the U.S. Patent and TrademarkOffice for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries outside the U.S. are nottypically published until at least 18 months from their first filing date. Similarly, publication of discoveries in the scientificor patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, orthe first to file patent applications relating to, our stent technologies. Third parties may initiate adversarial proceedings,known as an inter-partes review (IPR) in the U.S. Patent and Trademark Office to challenge the validity of our patent claims inthe United States. It is possible that we may be unsuccessful in the proceedings, resulting in a loss of some portion or all ofour patent rights in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, statutory differences in patentable subject matter among jurisdictions may limit the protection we can obtain on certainof the technologies we develop. The laws of some foreign jurisdictions do not offer the same protection to, or may make it moredifficult to effect the enforcement of, proprietary rights as in the United States. This risk may be exacerbated if we move ourmanufacturing to certain countries in Asia. If we encounter such difficulties or are otherwise precluded from effectively protectingour intellectual property rights in any foreign jurisdictions, our business prospects could be substantially harmed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourinitiation of litigation to enforce our patent rights may prompt adversaries in such litigation to challenge the validity, scope,ownership, or enforceability of our patents. Third parties can sometimes bring challenges against a patent holder to resolve theseissues, as well. If a court decides that any such patents are not valid, not enforceable, not wholly owned by us, or are of alimited scope, we may not have the right to stop others from using our inventions. Also, even if our patent rights are determinedby a court to be valid and enforceable, they may not be sufficiently broad to prevent others from marketing products similar toours or designing around our patents, despite our patent rights, nor do they provide us with freedom to operate unimpeded by thepatent and other intellectual property rights of others that may cover our products. We may be forced into litigation to upholdthe validity of the claims in our patent portfolio, as well as our ownership rights to such intellectual property, and litigationis often an uncertain and costly process.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay not be able to protect our trade secrets adequately. Although we rely on non-disclosure and confidentiality agreements withemployees, consultants and other parties to protect, in part, trade secrets and other proprietary technology, these agreementsmay be breached and we may not have adequate remedies for such breach. Moreover, others may independently develop equivalent proprietaryinformation, and third parties may otherwise gain access to our trade secrets and proprietary knowledge. Any disclosure of confidentialdata into the public domain or to third parties could allow competitors to learn our trade secrets and use the information incompetition against us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weface risks associated with litigation and claims.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues includingcontract disputes, employment actions, employee benefits, taxes, environmental, health and safety, fraud and abuse, personal injuryand product liability matters.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourbusiness and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe ordinary course of our business, we collect and store sensitive data, including intellectual property, research data, ourproprietary business information and that of our suppliers, technical information about our products, clinical trial plans andemployee records. Similarly, our third-party providers possess certain of our sensitive data and confidential information. Thesecure maintenance of this information is critical to our operations and business strategy. Despite the implementation of securitymeasures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,malware, ransomware, cyber fraud, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacksor cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systemsinside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, includingby computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophisticationof attempted attacks and intrusions from around the world have increased. Any such breach could compromise our networks and theinformation stored there could be accessed, publicly disclosed, encrypted, lost or stolen. Any such access, inappropriate disclosureof confidential or proprietary information or other loss of information, including our data being breached at third-party providers,could result in legal claims or proceedings, liability or financial loss under laws that protect the privacy of personal information,disruption of our operations or our product development programs and damage to our reputation, which could adversely affect ourbusiness. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delaysin our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 44; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           44           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Theloss of key members of our senior management team or our inability to attract and retain highly skilled scientists and laboratoryand field personnel could adversely affect our business         </i>        </b>        .       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedepend on the skills, experience and performance of our senior management and research personnel. The efforts of each of thesepersons will be critical to us as we continue to further develop our products, increase sales and broaden our product offerings.If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing ourtechnologies and implementing our business strategies. Our research and development programs and commercial laboratory operationsdepend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retainqualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses.There can be no assurance that we will be able to attract and retain necessary personnel on acceptable terms given the intensecompetition among medical device, biotechnology, pharmaceutical and healthcare companies, universities and non-profit researchinstitutions for experienced management, scientists, researchers, sales and marketing and manufacturing personnel. If we are unableto attract, retain and motivate our key personnel to accomplish our business objectives, we may experience constraints that willadversely affect our ability to support our operations, and our results of operations may be materially and adversely affected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare an international business, and we are exposed to various global and local risks that could have a material adverse effecton our financial condition and results of operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weoperate globally and develop and market products in multiple countries. Consequently, we face complex legal and regulatory requirementsin multiple jurisdictions, which may expose us to certain financial and other risks. In addition, we are subject to global eventsbeyond our control, including war, public health crises, such as pandemics and epidemics, trade disputes and other internationalevents. Any of these changes could have a material adverse effect on our reputation, business, financial condition or resultsof operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forexample, the COVID-19 pandemic has significantly affected most of the world, including each of our primary markets, resultingin, among other things, government-imposed quarantines and other public health safety measures. At this point, the extent to whichthe coronavirus may impact our business cannot be estimated; however, procedures with CGuard EPS, which are generally scheduledor non-emergency procedures, have seen extended postponements since the onset of COVID-19 as hospitals shift resources to patientsaffected by the coronavirus, and it is highly plausible that this trend will continue. The extent to which COVID-19 impacts ourresults will depend on future developments, which are highly uncertain and cannot be predicted, including new information whichmay emerge concerning the severity of the coronavirus, the actions to contain COVID-19 or treat its impact, the efficacy and scaleof the various vaccines currently deployed across the world, among others. Moreover, COVID-19 has had indeterminable adverse effectson general commercial activity and the world economy, and our business and results of operations could be adversely affected tothe extent that COVID-19 or any other epidemic continues to harm the global economy generally.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Internationalsales and operations are subject to a variety of risks, including:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           foreign    currency exchange rate fluctuations;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           greater    difficulty in staffing and managing foreign operations;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           greater    risk of uncollectible accounts;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           longer    collection cycles;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           logistical    and communications challenges;          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="vertical-align: top">         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           potential    adverse changes in laws and regulatory practices, including export license requirements, trade barriers, tariffs and tax laws;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 45; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           45           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           changes    in labor conditions;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           burdens    and costs of compliance with a variety of foreign laws;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           political    and economic instability;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    escalation of hostilities in Israel, which could impair our ability to manufacture our products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           increases    in duties and taxation;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           foreign    tax laws and potential increased costs associated with overlapping tax structures;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           greater    difficulty in protecting intellectual property;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    risk of third party disputes over ownership of intellectual property and infringement of third party intellectual property    by our products; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           general    economic and political conditions in these foreign markets.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Internationalmarkets are also affected by economic pressure to contain reimbursement levels and healthcare costs. Profitability from internationaloperations may be limited by risks and uncertainties related to regional economic conditions, regulatory and reimbursement approvals,competing products, infrastructure development, intellectual property rights protection and our ability to implement our overallbusiness strategy. We expect these risks will increase as we pursue our strategy to expand operations into new geographic markets.We may not succeed in developing and implementing effective policies and strategies in each location where we conduct business.Any failure to do so may harm our business, results of operations and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Operating in Israel        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weanticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues willbe generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect a substantial portion of our revenues will be generated in U.S. dollars and Euros, while a significant portion of our expenses,principally salaries and related personnel expenses, is paid in New Israeli Shekels, or NIS. As a result, we are exposed to therisk that the rate of inflation in Israel will exceed the rate of devaluation of the NIS in relation to the Euro or the U.S. dollar,or that the timing of this devaluation will lag behind inflation in Israel. Because inflation has the effect of increasing thedollar and Euro costs of our operations, it would therefore have an adverse effect on our dollar-measured results of operations.The value of the NIS, against the Euro, the U.S. dollar, and other currencies may fluctuate and is affected by, among other things,changes in Israel’s political and economic conditions. Any significant revaluation of the NIS may materially and adverselyaffect our cash flows, revenues and financial condition. Fluctuations in the NIS exchange rate, or even the appearance of instabilityin such exchange rate, could adversely affect our ability to operate our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifthere are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a materialadverse effect on our business relationships and profitability.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourexecutive office, sole manufacturing facility and certain of our key personnel are located in Israel. Our business is directlyaffected by the political, economic and military conditions in Israel and its neighbors. Since the establishment of the Stateof Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors. A state of hostility, varyingin degree and intensity, has caused security and economic problems in Israel. Although Israel has entered into peace treatieswith Egypt and Jordan, and various agreements with the Palestinian Authority, there has been a marked increase in violence, civilunrest and hostility, including armed clashes, between the State of Israel and the Palestinians since September 2000. The establishmentin 2006 of a government in the Gaza Strip by representatives of the Hamas militant group has created heightened unrest and uncertaintyin the region. In mid-2006, Israel engaged in an armed conflict with Hezbollah, a Shiite Islamist militia group based in Lebanon,and in June 2007, there was an escalation in violence in the Gaza Strip. From December 2008 through January 2009 and again inNovember and December 2012, Israel engaged in an armed conflict with Hamas, which involved missile strikes against civilian targetsin various parts of Israel and negatively affected business conditions in Israel. In July and August 2014, an armed conflict tookplace between Israel and Hamas, and since September 2015, there has been an increase in sporadic terror incidents conducted byindividuals not necessarily associated with terror organizations. Political uprisings and social unrest in Syria are affectingits political stability, which has led to the deterioration of the political relationship between Syria and Israel and have raisednew concerns regarding security in the region and the potential for armed conflict. Similar civil unrest and political turbulenceis currently ongoing in many countries in the region. The continued political instability and hostilities between Israel and itsneighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect ouroperations in Israel and adversely affect the market price of our shares of common stock. In addition, several countries restrictdoing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailmentof trade between Israel and its present trading partners could adversely affect our business, financial condition and resultsof operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 46; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           46           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, many of our officers or key employees may be called to active duty at any time under emergency circumstances for extendedperiods of time. See “— Our operations could be disrupted as a result of the obligation of certain of our personnelresiding in Israel to perform military service.”       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ouroperations could be disrupted as a result of the obligation of certain of our personnel residing in Israel to perform militaryservice.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Manyof our officers and employees reside in Israel and may be required to perform annual military reserve duty. Currently, all maleadult citizens and permanent residents of Israel under the age of 40 (or older, depending on their position with the Israeli DefenseForces reserves), unless exempt, are obligated to perform military reserve duty annually and are subject to being called to activeduty at any time under emergency circumstances. Our operations could be disrupted by the absence for a significant period of oneor more of our key officers and employees due to military service. Any such disruption could have a material adverse effect onour business, results of operations and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay not be able to enforce covenants not-to-compete under current Israeli law.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave non-competition agreements with most of our employees, many of which are governed by Israeli law. These agreements generallyprohibit our employees from competing with us or working for our competitors for a specified period following termination of theiremployment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all,to enforce those provisions for relatively brief periods of time in restricted geographical areas and only when the employee hasunique value specific to that employer’s business and not just regarding the professional development of the employee. Anysuch inability to enforce non-compete covenants may cause us to lose any competitive advantage resulting from advantages providedto us by such confidential information.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which couldresult in litigation and adversely affect our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asignificant portion of our intellectual property has been developed by our Israeli employees in the course of their employmentfor us. Under the Israeli Patent Law, 5727-1967 (the “Israeli Patent Law”), inventions conceived by an employee duringthe term and as part of the scope of his or her employment with a company are regarded as “service inventions,” whichbelong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights.The Israeli Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensationand Royalties Committee (the “C&amp;R Committee”), a body constituted under the Israeli Patent Law, shall determinewhether the employee is entitled to remuneration for his inventions. The C&amp;R Committee (decisions of which have been upheldby the Israeli Supreme Court) has held that employees may be entitled to remuneration for their service inventions despite havingspecifically waived any such rights. We generally enter into intellectual property assignment agreements with our employees pursuantto which such employees assign to us all rights to any inventions created in the scope of their employment or engagement withus. Although our employees have agreed to assign to us service invention rights and have specifically waived their right to receiveany special remuneration for such assignment beyond their regular salary and benefits, we may face claims demanding remunerationin consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remunerationor royalties to our current or former employees, or be forced to litigate such claims, which could negatively affect our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 47; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           47           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Itmay be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themajority of our assets other than cash are located outside the U.S. In addition, certain of our officers are nationals and/orresidents of countries other than the U.S., and all or a substantial portion of such persons’ assets are located outsidethe U.S. As a result, it may be difficult for investors to enforce within the United States any judgments obtained against usor any of our non-U.S. officers, including judgments predicated upon the civil liability provisions of the securities laws ofthe U.S. or any state thereof. Additionally, it may be difficult to assert U.S. securities law claims in actions originally institutedoutside of the U.S. Israeli courts may refuse to hear a U.S. securities law claim because Israeli courts may not be the most appropriateforums in which to bring such a claim. Even if an Israeli court agrees to hear a claim, it may determine that the Israeli law,and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, certain content of applicable U.S.law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still begoverned by the Israeli law. Consequently, you may be effectively prevented from pursuing remedies under U.S. federal and statesecurities laws against us or any of our non-U.S. directors or officers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thetax benefits that are currently available to us under Israeli law require us to satisfy specified conditions. If we fail to satisfythese conditions, we may be required to pay increased taxes and would likely be denied these benefits in the future.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InspireMDLtd. has been granted a “Beneficiary Enterprise” status by the Investment Center in the Israeli Ministry of IndustryTrade and Labor, and we are therefore eligible for tax benefits under the Israeli Law for the Encouragement of Capital Investments,1959. The main benefit is a two-year exemption from corporate tax, commencing when we begin to generate net income derived fromthe beneficiary activities in facilities located in Israel, and a reduced corporate tax rate for an additional five to eight years,depending on the level of foreign investment in each year. In addition, under the January 1, 2011 amendment to the Israeli Lawfor the Encouragement of Capital Investments, 1959, a uniform corporate tax rate of 16% applies to all qualifying income of “PreferredEnterprise,” which we may be able to apply as an alternative tax benefit.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetax benefits available to a Beneficiary Enterprise or a Preferred Enterprise are dependent upon the fulfillment of conditionsstipulated under the Israeli Law for the Encouragement of Capital Investments, 1959 and its regulations, as amended, which include,among other things, maintaining our manufacturing facilities in Israel. If we fail to comply with these conditions, in whole orin part, the tax benefits could be cancelled and we could be required to refund any tax benefits that we received in the past.If we are no longer eligible for these tax benefits, our Israeli taxable income would be subject to regular Israeli corporatetax rates. The standard corporate tax rate for Israeli companies in 2019 and thereafter is 23% of taxable income. The terminationor reduction of these tax benefits would increase our tax liability, which would reduce our profits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to losing eligibility for tax benefits currently available to us under Israeli law, if we do not maintain our manufacturingfacilities in Israel, we will not be able to realize certain tax credits and deferred tax assets, if any, including any net operatinglosses to offset against future profits.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thetax benefits available to Beneficiary Enterprises may be reduced or eliminated in the future. This would likely increase our taxliability.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheIsraeli government may reduce or eliminate in the future tax benefits available to Beneficiary Enterprises and Preferred Enterprises.Our Beneficiary Enterprise status and the resulting tax benefits may not continue in the future at their current levels or atany level. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-yearexemption and eight years of reduced tax rate can only be used within the next twelve years. The Company elected the year 2007,as a year of election and 2011 as an additional year of election. The 2011 amendment regarding Preferred Enterprise may not beapplicable to us or may not fully compensate us for the change. The termination or reduction of these tax benefits would likelyincrease our tax liability. The amount, if any, by which our tax liability would increase will depend upon the rate of any taxincrease, the amount of any tax benefit reduction, and the amount of any taxable income that we may earn in the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 48; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           48           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Our Common Stock, Preferred Stock and Warrants        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Themarket prices of our common stock and our publicly traded warrants are subject to fluctuation and have been and may continue tobe volatile, which could result in substantial losses for investors.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themarket prices of our common stock and our Series A Warrants and Series B Warrants have been and are likely to continue to be highlyvolatile and could fluctuate widely in response to various factors, many of which are beyond our control, including the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           technological    innovations or new products and services by us or our competitors;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           additions    or departures of key personnel;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to execute our business plan;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           operating    results that fall below expectations;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           loss    of any strategic relationship;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           industry    developments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           economic,    political and other external factors; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           period-to-period    fluctuations in our financial results.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelatedto the operating performance of particular companies. These market fluctuations may also significantly affect the market pricesof our common stock and our publicly traded warrants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          OurPlanned Reverse Split may not result in a proportional increase in the per share price of our common stock.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weintend to effect the Planned Reverse Split (as defined below) with the primary intent of increasing the price of our common stockin order to meet the initial listing requirements of the Nasdaq Capital Market and, secondly, to provide appropriate flexibilitywe require to issue shares in the event that our board of directors determines that it is necessary or appropriate to (i) raiseadditional capital through the sale of equity securities, (ii) enter into strategic business transactions, (iii) provide equityincentives to directors, officers and employees pursuant to equity compensation plans or (iv) further other corporate purposes.The effect of the Planned Reverse Split on the market price for our common stock cannot be accurately predicted. In particular,we cannot assure you that the proportionate increase in the price of our common stock immediately after the Planned Reverse Splitfrom the price for shares of our common stock immediately before the Planned Reverse Split will be maintained for us to meet theinitial listing requirements of the Nasdaq Capital Market or that the such market prices will be maintained for a substantialperiod of time. It is not uncommon for the market price of a company’s common stock to decline in the period following areverse stock split. If the market price of our common stock declines following the Planned Reverse Split, the percentage declinemay be greater than would occur in the absence of the Planned Reverse Split. The market price of our common stock may also beaffected by other factors which may be unrelated to the Planned Reverse Split or the number of shares outstanding.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Moreover,because some investors may view the Planned Reverse Split negatively, we cannot assure you that the Planned Reverse Split willnot adversely impact the market price of our common stock. Accordingly, our total market capitalization after the Planned ReverseSplit may be lower than the market capitalization before the Planned Reverse Split.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourcommon stock could be delisted from the NYSE American if we fail to meet the NYSE American’s stockholders’ equitycontinued listing standards. Our ability to publicly or privately sell equity securities and the liquidity of our common stockcould be adversely affected if we are delisted from the NYSE American.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 7, 2019, we received a notice indicating that we do not meet certain of the NYSE American’s continued listing standardsas set forth in Part 10 of the Company Guide. Specifically, we were not in compliance with Section 1003(a)(iii) of the CompanyGuide because we reported stockholders’ equity of less than $6 million as of June 30, 2019, and had net losses in our fivemost recent fiscal years ended December 31, 2018. As a result, we had become subject to the procedures and requirements of Section1009 of the Company Guide. On August 25, 2019, we submitted a plan of compliance to NYSE Regulation, addressing how we intendto regain compliance with Section 1003(a)(iii) of the Company Guide by August 7, 2020, and on October 11, 2019, NYSE Americanaccepted our plan. On August 7, 2020, the NYSE American approved such plan and, accordingly and as of such date, we are compliantwith all of the NYSE American LLC continued listing standards set forth in Part 10 of the NYSE American Company Guide. In particular,we regained compliance with the continued listing requirement under NYSE American Company Guide Section 1003(a)(iii).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 49; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           49           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NotwithstandingNYSE American’s approval of our plan, there is no assurance that we will be able to maintain compliance with Section 1003(a)(iii)of the Company Guide moving forward. Additionally, we will be subject to ongoing review for compliance with NYSE American requirementsand there can be no assurance that we will continue to remain in compliance with this standard.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe event the NYSE American issues a future notice and recommences proceedings against us, delisting from NYSE American wouldadversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantlyaffect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock.Delisting could also have additional negative ramifications, including the potential loss of confidence by employees, the lossof institutional investor interest and fewer business development opportunities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Alow trading price could lead the NYSE American to take actions toward delisting our common stock, including immediately suspendingtrading in our common stock.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJanuary 7, 2019, we received notification from the NYSE American that our shares of common stock have been selling for a low priceper share for a substantial period of time. Pursuant to Section 1003(f)(v) of the Company Guide, the NYSE American could takeaction to delist our common stock in the event that our common stock trades at levels viewed as abnormally low for a substantialperiod of time. NYSE American advised us that if our common stock trades below $0.20 on a 30 trading day average, then it willbe considered non-compliant with NYSE American’s low selling price requirement. On March 29, 2019, we effected a 1-for-50reverse stock split of our common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifin the future we fall below the continued listing criterion of a minimum average share price of $0.20 over a 30-day trading period,our common stock will be subject to immediate review by NYSE American. There can be no assurance that the market price of ourcommon stock will remain above the levels viewed as abnormally low for a substantial period of time. In any event, other factorsunrelated to the number of shares of our common stock outstanding, such as negative financial or operational results, could adverselyaffect the market price of our common stock, causing it to fall below the level viewed as a low selling price for a substantialperiod of time, and lead the NYSE American to immediately suspend trading in our common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, the NYSE American has advised us that its policy is to immediately suspend trading in shares of, and commence delistingprocedures with respect to, a listed company if the market price of its shares falls below $0.06 per share at any time duringthe trading day.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare subject to financial reporting and other requirements that place significant demands on our resources.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirementsof Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectivenessof our internal controls over financial reporting. These reporting and other obligations place significant demands on our management,administrative, operational, internal audit and accounting resources. Any failure to maintain effective internal controls couldhave a material adverse effect on our business, operating results and stock price. Moreover, effective internal control is necessaryfor us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud,we may not be able to manage our business as effectively as we would if an effective control environment existed, and our businessand reputation with investors may be harmed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 50; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           50           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thereare inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theongoing internal control provisions of Section 404 of the Sarbanes-Oxley Act of 2002 require us to identify material weaknessesin internal control over financial reporting, which is a process to provide reasonable assurance regarding the reliability offinancial reporting for external purposes in accordance with accounting principles generally accepted in the United States. Ourmanagement, including our chief executive officer and chief financial officer, does not expect that our internal controls anddisclosure controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provideonly reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the design of a controlsystem must reflect the fact that there are resource constraints and the benefit of controls must be relative to their costs.Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that allcontrol issues and instances of fraud, if any, in our company have been detected. These inherent limitations include the realitiesthat judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Further, controlscan be circumvented by individual acts of some persons, by collusion of two or more persons, or by management override of thecontrols. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events,and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.Over time, a control may be inadequate because of changes in conditions, such as growth of the company or increased transactionvolume, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effectivecontrol system, misstatements due to error or fraud may occur and not be detected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, discovery and disclosure of a material weakness, by definition, could have a material adverse impact on our financialstatements. Such an occurrence could discourage certain customers or suppliers from doing business with us and adversely affecthow our stock trades. This could in turn negatively affect our ability to access equity markets for capital.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Delawarelaw and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts thatstockholders may consider favorable.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourboard of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferencesand other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preferenceover our common stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adverselyaffect the voting or other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferencesand designations of the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even ifthat change of control might benefit our stockholders. In addition, we are subject to Section 203 of the Delaware General CorporationLaw. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” withan “interested stockholder” for a period of three years after the date of the transaction in which the person becamean interested stockholder, unless (i) prior to the date of the transaction, the board of directors of the corporation approvedeither the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; (ii)the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced,excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and alsoofficers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentiallywhether shares held subject to the plan will be tendered in a tender or exchange offer; or (iii) on or subsequent to the dateof the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders,and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned bythe interested stockholder.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Section203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourageattempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a priceabove the prevailing market price.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave a staggered board of directors, which could impede an attempt to acquire us or remove our management.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourboard of directors is divided into three classes, each of which serves for a staggered term of three years. This division of ourboard of directors could have the effect of impeding an attempt to take over our company or change or remove management, sinceonly one class will be elected annually. Thus, only approximately one-third of the existing board of directors could be replacedat any election of directors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 51; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           51           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Asa former shell company, resales of shares of our restricted common stock in reliance on Rule 144 of the Securities Act are subjectto the requirements of Rule 144(i).         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wepreviously were a “shell company” and, as such, sales of our securities pursuant to Rule 144 under the SecuritiesAct of 1933, as amended, cannot be made unless, among other things, at the time of a proposed sale, we are subject to the reportingrequirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, and have filed all reports and other materialsrequired to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 as amended, as applicable, during the preceding12 months, other than Form 8-K reports. Because, as a former shell company, the reporting requirements of Rule 144(i) will applyregardless of holding period, restrictive legends on certificates for shares of our common stock cannot be removed except in connectionwith an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registrationrequirements of, the Securities Act of 1933, as amended. Because our unregistered securities cannot be sold pursuant to Rule 144unless we continue to meet such requirements, any unregistered securities we issue will have limited liquidity unless we continueto comply with such requirements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifsecurities and/or industry analysts fail to continue publishing research about our business, if they change their recommendationsadversely or if our results of operations do not meet their expectations, our stock price and trading volume could decline.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetrading market for our common stock will be influenced by the research and reports that industry or securities analysts publishabout us or our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly,we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Inaddition, it is likely that in some future period our operating results will be below the expectations of securities analystsor investors. If one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet theirexpectations, our stock price could decline.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Aspectsof the tax treatment of the securities may be uncertain.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetax treatment of our preferred stock and our warrants is uncertain and may vary depending upon whether you are an individual ora legal entity and whether or not you are domiciled in the United States. In the event you are a non-U.S. investor, you shouldconsult your tax advisors as to the consequences, under the tax laws of the country where you are resident for tax purposes, ofacquiring, holding and disposing of our preferred stock and our warrants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         SPECIALNOTE REGARDING FORWARD-LOOKING STATEMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ThisAnnual Report on Form 10-K contains “forward-looking statements,” which include information relating to future events,future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,”“will,” “should,” “could,” “would,” “predicts,” “potential,”“continue,” “expects,” “anticipates,” “future,” “intends,” “plans,”“believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-lookingstatements. Forward-looking statements should not be read as a guarantee of future performance or results and will probably notbe accurate indications of when such performance or results will be achieved. Forward-looking statements are based on informationwe have when those statements are made or our management’s good faith belief as of that time with respect to future events,and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressedin or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limitedto:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or    difficult to obtain and could dilute out stockholders’ ownership interests;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    impact of the COVID-19 pandemic on our manufacturing, sales, business plan and the global economy;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           negative    clinical trial results or lengthy product delays in key markets;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to maintain compliance with the NYSE American listing standards;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to generate revenues from our products and obtain and maintain regulatory approvals for our products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    ability to adequately protect our intellectual property;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 52; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           52           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and    to increase production as necessary;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology    is an attractive alternative to other procedures and products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           market    acceptance of our products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    inability to secure and maintain regulatory approvals for the sale of our products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           intense    competition in our industry, with competitors having substantially greater financial, technological, research and development,    regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           entry    of new competitors and products and potential technological obsolescence of our products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           inability    to carry out research, development and commercialization plans;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           loss    of a key customer or supplier;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           technical    problems with our research and products and potential product liability claims;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           product    malfunctions;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           price    increases for supplies and components;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           adverse    economic conditions;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           insufficient    or inadequate reimbursement by governmental and other third-party payers for our products;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           our    efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           adverse    federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations,    logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability    in each jurisdiction;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    escalation of hostilities in Israel, which could impair our ability to manufacture our products; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           loss    or retirement of key executives and research scientists.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theforegoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained hereinor risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-lookingstatements. You should review carefully the risks and uncertainties described under the heading “Item 1A. Risk Factors”in this Annual Report on Form 10-K for a discussion of these and other risks that relate to our business and investing in sharesof our common stock. The forward-looking statements contained in this Annual Report on Form 10-K are expressly qualified in theirentirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement toreflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipatedevents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_004">         </a>         Item1B. Unresolved Staff Comments.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_005">         </a>         Item2. Properties.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourheadquarters are located in Tel Aviv, Israel, where we lease a 1,050 square meter office and manufacturing facility that has thecapacity to manufacture and assemble 1,200 stents per month, based upon the production schedule of one shift per day. We believethat our current facility is sufficient to meet anticipated future demand by adding additional shifts to our current productionschedule.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 53; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           53           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_006">         </a>         Item3. Legal Proceedings.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Fromtime to time, we may be involved in litigation that arises through the normal course of business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 10, 2019, Bosti Trading Ltd., a former distributor in Russia (“Bosti”), filed suit with the Tel Aviv-Jaffa DistrictCourt in Israel, or the Complaint, against InspireMD Ltd., claiming damages for alleged breaches by InspireMD Ltd. under the DistributionAgreement, dated May 26, 2011, between Bosti and InspireMD Ltd., in connection with the voluntary field corrective action of ourMGuard Prime EPS we initiated in 2014. Bosti claimed that Bosti and its Russian subsidiary returned 1,830 units of MGuard PrimeEPS to InspireMD Ltd. upon initiation of the voluntary filed action, and, since the Russian Ministry of Health prohibited distributionof MGuard Prime EPS on August 28, 2014, and did not approve distribution MGuard Prime EPS until September 20, 2016, Bosti wasentitled to recover from InspireMD Ltd. €1,830,000 (which is approximately $2 million), the amount Bosti was due to receivefrom its Russian subsidiary, or alternatively, €1,024,000 (which is approximately $1.1 million), the amount Bosti paid toInspireMD Ltd., for the MGuard Prime EPS returned to InspireMD Ltd. On January 31, 2020, InspireMD Ltd. filed with court its letterof defense in which it contested this matter vigorously. On January 21, 2021, we executed a Mediation Agreement with Bosti andInspireMD Ltd., pursuant to which Bosti agreed to release the Company from all claims stated in the Complaint in exchange fora payment of $580,000, which we paid on January 25, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof the date of this filing, we are not aware of any other material legal proceedings to which we or any of our subsidiaries isa party or to which any of our property is subject, nor are we aware of any such threatened or pending litigation or any suchproceedings known to be contemplated by governmental authorities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare not aware of any material proceedings in which any of our directors, officers or affiliates or any registered or beneficialstockholder of more than 5% of our common stock, or any associate of any of the foregoing, is a party adverse to or has a materialinterest adverse to, us or any of our subsidiaries.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_007">         </a>         Item4. Mine Safety Disclosures.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_008">         </a>         PARTII        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_009">         </a>         Item5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcommon stock has been quoted on the NYSE American since April 11, 2013 under the symbol “NSPR.” The last reportedsales price of our common stock on the NYSE American on March 5, 2021, was $0.73 per share. As of March 8, 2021, therewere approximately 267 holders of record of our common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weplan to effect a reverse split of our common stock, or the Planned Reverse Split, and, accordingly, share amounts, per share data,share prices, exercise prices or conversion rates in this annual report on Form 10-K are subject to change following the effectivenessof the Planned Reverse Split. The Planned Reverse Split will not change the authorized number of shares or the par value of ourcommon stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         DividendPolicy        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe past, we have not declared or paid cash dividends on our common stock. We do not intend to pay cash dividends in the future,rather, we intend to retain future earnings, if any, to fund the operation and expansion of our business and for general corporatepurposes.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theholders of Series C Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by our boardof directors. However, holders of our Series C Preferred Stock are entitled to receive dividends on shares of Series C PreferredStock equal (on an as-if-converted-to-common-stock basis, and without giving effect for such purposes to the 4.99% or 9.99% beneficialownership limitation, as applicable) to and in the same form as dividends actually paid on shares of the common stock when suchdividends are specifically declared by our board of directors. We are not obligated to redeem or repurchase any shares of SeriesC Preferred Stock. Shares of Series C Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinkingfund or analogous fund provision.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 54; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           54           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_010">         </a>         Item6. Selected Financial Data.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_011">         </a>         Item7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Thefollowing discussion and analysis of our financial condition and results of operations should be read in conjunction with theaccompanying consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Overview        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare a medical device company focusing on the development and commercialization of our proprietary MicroNet™ stent platformtechnology for the treatment of complex vascular and coronary disease. A stent is an expandable “scaffold-like” device,usually constructed of a metallic material, that is inserted into an artery to expand the inside passage and improve blood flow.Our MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurCGuard™ carotid embolic prevention system (“CGuard EPS”) combines MicroNet and a self-expandable nitinol stentin a single device for use in carotid artery applications. Our CGuard EPS received CE mark approval in the European Union in March2013 and was fully launched in Europe in September 2015. Subsequently, we launched CGuard EPS in Russia and certain countriesin Latin America and Asia, including India. In September 2020, we launched CGuard EPS in Brazil after receiving regulatory approvalin July 2020 and, as discussed below, on February 3, 2021 we executed a distribution agreement with Chinese partners for the purposeof expanding our presence in China. Currently, we are seeking strategic partners for a potential launch of CGuard EPS in Japan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 8, 2020, we received approval from the FDA of our Investigation Device Exemption (“IDE”), thereby allowingus to proceed with a pivotal study of our CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patientsin the United States. CARENET-lll is a prospective, multicenter, single-arm, pivotal study to evaluate the safety and efficacyof the CGuard™ Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patientsundergoing carotid artery stenting. The trial will enroll approximately 315 subjects in a maximum of 40 study sites located inthe United States. Additional sites in Europe may also participate in the study, contributing a maximum of ~50% of the total enrollees.The primary endpoint of the study will be the composite of the following: incidence of the following major adverse events: death(all- cause mortality), all stroke, and myocardial infarction (DSMI) through 30-days post-index procedure, based on the clinicalevents committee (CEC) adjudication or ipsilateral stroke from 31-365 day follow-up, based on Clinical Events Committee (CEC)adjudication.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we intend to continue to invest in current and future potential product and manufacturing enhancements for CGuard EPS that areexpected to reduce cost of goods and/or provide the best-in-class performing delivery system. In furtherance of our strategy thatfocuses on establishing CGuard EPS as a viable alternative to vascular surgery, we are exploring adding new delivery systems andaccessory solutions for procedural protection to our portfolio.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconsider the addressable market for our CGuard EPS to be individuals with diagnosed, symptomatic high-grade carotid artery stenosis(HGCS, ≥70% occlusion) for whom intervention is preferable to medical (drug) therapy. This group includes not only carotidartery stenting patients but also individuals undergoing carotid endarterectomy, as the two approaches compete for the same patientpopulation. Assuming full penetration of the intervention caseload by CGuard EPS, we estimate that the addressable market forCGuard EPS was approximately $1.0 billion in 2017 (source: Health Research International 2017 Results of Update Report on GlobalCarotid Stenting Procedures and Markets by Major Geography and Addressable Markets).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 55; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           55           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OurMGuard™ Prime™ embolic protection system (“MGuard Prime EPS”) is marketed for use in patients with acutecoronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypasssurgery). MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent. MGuard Prime EPS received CE markapproval in the European Union in October 2010 for improving luminal diameter and providing embolic protection. However, as aresult of a shift in industry preferences away from bare-metal stents in favor of drug-eluting (drug-coated) stents, in 2014 wedecided to curtail further development of this product in order to focus on the development of a drug-eluting stent product, MGuardDES™. Due to limited resources, however, our efforts have been limited to testing drug-eluting stents manufactured by potentialpartners for compatibility with MicroNet and seeking to incorporate MicroNet onto a drug-eluting stent manufactured by a potentialpartner. The FDA has clarified that the primary mode of action for drug-eluting cardiovascular stents, which are regulated ascombination products, is that of the device component and has assigned the FDA Center for Devices and Radiological Health (CDRH)primary responsibility for premarket review and regulation, providing some clarity about what to expect regarding the regulatoryframework related to the development of MGuard DES™.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wealso intend to develop a pipeline of other products and additional applications by leveraging our MicroNet technology to new applicationsto improve peripheral vascular and neurovascular procedures, such as the treatment of the superficial femoral artery disease,vascular disease below the knee and neurovascular stenting to seal aneurysms in the brain.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Presently,none of our products may be sold or marketed in the United States.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CriticalAccounting Policies        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weprepared our consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).U.S. GAAP represents a comprehensive set of accounting and disclosure rules and requirements, and applying these rules and requirementsrequires management judgments and estimates including, in certain circumstances, choices between acceptable U.S. GAAP alternatives.The following is a discussion of our most critical accounting policies, judgments and uncertainties that are inherent in our applicationof U.S. GAAP.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Useof estimates         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepreparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions thataffect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of thefinancial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differfrom those estimates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 56; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           56           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asapplicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations,assessing the likelihood of exercise of options to extend the lease term and legal contingencies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Concentrationof credit risk and allowance for doubtful accounts         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Financialinstruments that may potentially subject us to a concentration of credit risk consist of cash and cash equivalents, which aredeposited in major financially sound institutions in the United States, Israel and Germany, and trade accounts receivable. Ourtrade accounts receivable is derived from revenues earned from customers from various countries. We perform ongoing credit evaluationsof our customers’ financial condition and, generally, require no collateral from customers. We also have a credit insurancepolicy for some customers. We maintain an allowance for doubtful accounts receivable based upon the expected ability to collectthe accounts receivable. We review our allowance for doubtful accounts quarterly by assessing individual accounts receivable andall other balances based on historical collection experience and an economic risk assessment. If we determine that a specificcustomer is unable to meet its financial obligations to us, we provide an allowance for credit losses to reduce the receivableto the amount management reasonably believes will be collected, which is netted against “Accounts receivable — Trade”.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Inventory         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inventoriesare stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. Ourinventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. We regularlyevaluate the carrying value of our inventories and when, based on such evaluation, factors indicate that impairment has occurred,we impair the inventories’ carrying value.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Leases         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InFebruary 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognizeleases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use (ROU)model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as financeor operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.We adopted the new standard on January 1, 2019 using the modified retrospective transition method and we did not restate comparativeperiods. The new standard provides a number of optional practical expedients in transition. We have elected the ‘packageof practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification,lease classification and initial direct costs for leases entered into prior to adoption of Topic 842.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we did not separate lease and non-lease components for all of our leases. We elected the short-term lease recognition exemptionfor all leases that qualify. This means, for those leases that qualify, we will not recognize ROU assets or lease liabilities,and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition.Instead, we will continue to recognize the lease payments for those leases in profit or loss on a straight-line basis over thelease term.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 57; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           57           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thenew standard had a material effect on our financial statements. The most significant effects of adoption relate to (1) the recognitionof new operating lease ROU assets and operating lease liabilities on its balance sheet for real estate operating; and (2) providingsignificant new disclosures about its leasing activities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Uponadoption, we recognized additional operating lease liabilities, of approximately $1.2 million based on the present value of theremaining lease payments under current leasing standards for existing operating leases. We also recognized corresponding ROU assetsof approximately $1.2 million. Lease terms may include options to extend or terminate the lease when we are reasonably certainthat the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. Our leases may includevariable payments based on measures that include changes in price index which are expensed as incurred and presented as operatingexpense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Revenuerecognition         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Acontract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform theirrespective obligations, 2) we can identify each party’s rights regarding the distinct goods or services to be transferred(“Performance Obligations”), 3) we can determine the transaction price for the goods or services to be transferred,4) the contract has commercial substance and 5) it is probable that we will collect the consideration to which it will be entitledin exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of considerationto which we expect to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excludingsales taxes.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Revenuefrom sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once wehave a present right to payment, legal title, and risk and rewards of ownership are obtained by the customer. This occurs whenproducts are shipped.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Werecognize the incremental costs of obtaining contracts as an expense since the amortization period of the assets that we otherwisewould have recognized is one year or less. The costs are recorded under selling and marketing expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Werecognize revenue net of value added tax (VAT).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Researchand development costs         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Researchand development costs are charged to the statement of operations as incurred.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Share-basedcompensation         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Employeeoption awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-basedawards is estimated using the Black-Scholes valuation model and expensed over the requisite service period, net of estimated forfeitures.We elected to account for forfeitures as they occur.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weelected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using theaccelerated multiple option approach.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Fairvalue measurement         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemeasure fair value and disclose fair value measurements for financial assets and liabilities. Fair value is based on the pricethat would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participantsat the measurement date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fairvalue into three broad levels, which are described below:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Level1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fairvalue hierarchy gives the highest priority to Level 1 inputs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 58; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           58           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Level2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Level3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priorityto Level 3 inputs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indetermining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservableinputs to the extent possible and consider counterparty credit risk in our assessment of fair value.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Resultsof Operations        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Twelvemonths ended December 31, 2020 compared to the twelve months ended December 31, 2019         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Revenues        </i>        .For the twelve months ended December 31, 2020, revenue decreased by $1,236,000, or 33.2%, to $2,485,000, from $3,721,000 duringthe twelve months ended December 31, 2019. Revenues were negatively impacted by 15.6% due to a settlement of litigation with aformer distributor in 2014 (see Part I, Item 3. “Legal Proceedings”) under which we agreed to pay them $580,000. UnderUS GAAP we were required to charge that amount against revenues. In addition, there was a 15.3% decrease in sales volume of CGuardEPS from $3,265,000 during the twelve months ended December 31, 2019, to $2,764,000 during the twelve months ended December 31,2020, mainly due to the postponement of procedures with CGuard EPS, which are generally scheduled or nonemergency procedures,as hospitals shifted resources to patients affected by COVID-19. There was a 34.0% decrease in sales volume of MGuard Prime EPSfrom $456,000 during the twelve months ended December 31, 2019, to $301,000 during the twelve months ended December 31, 2020,mainly due to the postponement of procedures with MGuard Prime EPS, which are generally scheduled or nonemergency procedures,as hospitals shifted resources to patients affected by COVID-19.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Withrespect to regions, the decrease in revenue was primarily attributable to a decrease of $985,000 in revenue from sales made inEurope (driven by $580,000 decrease of the settlement with a former distributor and $329,000 decrease of CGuard EPS and $76,000decrease of MGuard Prime EPS for the reasons discussed in the paragraph above), a decrease of $131,000 in revenue of CGuard fromsales made in Asia due to the same COVID-19-related factor, as well as a decrease of $79,000 in revenue from sales made in LatinAmerica (primarily driven by a $68,000 decrease of MGuard Prime EPS sales due to the same COVID-19-related factor).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         GrossProfit.        </i>        For the twelve months ended December 31, 2020, gross profit (revenue less cost of revenues) decreased by 89.0%, or$673,000, to $83,000, compared to a $756,000 for the same period in 2019. This decrease in gross profit resulted from the impactof the $580,000 settlement with our former distributor in 2014 as well as $198,000 decrease in revenues less the related materialand labor costs (as mentioned above). This decrease was partially offset by a decrease of $69,000 in expenses related to upgradesmade to our production facilities during the year ended December 31, 2019, which did not reoccur during the year ended December31, 2020 and a decrease of $36,000 in miscellaneous expenses during the year ended December 31, 2020. Gross margin (gross profitsas a percentage of revenue) decreased to 3.3% during the year ended December 31, 2020 from 20.3% during the year ended December31, 2019, driven mainly by a negative effect on gross margin of 18.3% due to the settlement with our former distributor offsetby a 1.3% gross margin increase due to the upgrades made to our production facilities and miscellaneous expenses as mentionedabove.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Researchand Development Expenses        </i>        . For the twelve months ended December 31, 2020, research and development expenses decreased by 24.4%,or $721,000, to $2,233,000, from $2,954,000 during the twelve months ended December 31, 2020. This decrease resulted primarilyfrom: a decrease of $861,000 in clinical expenses associated with CGuard EPS, mainly related to the IDE approval process, of whichan approval from the FDA was received on September 8, 2020, a decrease of $354,000 due to settlement expenses that were paid toa former service provider pursuant to a settlement agreement during the year ended December 31, 2019, which did not reoccur duringthe year ended December 31, 2020, and a decrease of $136,000 in quality assurance and regulatory expenses related to the developmentof various projects during the year ended December 31, 2019, which were significantly reduced during the year ended December 31,2020. These decreases were partially offset by an increase of $531,000 in development expenses related to the CGuard EPS new deliverysystem and accessory solutions and an increase of $99,000 in miscellaneous expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 59; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           59           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Sellingand Marketing Expenses        </i>        . For the twelve months ended December 31, 2020, selling and marketing expenses decreased by 12.2%,or $293,000, to $2,103,000, from $2,396,000 during the twelve months ended December 31, 2020. This decrease resulted primarilyfrom: a decrease in travel expenses of $268,000 in light of restrictions imposed by governments worldwide in order to mitigatethe spread of COVID-19 during year ended December 31, 2020, a decrease of $129,000 in promotional expenses, primarily relatedto having already built our social media infrastructure in 2019, and a decrease of $88,000 in miscellaneous expenses. These decreaseswere partially offset by an increase of $192,000 in compensation expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Generaland Administrative Expenses        </i>        . For the twelve months ended December 31, 2020, general and administrative expenses increasedby 17.3%, or $905,000, to $6,127,000, from $5,222,000 during the twelve months ended December 31, 2020. This increase resultedprimarily from an increase of $400,000 due to expenses for the settlement agreement with the underwriter of our prior offeringspaid during the year ended December 31, 2020, an increase in our Directors’ and Officers’ Liability Insurance expensesof $249,000 partially due to recent economic effects on the insurance industry caused by the COVID-19 pandemic, an increase inregulatory expenses of $177,000 required for new regulatory standards and an increase of $79,000 in miscellaneous expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         FinancialExpenses        </i>        . For the twelve months ended December 31, 2020, financial expenses decreased by 20.0%, or $40,000, to $160,000, from$200,000 during the year ended December 31, 2020. The decrease in financial expenses primarily resulted from a decrease of $66,000in financial expenses related to changes in exchange rates, offset, in part, by an increase of $26,000 in miscellaneous expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         TaxExpenses (Income).        </i>        For the twelve months ended December 31, 2020, tax expenses decreased by $20,000 compared to the twelvemonths ended December 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         NetLoss        </i>        . Our net loss increased by $504,000, or 5.0%, to $10,544,000, for the twelve months ended December 31, 2020, from $10,040,000during the twelve months ended December 31, 2019. The increase in net loss resulted primarily from a decrease of $673,000 in grossprofit, offset, in part, by a decrease of $109,000 in operating expenses, a decrease of $40,000 in financial expenses and a decreaseof $20,000 in tax expenses.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Liquidityand Capital Resources        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof the date of issuance of the consolidated financial statements, we have the ability to fund our planned operations for at leastthe next 12 months. However, we expect to continue incurring losses and negative cash flows from operations until our products(primarily CGuard™ EPS) reach commercial profitability. Therefore, in order to fund our operations until such time thatwe can generate substantial revenues, we may need to raise additional funds.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         EquityFinancings        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnApril 8, 2019, we closed an underwritten public offering of 486,957 shares of our common stock at a price to the public of $5.00per share. We received net proceeds of approximately $2.0 million from the offering, after deducting underwriter discounts andcommissions and offering expenses payable by us. As a result of such offering, the conversion price for each of our Series B PreferredStock and Series C Preferred was reduced to $5.00 per share. In connection with this public offering, on April 12, 2019, the underwriterpartially exercised its over-allotment option and purchased an additional 12,393 shares of our common stock at a price to thepublic of $5.00 per share. We received net proceeds of approximately $47,000 from the exercise of the over-allotment option.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 24, 2019, we closed an underwritten public offering of (i) 539,000 common units, with each common unit being comprisedof one share of our common stock and one Series E Warrant to purchase one share of common stock and (ii) 2,238,777 pre-fundedunits, with each pre-funded unit being comprised of one pre-funded warrant to purchase one share of common stock and one SeriesE Warrant. In connection with this public offering, the underwriter partially exercised its over-allotment option and purchasedan additional 194,444 Series E Warrants to purchase 194,444 shares of common stock. The offering price to the public was $1.80per common unit and $1.79 per pre-funded unit. The net proceeds to us from the offering of common units and pre-funded units andthe exercise of the underwriter’s option to purchase 194,444 additional Series E Warrants to purchase an aggregate of 194,444shares of common stock was approximately $4.2 million, excluding the proceeds, if any, from the exercise of the Series E Warrantsand the pre-funded warrants sold in the offering, and after deducting underwriting discounts and commissions and payment of otherestimated expenses associated with the offering that were payable by us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 60; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           60           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJune 5, 2020, we closed an underwritten public offering of (i) 7,635,800 Units, with each Unit being comprised of one share ofour common stock, par value $0.0001 per share, and one Series F warrant to purchase one share of common stock, and (ii) 14,586,400Pre-Funded Units, with each Pre-Funded Unit being comprised of one Pre-Funded Warrant to purchase one share of common stock andone Series F Warrant. In connection with this public offering, the underwriter exercised the option practically in full, for 3,333,300shares of common stock and 3,333,300 Series F Warrants. The offering price to the public was $0.45 per Unit and $0.449 per Pre-FundedUnit. Our net proceeds from the offering and the exercise of the underwriter’s over-allotment option were approximately$10.7 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated withthe offering, but excluding the proceeds, if any, from the exercise of Series F Warrants and the Pre-Funded Warrants sold in theoffering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 28, 2020, we entered into a Sales Agreement with A.G.P. in connection with the ATM Facility. Any shares to be offered andsold under the Sales Agreement will be issued and sold pursuant to the Company’s Registration Statement on Form S-3 (FileNo. 333-223130), filed with the SEC on February 21, 2018 and the prospectus supplement thereto filed with the SEC on July 28,2020, by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the SecuritiesAct of 1933, as amended, or if specified by us, by any other method permitted by law. On January 11, 2021, we increased the aggregateamount of our shares of common stock that may be sold under the Sales Agreement from $9,300,000 to $10,382,954, and, as a result,utilized and sold the maximum amount allowable under the ATM Facility, which resulted in an aggregate amount of $10,381,958.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 8, 2021, we closed an underwritten public offering of 29,032,258 units, with each such unit being comprised of one shareof our common stock, par value $0.0001 per share, and one Series G Warrant to purchase one-half of one share of common stock.The offering price to the public was $0.62 per unit. The Series G Warrants were immediately exercisable at a price of $0.682 pershare, subject to adjustment in certain circumstances, and expire five years from the date of issuance. We also granted the underwriterof the offering an option to purchase an additional 4,354,838 shares of common stock and Series G Warrants to purchase 2,177,419shares of common stock, which the underwriter exercised in full. In connection with the offering, we granted to the underwritera compensation warrant to purchase up to 1,669,355 shares of common stock with an exercise price of $0.682 per share and whichare exercisable for five years from February 3, 2021, the date of effectiveness of the registration statement filed in connectionwith the offering. Our net proceeds from the offering, after giving effect to the exercise of the underwriter’s over-allotmentoption, were approximately $18.9 million, after deducting underwriting discounts and commissions and payment of other estimatedexpenses associated with the offering, but excluding the proceeds, if any, from the exercise of Series G Warrants sold in theoffering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnFebruary 3, 2021, we entered into a Distribution Agreement with three China-based partners and on the same day, we entered intoan investment transaction with QIDI, which included (i) an SPA, pursuant to which QIDI agreed to invest $900,000 in exchange forshares of our common stock at a purchase price of $0.6708 per share, and (ii) an IRA, whereby QIDI was provided certain customaryregistration rights, including a commitment by us to file a registration statement with the SEC on Form S-1 or Form S-3 and havesuch registration statement become effective not later than 150 days following the closing of the transactions under the SPA.The transaction closed on February 5, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Twelvemonths ended December 31, 2020 compared to the twelve months ended December 31, 2019         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         General        </i>        .At December 31, 2020, we had cash and cash equivalents of $12,645,000, as compared to $5,514,000 as of December 31, 2019. We havehistorically met our cash needs through a combination of issuing new shares, borrowing activities and product sales. Our cashrequirements are generally for research and development, marketing and sales activities, finance and administrative cost, capitalexpenditures and general working capital.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe twelve months ended December 31, 2020, net cash used in our operating activities decreased by $729,000 to $9,081,000, from$9,810,000 during the same period in 2019. The primary reason for the decrease in cash used in our operating activities was adecrease of $1,293,000 in payments for third party related expenses and for professional services (primarily due to productionrelated payments and payments related to IDE application process), offset, in part, by an increase of $408,000 in salary and bonuspayments from $5,690,000 in the twelve months ended December 31, 2019 to $6,098,000 during the same period in 2020 and a decreaseof $156,000 in payments received from customers to $3,447,000 during the twelve months ended December 31, 2020, from $3,603,000during the same period in 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 61; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           61           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Cashused by our investing activities was $187,000 during the twelve months ended December 31, 2020 compared to $387,000 during thetwelve months ended December 31, 2019. The primary reasons for the decrease in cash used by our investing activities was a decreaseof $218,000 in net payments made for purchase of property, plant and equipment to $66,000 during the twelve months ended December31, 2020, from $284,000 during the same period in 2019, offset, in part, by an increase of $18,000 in cash deposited to employeefunds, to $121,000 during the twelve months ended December 31, 2020, from $103,000 during the same period in 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Cashprovided by financing activities for the twelve months December 31, 2020 was $16,395,000, compared to $6,335,000 during the sameperiod in 2019. The principal sources of the cash provided by financing activities during the twelve months ended December 31,2020 were our June 2020 public offering of common stock, pre-funded warrants and warrants, the subsequent exercise of the pre-fundedwarrants sold in the offering, as well as exercise of warrants F and Unit Purchase Options, that resulted in approximately $12,169,000of aggregate net proceeds, and funds received from our ATM Facility that resulted in approximately $ 4,126,000 of aggregate netproceeds. The principal source of the cash provided by financing activities during the twelve months ended December 31, 2019,was the funds received from our December 2019 public offering of common stock, pre-funded warrants and warrants, as well as thesubsequent exercise of the pre-funded warrants sold in the offering, that resulted in approximately $4,289,000 of aggregate netproceeds, and funds received from our April 2019 public offering of common stock that resulted in approximately $2,046,000 ofaggregate net proceeds.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, our current assets exceeded our current liabilities by a multiple of 4.1. Current assets increased by $7,529,000during the period and current liabilities increased by $590,000 during the period. As a result, our working capital increasedby $6,939,000 to $11,634,000 as of December 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OffBalance Sheet Arrangements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other relationships withunconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financialcondition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 62; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           62           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RecentAccounting Pronouncements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJune 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on FinancialInstruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognitionand at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit lossesexpected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonableand supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326),Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of thisamendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies andall other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additionaltime to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscalyears beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permittedto defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15,2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and is adoptingthe deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effectadjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoptionof ASU 2016-13 on its consolidated financial statements, but does not believe the adoption of this standard will have a materialimpact on its consolidated financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FactorsThat May Affect Future Operations        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Webelieve that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors,including the cyclical nature of the ordering patterns of our distributors, timing of regulatory approvals, the implementationof various phases of our clinical trials and manufacturing efficiencies due to the learning curve of utilizing new materials andequipment. Our operating results could also be impacted by a weakening of the Euro and strengthening of the NIS, both againstthe U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursementpolicies pertaining to our products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_012">         </a>         Item7A. Quantitative and Qualitative Disclosures About Market Risk.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_013">         </a>         Item8. Financial Statements and Supplementary Data.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing financial statements are included as part of this Report (See Item 15):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_001">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Report of Kesselman &amp; Kesselman, Independent Registered Public Accounting Firm           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_002">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Balance Sheets as of December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_003">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_005">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Changes in Equity for the Years Ended December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_006">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_007">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Notes to Consolidated Financial Statements           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_014">         </a>         Item9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 63; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           63           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_015">         </a>         Item9A. Controls and Procedures.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Management’sConclusions Regarding Effectiveness of Disclosure Controls and Procedures        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconducted an evaluation of the effectiveness of our “disclosure controls and procedures”, as defined by Rules 13a-15(e)and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of December 31, 2020, the end of the period covered by thisAnnual Report on Form 10-K. The disclosure controls and procedures evaluation was done under the supervision and with the participationof management, including our chief executive officer and chief financial officer. There are inherent limitations to the effectivenessof any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only providereasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chieffinancial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance levelas of December 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Management’sReport on Internal Control Over Financial Reporting        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Managementis responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f)and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designedto provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financialstatements for external reporting purposes in accordance with generally accepted accounting principles.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Becauseof its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projectionsof any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk thatcontrols may become inadequate because of changes in conditions or that the degree of compliance with the policies or proceduresmay deteriorate over time.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Management,including our chief executive officer and our chief financial officer, assessed the effectiveness of our internal control overfinancial reporting as of December 31, 2020. In making this assessment, management used the criteria set forth by the Committeeof Sponsoring Organizations of the Treadway Commission in        <i>         Internal Control—Integrated Framework 2013        </i>        . Based on itsassessment and those criteria, management has concluded that we maintained effective internal control over financial reportingas of December 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Changesin Internal Control over Financial Reporting        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Therehave been no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2020 that havematerially affected, or are reasonably likely to materially affect, our internal control over financial reporting.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_016">         </a>         Item9B. Other Information.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_017">         </a>         PARTIII        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_018">         </a>         Item10. Directors, Executive Officers and Corporate Governance.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         ExecutiveOfficers and Directors        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table sets forth information regarding our executive officers and the members of our board of directors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Name           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Age           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 67%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Position           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Marvin    Slosman          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           President,    Chief Executive Officer and Director          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Craig    Shore          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           59          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chief    Financial Officer, Chief Administrative Officer, Secretary and Treasurer          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Michael    Berman           <sup>            (1)(2)           </sup>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           63          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Campbell    Rogers, M.D.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           59          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Paul    Stuka           <sup>            (1)(2)(3)           </sup>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           66          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chairman    of the Board of Directors          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Thomas    J. Kester           <sup>            (1)(3)           </sup>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           74          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Gary    Roubin, M.D.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           72          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Member    of our audit committee          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Member    of our nominating and corporate governance committee          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Member    of our compensation committee          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 64; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           64           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourdirectors hold office until the earlier of their death, resignation or removal by stockholders or until their successors havebeen qualified. Our directors are divided into three classes. Paul Stuka and Gary Roubin are our Class 1 directors, with theirterms of office to expire at our 2021 annual meeting of stockholders. Michael Berman and Campbell Rogers, M.D. are our Class 2directors, with their terms of office to expire at our 2022 annual meeting of stockholders. Marvin Slosman and Thomas J. Kesterare our Class 3 directors, with their terms of office to expire at our 2023 annual meeting of stockholders. At each annual meetingof stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expireat the third succeeding annual meeting of stockholders after their election, with each director to hold office until his or hersuccessor shall have been duly elected and qualified.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourofficers hold office until the earlier of their death, resignation or removal by our board of directors or until their successorshave been selected. They serve at the pleasure of our board of directors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         MarvinSlosman        </b>        has served as our president, chief executive officer and director since January 1, 2020. Mr. Slosman has served aschief operating officer for MEDCURA Inc. from May 2019 to December 2019. From September 2017 to September 2019, Mr. Slosman servedas a Business Consultant, overseeing international commercial strategy and market development, at Integra Life Sciences, a leadinginnovator in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. From 2010 to 2014 Mr. Slosmanserved as President of Itamar Medical, Inc., a medical technology company focused on cardiovascular and sleep diagnostics. Mr.Slosman also served as chief executive officer of Ovalum Vascular Ltd. from 2008 to 2010. Mr. Slosman’s qualifications toserve on the board of directors of the Company include his significant experience in senior management positions of leading medicaldevice companies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CraigShore        </b>        has served as our chief financial officer, secretary and treasurer since March 31, 2011 and as our chief administrativeofficer since May 3, 2013. In addition, from November 10, 2010 through March 31, 2011, Mr. Shore served as InspireMD Ltd.’svice president of business development. Mr. Shore has over 30 years of experience in financial management in the United States,Europe and Israel for companies such as Pfizer Pharmaceuticals, Bristol Myers Squibb and General Electric. His experience includesraising capital both in the private and public markets. Mr. Shore graduated with honors and received a B.Sc. in Finance from PennsylvaniaState University and an M.B.A. from George Washington University.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         MichaelBerman        </b>        has served as our director since February 7, 2013. Mr. Berman is a medical device entrepreneur who works with high-potentialdevelopment and early-stage commercial companies. From 2005 to 2012, when the company was sold to Boston Scientific, Mr. Bermanwas a co-founder and the chairman of BridgePoint Medical, Inc., which developed technology to treat coronary and peripheral vascularchronic total occlusions. Mr. Berman was also a member of the board of Lutonix, Inc. from 2007 until 2011, when the company wassold to C.R. Bard, Inc. From 2011 to 2019, Mr. Berman served as a co-founder and director of Rebiotix Inc., a company developingan innovative treatment for C Diff colitis. Rebiotix was sold to Ferring Pharmaceuticals in 2018. From 2014 till 2018 Mr. Bermanserved as a director Mazor Robotics, a company pioneering Spinal Robotic Surgery. Mr. Berman has served (i) since 2011 as an advisorto, and since 2012 as a director of, Cardiosonic, Inc., a company developing a system for hypertension reduction via renal denervation,(ii) since 2005 as a director of PharmaCentra, LLC, which creates customizable marketing programs that help pharmaceutical companiescommunicate with physicians and patients, (iii) since 2018 as a Director of STMedical, a medical device company that has developeda temporary stent for the treatment of chronic sinusitis, (iv) since 2019 as a director of CardiacSense Inc, a medical devicecompany that has developed a smart watch vital sign monitor, (v) since 2017 as a Director of Owlytics Healthcare, (vi) since 2013as a Director of ClearCut Inc., a medical device company that has developed an MRI system for tumor margin assessment, (vii) since2013 as a director of PulmOne Ltd., a medical device company developing an innovative Pulmonary Function Testing system, (viii)since 2014 as a director of SoniVie, a medical device company, (ix) since 2014 as a venture partner at RiverVest Ventures and(x) since 2017 as a Director of Truleaf Medical. Mr. Berman brings to the board his extensive executive and entrepreneurial experiencesin the field of medical devices and vascular intervention, which should assist in strengthening and advancing our strategic focus.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 65; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           65           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CampbellRogers, M.D.        </b>        has served as a director since September 3, 2013. Dr. Rogers is the executive vice president and chief medicalofficer of HeartFlow, Inc., a cardiovascular diagnostics company, since March 2012. Prior to joining HeartFlow, Inc., he was thechief scientific officer and global head of research and development at Cordis Corporation (currently part of Cardinal Health,Inc.), Johnson &amp; Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior tothat, he was associate professor of medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences andTechnology and director of the cardiac catheterization and experimental cardiovascular interventional laboratories at Brighamand Women’s Hospital. He served as principal investigator for numerous interventional cardiology device, diagnostic, andpharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and othercardiovascular diseases and was the recipient of research grant awards from the National Institute of Health and the AmericanHeart Association. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr. Rogers’ qualificationsto serve on the board include his significant experience in cardiovascular devices, as well as his familiarity with the operationsof medical device companies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         PaulStuka        </b>        has served as a director since August 8, 2011 and has served as our chairman since June 2, 2017. Mr. Stuka has servedas the managing member of Osiris Partners, LLC, an investment fund, since 2000. Prior to forming Osiris Partners, LLC, Mr. Stuka,with 40 years of experience in the investment industry, was a managing director of Longwood Partners, managing small cap institutionalaccounts. In 1995, Mr. Stuka joined State Street Research and Management as manager of its Market Neutral and Mid Cap Growth Funds.From 1986 to 1994, Mr. Stuka served as the general partner of Stuka Associates, where he managed a U.S.-based investment partnership.Mr. Stuka began his career in 1980 as an analyst at Fidelity Management and Research. As an analyst, Mr. Stuka followed a widearray of industries including healthcare, energy, transportation, and lodging and gaming. Early in his career he became the assistantportfolio manager for three Fidelity Funds, including the Select Healthcare Fund which was recognized as the top performing fundin the United States for the five-year period ending December 31, 1985. Mr. Stuka has been serving as a director of Caliber Imaging&amp; Diagnostics, Inc. (formerly Lucid, Inc.) since June 2013. Mr. Stuka’s qualifications to serve on the board includehis significant strategic and business insight from his years of experience investing in the healthcare industry.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         ThomasJ. Kester        </b>        has served as a director since September 6, 2016. Mr. Kester has been serving as the chief financial officer ofKester Search Group, Inc., a private executive search firm specializing in sales force placement for medical, dental and diagnosticdevice companies, since October 2014. From 2004 to 2010, Mr. Kester served as a director of Orthofix International, NV (NASDAQ:OFIX), a global medical device company. Mr. Kester’s experience includes 28 years at KPMG LLP, including 18 years as anaudit partner, advising public and private companies in connection with annual audit and financings. Mr. Kester’s qualificationsto serve on the board include his significant strategic and business insight from his years of experience auditing global companiesand serving on the boards of several public and not-for-profit organizations. Mr. Kester received his B.S. in mechanical engineeringfrom Cornell University and an M.B.A. from Harvard University.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         GaryRoubin, M.D.        </b>        has served as a director since October 13, 2020. Dr. Roubin cofounded Essential Medical Inc., which has had successin bringing a large bore vascular closure device to world markets and was recently acquired by Teleflex Inc. From 2002 to 2003,Dr. Roubin served as Chief Medical Officer of the Medicines Company during the release of its Angiomax product. From 2003 to 2012,Dr. Roubin served as Department Chairman and Chief of Service of the Lenox Hill Hospital Cardiac and Vascular program in New York.From 1989 to 1997, he served as Chief of Interventional Cardiology at the University of Alabama at Birmingham, to which he joinedin 1989 as Professor of Medicine and Radiology and Director of the Cardiac Catheterization Laboratories and Interventional CardiologySection at the University Hospital. In 2001, Dr. Roubin played a pivotal role in the success of Mednova Inc., which was acquiredby Abbott Vascular, resulting in the introduction and marketing in the U.S. of the top selling carotid embolic protection system(NAV6) and stent system (XACT). In 1987, he developed and placed the world’s first balloon expandable coronary stent. In1984, Dr. Roubin joined Andreas Gruentzig at Emory University to continue his post-doctoral research. He is also acknowledgedfor the development of coronary stenting and the first FDA-approved coronary stent. Dr. Roubin received his M.D. from the Universityof Queensland medical school and his Ph.D. from Sydney University.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Mr.Slosman and Mr. Shore are parties to certain agreements related to their service as executive officers and directors describedunder “Executive Compensation – Agreements with Executive Officers.”       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FamilyRelationships        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave no family relationships amongst our directors and executive officers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 66; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           66           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         BoardCommittees        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourboard of directors has established an audit committee, a nominating and corporate governance committee and a compensation committee,each of which has the composition and responsibilities described below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         AuditCommittee        </i>        . Our audit committee is currently comprised of Messrs. Berman, Stuka and Kester, each of whom our board hasdetermined to be financially literate and qualify as an independent director under Section 803(B)(2) of the NYSE American rules.Mr. Kester is the chairman of our audit committee and qualifies as a financial expert, as defined in Item 407(d)(5)(ii) of RegulationS-K. The audit committee’s duties are to recommend to our board of directors the engagement of independent auditors to auditour financial statements and to review our accounting and auditing principles. The audit committee will review the scope, timingand fees for the annual audit and the results of audit examinations performed by the internal auditors and independent publicaccountants, including their recommendations to improve the system of accounting and internal controls. The audit committee operatesunder a formal charter adopted by the board of directors that governs its duties and conduct. Copies of the charter can be obtainedfree of charge from the Company’s web site, www.inspiremd.com, by contacting the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Nominatingand Corporate Governance Committee        </i>        .  Our nominating and corporate governance committee is currently comprised of Messrs.Berman and Stuka, each of whom qualify as an independent director under Section 803(A) of the NYSE American rules. Mr. Bermanis the chairman of our nominating and corporate governance committee. The nominating and corporate governance committee identifiesand recommends to our board of directors individuals qualified to be director nominees. In addition, the nominating and corporategovernance committee recommends to our board of directors the members and chairman of each board committee who will periodicallyreview and assess our code of business conduct and ethics and our corporate governance guidelines. The nominating and corporategovernance committee also makes recommendations for changes to our code of business conduct and ethics and our corporate governanceguidelines to our board of directors, reviews any other matters related to our corporate governance and oversees the evaluationof our board of directors and our management. The nominating and corporate governance committee operates under a formal charteradopted by the board of directors that governs its duties and conduct. Copies of the charter can be obtained free of charge fromthe Company’s web site, www.inspiremd.com, by contacting the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         CompensationCommittee        </i>        .  Our compensation committee is currently comprised of Messrs. Stuka and Kester, each of whom qualify as anindependent director under Sections 803(A) and 805(c)(1) of the NYSE American rules. Mr. Stuka is the chairman of our compensationcommittee. The compensation committee reviews and approves our salary and benefits policies, including compensation of executiveofficers and directors. The compensation committee also administers our stock option plans and recommends and approves grantsof stock options under such plans. The compensation committee operates under a formal charter adopted by the board of directorsthat governs its duties and conduct. Copies of the charter can be obtained free of charge from the Company’s web site, www.inspiremd.com,by contacting the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Codeof Ethics        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave adopted a code of ethics and business conduct that applies to our officers, directors and employees, including our principalexecutive officer, principal financial officer and principal accounting officer, which is posted on our website at        <i>         www.inspiremd.com        </i>        .We intend to disclose future amendments to certain provisions of the code of ethics, or waivers of such provisions granted toexecutive officers and directors, on this website within four business days following the date of such amendment or waiver.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_019">         </a>         Item11. Executive Compensation.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         SummaryCompensation Table        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetable below sets forth the compensation earned by our named executive officers for the twelve-month period ended December 31,2020 and 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">          Name and Principal Position         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Salary            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Bonus ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Restricted            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stock            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Awards            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($)             <sup>              (1)             </sup>            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Awards            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($)             <sup>              (1)             </sup>            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             All Other            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Compensation            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Total          <br/>          ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 37%; text-align: left">          Marvin Slosman         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          2020         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          366,666         </td>         <td style="width: 1%; text-align: left">          <sup>           (2)          </sup>         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          150,000         </td>         <td style="width: 1%; text-align: left">          <sup>           (3)          </sup>         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          658,981         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          196,162         </td>         <td style="width: 1%; text-align: left">          <sup>           (7)          </sup>         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          10,309         </td>         <td style="width: 1%; text-align: left">          <sup>           (4)          </sup>         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 5%; text-align: right">          1,382,118         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-style: italic; text-align: left">          President and Chief Executive Officer         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Craig Shore         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2020         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          265,004         </td>         <td style="text-align: left">          <sup>           (2)(5)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          138,692         </td>         <td style="text-align: left">          <sup>           (3)(5)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          264,745         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          78,955         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          121,626         </td>         <td style="text-align: left">          <sup>           (6)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          869,022         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-style: italic; text-align: left">          Chief Financial Officer, Secretary and Treasurer         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2019         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          269,758         </td>         <td style="text-align: left">          <sup>           (5)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          60,000         </td>         <td style="text-align: left">          <sup>           (5)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          57,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          114,395         </td>         <td style="text-align: left">          <sup>           (6)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          501,153         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 67; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           67           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           For    awards of stock, the aggregate grant date fair value is computed in accordance with FASB ASC Topic 718. Fair value is based    on the Black-Scholes option pricing model using the fair value of the underlying shares at the measurement date.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           On    April 21, 2020, Mr. Slosman and Mr. Shore each signed waivers in connection with the COVID-19 pandemic and certain cost-reduction    measures, whereby Mr. Slosman’s monthly base salary was reduced from $33,333 to $16,666 and Mr. Shore’s monthly    base salary was reduced from NIS 80,125 to NIS 40,063. On June 10, 2020, following the closing of our underwritten public    offering in June 2020, each of Mr. Slosman’s and Mr. Shore’s monthly base salaries were reinstated to $33,333    and NIS 80,125, respectively, effective as of June 1, 2020.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Cash    bonus awards for the 2020 calendar year were approved by the compensation committee in January 2021.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (4)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mr.    Slosman’s other compensation for 2020 consisted of benefits related to health insurance.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (5)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Compensation    amounts received in non-U.S. currency have been converted into U.S. dollars using the average exchange rate for the applicable    period, except for bonus amounts which have been converted into U.S. dollars using 3.215 NIS per dollar which was the exchange    rate as of December 31, 2020. The average exchange rate for the twelve month period ended December 31, 2020 and 2019 were    3.437 NIS per dollar and 3.564 NIS per dollar, respectively.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (6)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mr.    Shore’s other compensation consisted solely of benefits in the twelve months ended December 31, 2020 and 2019. In each    of the periods reported, Mr. Shore’s benefits included our contributions to his severance, pension, vocational studies    and disability funds, an annual recreation payment, a company car or car allowance and cell phone, and a daily food allowance.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (7)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           182,381    shares of common stock issuable upon the exercise of Restricted Stock Units outside our 2013 Long-Term Incentive Plan.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Agreementswith Executive Officers        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          MarvinSlosman         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnDecember 9, 2019, we entered into an Employment Agreement with Marvin Slosman, which was subsequently amended on December 31,2019 (as amended, the “Slosman Employment Agreement”), pursuant to which Mr. Slosman was appointed as our new chiefexecutive officer and president. Mr. Slosman’s term of employment commenced on January 1, 2020, which will remain in effectfor three years (the “Initial Employment Term”), unless earlier terminated, and to be automatically renewed for successiveone-year terms after the Initial Employment Term. Mr. Slosman was also appointed as a Class 3 director, effective January 1, 2020,with a term expiring on the 2020 annual meeting of our stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asconsideration for his services as chief executive officer, Mr. Slosman will be entitled to receive (i) an annual base salary of$400,000, less applicable payroll deductions and tax (“Base Salary”), which will be reviewed by the Board on an annualbasis for increase; (ii) reimbursement of up to $50,000 for any reasonable and customary, documented out-of-pocket relocationexpenses actually incurred by Mr. Slosman in 2019 or 2020 calendar years, in connection with his relocation to Europe; (iii) annualperformance bonuses in an amount up to 50% percent of the Base Salary, as may be in effect from time to time, for each calendaryear during his employment with us based on the extent to which performance criteria/financial results for the applicable yearhave been met; and (iv) equity awards as of the date of the Slosman Employment Agreement that represent, in the aggregate, 5%of the Company’s issued and outstanding common stock determined on a fully diluted basis as of the date of grant (the “EquityAwards”), with 75% of the Equity Awards being granted as restricted stock units and with the remaining 25% of the EquityAwards being granted as stock options, all of which Equity Awards shall be outside of the 2013 Long-Term Incentive Plan and subjectto terms and conditions of the award agreements entered by Mr. Slosman. In addition, on or before December 31, 2020, Mr. Slosmanshall become eligible to receive an additional grant of equity awards under the 2013 Long-Term Incentive Plan and the applicableaward agreements up to 5% (including the Equity Awards) of the Company’s actual outstanding shares of Common Stock on thedate of grant, provided that the actual amount of the grant shall be based on the achievement of certain performance/financialcriteria as established by the Board after consultation with Mr. Slosman, in its reasonable discretion. For the purposes of theequity award calculation, “fully diluted basis” is defined as the sum of the total shares of common stock then outstanding,the shares of common stock issuable upon the conversion of our then outstanding shares of Series B Convertible Preferred Stockand Series C Convertible Preferred Stock and the shares of common stock issuable upon the exercise of our then outstanding pre-fundedwarrant. On January 2, 2020, pursuant to the Slosman Employment Agreement, we granted Mr. Slosman restricted stock units for 182,381shares and a stock option to purchase 60,794 shares of common stock at $1.10 per share.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 68; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           68           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe event Mr. Slosman voluntarily resigns without good reason, we may, in our sole discretion, shorten the notice period and determinethe date of termination without any obligation to pay Mr. Slosman any additional compensation other than the accrued obligationsand without triggering a termination of Mr. Slosman’s employment without cause. In the event the Slosman Employment Agreementexpires, or we terminate Mr. Slosman’s employment for cause or Mr. Slosman voluntarily resigns without good reason, we shallhave no further liability or obligation to Mr. Slosman under the Slosman Employment Agreement. Notwithstanding the foregoing,in the event that this the Slosman Employment Agreement expires as a result of our decision not to renew the Slosman EmploymentAgreement, we shall, subject to the execution and timely return by Mr. Slosman of a release of claims, pay Mr. Slosman cash paymentstotaling $100,000 in the aggregate, payable in equal installments on our regular pay dates that occur during the period commencingon 60th day following his employment termination date and ending on the last day of the Restricted Period (as defined below);provided, however, that if, at any time within the period commencing on the date that is 3 months prior to the expiration of theInitial Employment Term or the then current renewal term, as applicable, and ending on the date that is 3 months following theexpiration of the Slosman Employment Agreement, we and a third party execute a definitive, written, and binding agreement (a “SaleAgreement”) to enter into certain transactions described therein that, if consummated, would constitute a change in controlin us, then Mr. Slosman’s termination shall be deemed a termination by us without cause or for good reason, as of the datesuch Sale Agreement is executed, provided further that any amounts payable to Mr. Slosman pursuant to such termination shall bereduced by any amounts previously paid to him upon expiration of the Slosman Employment Agreement, termination by us for causeor voluntary resignation by Mr. Slosman without good reason.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        IfMr. Slosman’s employment is terminated (i) by us without cause or (ii) by Mr. Slosman for good reason, then we must payMr. Slosman, (a) a severance pay in an amount equal to twelve months of his then-current base salary, (b) his entire performancebonus for any calendar year for which Mr. Slosman has already worked the entire year but the bonus has yet to be paid, (c) a pro-ratedperformance bonus in an amount equal to the target annual performance bonus to which Mr. Slosman may have been entitled for theyear in which the termination occurs that he would have received had his employment not been terminated during such year. In addition,50% of all unvested stock options, shares of restricted stock, restricted stock units, stock appreciation rights, or similar stock-basedrights granted to Mr. Slosman shall vest and, if applicable, be immediately exercisable and any risk of forfeiture included insuch restricted or other stock grants previously made to Mr. Slosman shall immediately lapse, and Mr. Slosman may exercise anyoutstanding stock options or stock appreciation rights until the earlier of (x) the last date on which such stock options or stockappreciation rights could have been exercised pursuant to the terms of the applicable award agreement, irrespective of Mr. Slosman’stermination of employment; and (y) the date that is two years following his employment termination date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CraigShore         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave been a party to an employment agreement with Craig Shore since November 28, 2010. On May 5, 2014, we entered into an amendedand restated employment agreement with Mr. Shore, which was amended on January 5, 2015, July 25, 2016, and on March 25, 2019.The employment agreement, as amended, has an initial term that ends on December 31, 2020, and will automatically renew for additionalone-year periods on January 1st thereafter unless either party gives the other party written notice of its election not to extendsuch employment at least six months prior to the next January 1st renewal date. If a change in control occurs when less than twofull years remain in the initial term or during any renewal term, the employment agreement will automatically be extended fortwo years from the change in control date and will terminate on the second anniversary of the change in control date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 69; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           69           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe terms of the employment agreement, as amended by the third amendment to the amended and restated employment agreement, datedMarch 25, 2019, Mr. Shore is entitled to an annual base salary of at least $250,000. Such amount may be reduced only as part ofan overall cost reduction program that affects all of our senior executives and does not disproportionately affect Mr. Shore,so long as such reduction does not reduce the base salary to a rate that is less than 90% of the amount set forth above (or 90%of the amount to which it has been increased). The base salary will be reviewed annually by our chief executive officer for increase(but not decrease, except as permitted as part of an overall cost reduction program) as part of our annual compensation review.Mr. Shore is also eligible to receive an annual bonus in an amount equal to 60% of his then-annual salary upon the achievementof reasonable target objectives and performance goals, to be determined by the board of directors in consultation with Mr. Shore.Mr. Shore is eligible to receive the percentage of his annual bonus corresponding to the percentage of his achievement of suchtarget objectives and performance goals. The annual bonus will be reviewed annually by our chief executive officer for increasein the amount of the percentage of his then-base salary (but not decrease), as well as the criteria and the goals, as part ofour annual compensation review. In addition, Mr. Shore is eligible to receive such additional bonus or incentive compensationas the board may establish from time to time in its sole discretion. Mr. Shore will also be considered for grants of equity awardseach year as part of the board’s annual compensation review, which will be made at the sole discretion of the board of directors.Each grant will, with respect to any awards that are options, have an exercise price equal to the fair market value of our commonstock as of the date of grant, and will be subject to a three-year vesting period subject to Mr. Shore’s continued servicewith us, with one-third of each additional grant vesting equally on the first, second, and third anniversary of the date of grantfor such awards.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifduring the term of the employment agreement, Mr. Shore’s employment is terminated upon his death or disability, by us withoutcause (as such term is defined in Mr. Shore’s employment agreement), or upon his resignation for “good reason”(as such term is defined in Mr. Shore’s employment agreement), Mr. Shore will be entitled to receive, in addition to anyamounts he is entitled to receive under the manager’s insurance policy: (i) any unpaid base salary and accrued unpaid vacationor earned incentive compensation and the pro rata amount of any bonus plan incentive compensation for the fiscal year of suchtermination (based on the number of business days he was actually employed by us during the fiscal year of such termination andbased on the percentage of the goals that he actually achieved under the bonus plan) that he would have received had his employmentnot been terminated; (ii) a one-time lump sum severance payment equal to 100% of his base salary, provided that he executes arelease relating to employment matters and the circumstances surrounding his termination in favor of us, our subsidiaries andour officers, directors and related parties and agents, in a form reasonably acceptable to us at the time of such termination;(iii) vesting of all unvested stock options, stock appreciation rights or similar stock-based rights granted to him and immediatelapse of any risk of forfeiture included in restricted or other stock grants previously made to Mr. Shore; (iv) an extension ofthe exercise period of all vested stock options granted to Mr. Shore until the earlier of (a) two years from the date of terminationor (b) the latest date that each stock option would otherwise expire by its original terms; (v) to the fullest extent permittedby our then-current benefit plans, continuation of health, dental, vision and life insurance coverage for the lesser of 12 monthsafter termination or until Mr. Shore obtains coverage from a new employer; and (vi) reimbursement of up to $30,000 for executiveoutplacement services, subject to certain restrictions. The severance payment described in (ii) of the foregoing sentence uponMr. Shore’s death or disability will be reduced by any payments received by Mr. Shore pursuant to any of our employee welfarebenefit plans providing for payments in the event of death or disability. If, during or after the term of his employment agreement,Mr. Shore’s employment is terminated by us for cause or by Mr. Shore voluntarily, Mr. Shore will only be entitled to unpaidamounts owed to him (e.g., base salary, accrued vacation and earned incentive compensation through the date of such termination)and whatever rights, if any, are available to him pursuant to our stock-based compensation plan or any award documents relatedto any stock-based compensation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Mr.Shore may terminate his employment for good reason by delivering a notice of termination to us 30 days in advance of the dateof termination; provided, however, that Mr. Shore agreed to not terminate his employment for good reason until he has given usat least 30 days’ notice from which to cure the circumstances set forth in the notice of termination constituting good reason,and if such circumstances are not cured by the 30th day, Mr. Shore’s employment shall terminate on such date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto terms contained in Mr. Shore’s stock option and restricted stock award agreements, in the event of a change of controlof our company, the stock options and restricted stock granted to Mr. Shore that were unvested will vest immediately upon suchchange of control, in the case of stock options, if such stock options are not assumed or substituted by the surviving company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 70; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           70           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe terminate Mr. Shore’s employment without cause, Mr. Shore will be entitled, under Israeli law, to severance paymentsequal to his last month’s salary multiplied by the number of years Mr. Shore has been employed with us. In order to financethis obligation, we make monthly contributions equal to 8.33% of Mr. Shore’s salary to a severance payment fund. The totalamount accumulated in Mr. Shore’s severance payment fund as of December 31, 2020 was $206,000, as adjusted for conversionfrom New Israeli Shekels to U.S. Dollars. However, if Mr. Shore’s employment is terminated without cause, on account ofa disability or upon his death, as of December 31, 2020, Mr. Shore would have been entitled to receive $270,000 in severance underIsraeli law, thereby requiring us to pay Mr. Shore $64,000, in addition to releasing the $206,000 in Mr. Shore’s severancepayment fund. On the other hand, pursuant to his employment agreement, Mr. Shore is entitled to the total amount contributed toand accumulated in his severance payment fund in the event of the termination of his employment as a result of his voluntary resignation.In addition, Mr. Shore would be entitled to receive his full severance payment under Israeli law, including the total amount contributedto and accumulated in his severance payment fund, if he retires from our company at or after age 67.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare entitled to terminate Mr. Shore’s employment immediately at any time for “cause” (as such term is definedin the agreement and the Israeli Severance Payment Act 1963), upon which, after meeting certain requirements under the applicablelaw and recent Israeli Labor court requirements, we believe we will have no further obligation to compensate Mr. Shore.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Also,upon termination of Mr. Shore’s employment for any reason, we will compensate him for all unused or previously uncompensatedvacation days accrued.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theemployment agreement also contains certain standard noncompetition, non-solicitation, confidentiality, and assignment of inventionsrequirements for Mr. Shore.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Mr.Shore is also entitled to participate in or receive benefits under our social insurance and benefits plans, including but notlimited to our manager’s insurance policy and education fund, which are customary benefits provided to executive employeesin Israel. A management insurance policy is a combination of severance savings (in accordance with Israeli law), defined contributiontax-qualified pension savings and disability pension payments. An education fund is a savings fund of pre-tax contributions tobe used after a specified period of time for advanced educational training and other permitted purposes, as set forth in the by-lawsof the education fund. We will make periodic contributions to these insurance and social benefits plans based on certain percentagesof Mr. Shore’s base salary, including (i) 7.5% to the education fund and (ii) 15.83% to the manager’s insurance policy,of which 8.33% will be allocated to severance pay, 5.5% to pension fund payments and up to 2.5% to disability pension payments.Upon the termination of Mr. Shore’s employment for any reason other than for cause, Mr. Shore will be entitled to receivethe total amount contributed to and accumulated in his manager insurance policy fund.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 14, 2020, we entered into the fourth amendment to that certain Amended and Restated Employment Agreement dated as of May5, 2014, as amended on January 5, 2015, July 25, 2016, and on March 25, 2019, in order to, among other things, (i) amend the termof Mr. Shore’s employment, so that the initial term of Mr. Shore employment will end on July 31, 2022, which will automaticallybe renewed for additional one-year periods on August 1, 2022 and on each August 1 thereafter; (ii) increase Mr. Shore’smonthly base salary to NIS 86,000; and (iii) amend certain terms related to termination of Mr. Shore’s employment withoutCause (as defined therein)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Changeof Control Agreements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedo not currently have any plans providing for the payment of retirement benefits to our officers or directors, other than as describedunder “Agreements with Executive Officers” above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedo not currently have any change-of-control or severance agreements with any of our executive officers or directors, other thanas described under “Agreements with Executive Officers” above. In the event of the termination of employment of thenamed executive officers, any and all unexercised stock options shall expire and no longer be exercisable after a specified timefollowing the date of the termination, other than as described under “Agreements with Executive Officers” above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 71; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           71           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OutstandingEquity Awards at December 31, 2020        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table shows information concerning unexercised options and unvested shares of restricted stock outstanding as of December31, 2020 for each of our named executive officers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td colspan="17" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Option Awards         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Stock Awards         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">          Name         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of securities underlying unexercised options (#) exercisable         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of securities underlying unexercised options (#) unexercisable         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Option exercise price ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Option expiration date         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of shares of stock that have not vested (#)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Market value of shares of stock that have not vested ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 40%; text-align: left">          Marvin Slosman (1)         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">          60,794         </td>         <td style="width: 1%; text-align: left">          <sup>           (2)          </sup>         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">          1.10         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1/2/2030          </font>         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          182,381         </td>         <td style="text-align: left">          <sup>           (3)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          62,010         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          391,762         </td>         <td style="text-align: left">          <sup>           (4)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.39         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           8/31/2030          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,175,287         </td>         <td style="text-align: left">          <sup>           (5)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          399,598         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Craig Shore         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          11         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8,312.50         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           07/25/2026          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,000         </td>         <td style="text-align: left">          <sup>           (6)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,360         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          226,278         </td>         <td style="text-align: left">          <sup>           (4)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.39         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           8/31/2030          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          678,834         </td>         <td style="text-align: left">          <sup>           (7)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          230,804         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Mr.    Slosman was appointed as chief executive officer effective as of January 1, 2020          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           These    options vest annually, with one-third vesting on each of January 2, 2021, January 2, 2022 and January 2, 2023.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           These    RSU’s vest annually, with one-third vesting on each of January 2, 2021, January 2, 2022 and January 2, 2023.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (4)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           These    options vest annually, with one-third vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (5)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           These    RSU’s vest annually, with one-third vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (6)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           These    restricted shares vest annually, with one-half vesting on each of February 4, 2021 and February 4, 2022.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (7)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           These    Restricted Stock vest annually, with one-third vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OptionExercises and Stock Vested        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Therewere no stock options exercised by our named executive officers during the twelve months ended December 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         2011UMBRELLA Option Plan        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 28, 2011, our board of directors and stockholders adopted and approved the InspireMD, Inc. 2011 UMBRELLA Option Plan, whichwas subsequently amended on October 31, 2011 and December 21, 2012. Under the InspireMD, Inc. 2011 UMBRELLA Option Plan, we havereserved 11 shares of our common stock as awards to the employees, consultants, and service providers to InspireMD, Inc. and itssubsidiaries and affiliates worldwide.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheInspireMD, Inc. 2011 UMBRELLA Option Plan currently consists of three components, the primary plan document that governs all awardsgranted under the InspireMD, Inc. 2011 UMBRELLA Option Plan, and two appendices: (i) Appendix A, designated for the purpose ofgrants of stock options and restricted stock awards to Israeli employees, consultants, officers and other service providers andother non-U.S. employees, consultants, and service providers, and (ii) Appendix B, which is the 2011 U.S. Equity Incentive Plan,designated for the purpose of grants of stock options and restricted stock awards to U.S. employees, consultants, and serviceproviders who are subject to the U.S. income tax. On December 21, 2012, the stockholders approved the awarding of “incentivestock options” pursuant to the U.S. portion of the plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 72; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           72           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepurpose of the InspireMD, Inc. 2011 UMBRELLA Option Plan is to provide an incentive to attract and retain employees, officers,consultants, directors, and service providers whose services are considered valuable, to encourage a sense of proprietorship andto stimulate an active interest of such persons in our development and financial success. The InspireMD, Inc. 2011 UMBRELLA OptionPlan is administered by our compensation committee. Unless terminated earlier by the board of directors, the InspireMD, Inc. 2011UMBRELLA Option Plan will expire on March 27, 2021. We have no shares of common stock available for future issuance under our2011 UMBRELLA Option Plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         2013Long-Term Incentive Plan        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnDecember 16, 2013, our stockholders approved the InspireMD, Inc. 2013 Long-Term Incentive Plan, which was adopted by our boardof directors on October 25, 2013.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepurpose of the InspireMD, Inc. 2013 Long-Term Incentive Plan is to provide an incentive to attract and retain employees, officers,consultants, directors, and service providers whose services are considered valuable, to encourage a sense of proprietorship andto stimulate an active interest of such persons in our development and financial success. The InspireMD, Inc. 2013 Long-Term IncentivePlan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock,restricted stock units, performance awards, dividend equivalent rights, and other awards, which may be granted singly, in combination,or in tandem. The InspireMD, Inc. 2013 Long-Term Incentive Plan is administered by our compensation committee.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheInspireMD, Inc. 2013 Long-Term Incentive Plan is intended to serve as an “umbrella” plan for us and our subsidiariesworldwide. Therefore, if so required, appendices may be added to the InspireMD, Inc. 2013 Long-Term Incentive Plan in order toaccommodate local regulations that do not correspond to the scope of the InspireMD, Inc. 2013 Long-Term Incentive Plan. Attachedas Appendix A to the InspireMD, Inc. 2013 Long-Term Incentive Plan is the InspireMD, Inc. 2013 Employee Stock Incentive Plan,for the purpose of making grants of stock options, restricted stock, and other stock incentive awards pursuant to Sections 102and 3(i) of the Israeli Income Tax Ordinance (New Version), 1961 to Israeli employees and officers and any other service providersor control holders of us who are subject to Israeli Income Tax.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whenthe InspireMD, Inc. 2013 Long-Term Incentive Plan was adopted, a total of 11 shares of common stock were reserved for awards underthe InspireMD, Inc. 2013 Long-Term Incentive Plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 9, 2015, our stockholders approved an amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to increase thenumber of shares of common stock available for issuance pursuant to awards under the InspireMD, Inc. 2013 Long-Term IncentivePlan by 11 shares of common stock, to a total of 22 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 24, 2016, our stockholders approved the second amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to increasethe number of shares of common stock available for issuance pursuant to awards under the InspireMD, Inc. 2013 Long-Term IncentivePlan by 229 shares of common stock, to a total of 251 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 28, 2016, our stockholders approved the third amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to increasethe number of shares of common stock available for issuance pursuant to awards under the InspireMD, Inc. 2013 Long-Term IncentivePlan by 144 shares of common stock, to a total of 395 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 24, 2018, our stockholders approved the fourth amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to (i) increasethe number of shares of common stock available for issuance pursuant to awards under such InspireMD, Inc. 2013 Long-Term IncentivePlan by 178,000 shares, to a total of 178,395 shares of common stock, and (ii) remove the cap on the number of shares of commonstock with respect to which stock options or stock appreciation rights may be granted to certain executive officers of the Companyduring any calendar year.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 21, 2019, our stockholders approved the fifth amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to increasethe total number of shares of common stock issuable under the InspireMD, Inc. 2013 Long-Term Incentive Plan by 500,000 sharesto a total of 678,395 shares of common stock       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 73; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           73           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 31, 2020, our stockholders approved the sixth amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to increasethe total number of shares of common stock issuable under the InspireMD, Inc. 2013 Long-Term Incentive Plan by 6,500,000 sharesto a total of 7,178,395 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, we had 2,306,956 shares of common stock available for future issuance under our 2013 Long-Term IncentivePlan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof March 8, 2021, we had 2,234,642 shares of common stock available for future issuance under our 2013 Long-Term Incentive Plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         DirectorCompensation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table shows information concerning our directors during the twelve months ended December 31, 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">          Name         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          <p style="margin-top: 0; margin-bottom: 0">           Fees          </p>          <p style="margin-top: 0; margin-bottom: 0">           Earned           <br/>           or Paid in Cash           <br/>           ($)          </p>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Stock          <br/>          Awards          <br/>          ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Option          <br/>          Awards          <br/>          ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          All Other          <br/>          Compensation          <br/>          ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Total          <br/>          ($)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 35%; text-align: left">          Paul Stuka         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 9%; text-align: right">          47,250         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 9%; text-align: right">          93,191         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 9%; text-align: right">          27,792         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 9%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 9%; text-align: right">          168,233         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Michael Berman         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          29,750         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          61,633         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          18,381         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          109,764         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Campbell Rogers, M.D.         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          21,875         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          61,633         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          18,381         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          101,889         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Thomas Kester         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          35,875         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          61,633         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          18,381         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          115,889         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Gary Roubin, M.D.         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,503         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          78,854         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          23,516         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          107,873         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe 2020 calendar year, our board approved the following compensation for our independent directors: (i) a $40,000 stipend, payablequarterly to the chairman of the board; (ii) a $25,000 stipend, payable quarterly to the other directors; (iii) annual committeechair compensation of $12,000 for the chairman of the audit committee, $8,000 for the chairman of the compensation committee and$5,000 for the chairmen of the nominating and corporate governance committee and the research and development committee; and (iv)annual committee membership compensation of $4,000 for members of the audit committee and the compensation committee and $2,000for members of the nominating and corporate governance committee and the research and development committee for members of thenominating and corporate governance committee and the research and development committee. Notwithstanding the foregoing, effectiveApril 1, 2020, the Board approved a 50% decrease in the annual cash compensation for non-employee directors from an aggregateamount of $154,000 to $77,000, and on July 1, 2020, the Board reinstated the original annual cash compensation for non-employeedirectors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Directors’and Officers’ Liability Insurance        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wecurrently have directors’ and officers’ liability insurance insuring our directors and officers against liabilityfor acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance also insuresus against losses which we may incur in indemnifying our officers and directors. In addition, we have entered into indemnificationagreements with key officers and directors and such persons shall also have indemnification rights under applicable laws, andour certificate of incorporation and bylaws.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_020">         </a>         Item12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table sets forth information with respect to the beneficial ownership of our common stock as of March 8, 2021 by:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           each    person known by us to beneficially own more than 5.0% of our common stock;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           each    of our directors;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           each    of the named executive officers; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           all    of our directors and executive officers as a group.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 74; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           74           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepercentages of common stock beneficially owned are reported on the basis of regulations of the Securities and Exchange Commission(the “SEC”) governing the determination of beneficial ownership of securities. Under the rules of the SEC, a personis deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote orto direct the voting of the security, or investment power, which includes the power to dispose of or to direct the dispositionof the security.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Exceptas indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investmentpower with respect to all shares beneficially owned and each person’s address is c/o InspireMD, Inc., 4 Menorat Hamaor St.,Tel Aviv, Israel 6744832. As of March 8, 2021, we had 117,832,226 shares outstanding       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">          Name of Beneficial Owner         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number of            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Shares            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Beneficially            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Owned             <sup>              (1)             </sup>            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Percentage            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Beneficially            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Owned             <sup>              (1)             </sup>            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-style: italic; text-align: left">          5% Owners         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 64%; text-align: left">          Armistice Capital, LLC         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 14%; text-align: right">          9,677,415         </td>         <td style="width: 1%; text-align: left">          <sup>           (2)          </sup>         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 14%; text-align: right">          8.2         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          FiveT Capital AG         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7,258,050         </td>         <td style="text-align: left">          <sup>           (3)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          6.2         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-style: italic; text-align: left">          Officers and Directors         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Marvin Slosman         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          252,638         </td>         <td style="text-align: left">          <sup>           (4)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Craig Shore         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,499,251         </td>         <td style="text-align: left">          <sup>           (5)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.27         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Michael Berman         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          120,976         </td>         <td style="text-align: left">          <sup>           (6)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Campbell Rogers, M.D.         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          160,650         </td>         <td style="text-align: left">          <sup>           (7)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Paul Stuka         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          243,634         </td>         <td style="text-align: left">          <sup>           (8)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Thomas Kester         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          392,081         </td>         <td style="text-align: left">          <sup>           (9)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Gary Roubin, M.D.         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,046,291         </td>         <td style="text-align: left">          <sup>           (10)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          All directors and executive officers as a group (7 persons)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,715,521         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3.14         </td>         <td style="text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Represents    ownership of less than one percent.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Shares    of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assumes the exercise    of all options, warrants and other securities convertible into common stock beneficially owned by such person or entity currently    exercisable or exercisable within 60 days of March 8, 2021. Shares issuable pursuant to the exercise of stock options and    warrants exercisable within 60 days are deemed outstanding and held by the holder of such options or warrants for computing    the percentage of outstanding common stock beneficially owned by such person, but are not deemed outstanding for computing    the percentage of outstanding common stock beneficially owned by any other person.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 6,451,610 shares of common stock purchased in connection with the February 2021 Offering, and (ii) warrants to purchase    3,225,805 shares of common stock, at an exercise price of $0.682 per share, purchased in the February 2021 Offering. We are    not aware whether this stockholder has sold any of the foregoing securities it purchased in the February 2021    Offering.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 4,838,700 shares of common stock purchased in the February 2021 Offering, and (ii) warrants to purchase 2,419,350 shares    of common stock, at an exercise price of $0.682 per share, purchased in the February 2021 Offering. We are not aware whether    this stockholder has sold any of the foregoing securities it purchased in the February 2021 Offering.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 75; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           75           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (4)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 95,870 shares of common stock, (ii) 60,794 Restricted Stock Units granted outside the plan that are currently exercisable    or exercisable within 60 days of March 8, 2021, (iii) options to purchase 20,264 shares of common stock that are currently    exercisable or exercisable within 60 days of March 8, 2021, and (iv) 75,710 warrants to purchase shares of common stock that    are currently exercisable.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (5)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 4,021 shares of common stock, (ii) options to purchase 11 shares of common stock that are currently exercisable or    exercisable within 60 days of March 8, 2021, (iii) 680,828 shares of restricted stock granted under the Israeli Appendix of    the InspireMD, Inc. 2013 Long-Term Incentive Plan and (iv) 814,391 shares of restricted stock granted to employees under the    Israeli Appendix of the InspireMD, Inc. 2013 Long-Term Incentive Plan held in trust, and with respect to which Mr. Shore was    granted a proxy with the right to vote such shares at his discretion.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (6)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 80,642 shares of common stock, (ii) 40,320 warrants to purchase shares of common stock that are currently exercisable,    and (iii) options to purchase 14 shares of common stock that are currently exercisable or exercisable within 60 days of March    8, 2021. Excludes 160,633 shares of common stock and restricted stock granted under the Israeli Appendix of InspireMD, Inc.    2013 Long-Term Incentive Plan held in trust, with respect to which the trustee has a proxy with the right to vote such shares    at his discretion.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (7)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 1,736 shares of common stock, (ii) 158,899 shares of restricted stock granted under the InspireMD, Inc. 2013 Long-Term    Incentive Plan, (iii) options to purchase 14 shares of common stock that are currently exercisable or exercisable within 60    days of March 8, 2021, and (iv) one warrant to purchase a share of common stock that is currently exercisable or exercisable    within 60 days of March 8, 2021.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (8)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Paul    Stuka is the principal and managing member of Osiris Investment Partners, L.P., and, as such, has beneficial ownership of    (A) (i) 264 shares of common stock, (ii) warrants to purchase 6 shares of common stock that are currently exercisable or exercisable    within 60 days of March 8, 2021 in addition to (B) personally holding (i) options to purchase 15 shares of common stock that    are currently exercisable or exercisable within 60 days of March 8, 2021, (ii) 240,250 shares of restricted stock granted    under the InspireMD, Inc. 2013 Long-Term Incentive Plan, (iii) warrants to purchase 7 shares of common stock that are currently    exercisable or exercisable within 60 days of March 8, 2021, and (iv) 3,092 shares of common stock.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (9)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 172,694 shares of common stock, (ii) 158,899 shares of restricted stock granted under the InspireMD, Inc. 2013 Long-Term    Incentive Plan, (iii) 60,480 warrants to purchase shares of common stock that are currently exercisable and (iv) options to    purchase 8 shares of common stock that are currently exercisable or exercisable within 60 days of March 8, 2021.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (10)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Consists    of (i) 464,153 shares of common stock, (ii) 238,950 shares of restricted stock granted under the InspireMD, Inc. 2013 Long-Term    Incentive Plan, and (iii) 343,188 warrants to purchase shares of common stock that are currently exercisable.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         EquityCompensation Plan Information        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table provides certain information as of December 31, 2020, with respect to our equity compensation plans under whichour equity securities are authorized for issuance:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Plan Category         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of securities to be issued upon exercise of outstanding options, warrants and rights         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Weighted-average exercise price of outstanding options, warrants and rights         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: center">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            (a)           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            (b)           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            (c)           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 28%; text-align: left">          Equity compensation          <br/>          plans approved by          <br/>          security holders         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 20%; text-align: right">          1,169,665         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 20%; text-align: right">          37.69         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 20%; text-align: right">          2,306,956         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Equity compensation          <br/>          plans not approved          <br/>          by security holders         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          205,615         </td>         <td style="text-align: left">          <sup>           (1)          </sup>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          50.36         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Total         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,375,280         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          39.59         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,306,956         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 76; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           76           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 98%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Comprised    of awards made to individuals outside the InspireMD, Inc. 2011 UMBRELLA Option Plan and 2013 Long Term Incentive Plan, as    described below:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Options    issued to former director: In November 2011, we issued options to purchase an aggregate of 3 shares of common stock to Dr.    Barer, then chairman of our board of directors who resigned from the board of directors effective as of June 2, 2017. The    exercise price of these options is $3,412,500 per share and the options may be exercised at any time prior to the tenth anniversary    of the grant date, pursuant to the nonqualified stock option agreement, as amended on June 2, 2017.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           On    January, 2020, we issued to Mr. Marvin Slosman, our Chief Executive Officer, President and Director, 182,381 shares of restricted    stock and 60,794 shares of common stock, as inducement awards outside the Company’s 2013 Long-Term Incentive Plan.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           On    October 6, 2020, we issued to Mr. Patrick Jamnik, our Vice President of Business Development and Strategic Initiatives, options    to purchase 54,307 shares of our common stock, as inducement awards outside the Company’s 2013 Long-Term Incentive Plan.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           On    November 3, 2020, we issued to Mr. Andrea Tommasoli, our Senior Vice President of Global Sales and Marketing, options to purchase    90,511 shares of our common stock, as inducement awards outside the Company’s 2013 Long-Term Incentive Plan.]          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_021">         </a>         Item13. Certain Relationships and Related Transactions, and Director Independence.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaccordance with our audit committee charter, the audit committee is required to approve all related party transactions. In general,the audit committee will review any proposed transaction that has been identified as a related party transaction under Item 404of Regulation S-K. A related party includes (i) a director, director nominee or executive officer of us, (ii) a security holderknown to be an owner of more than 5% of our voting securities, (iii) an immediate family member of the foregoing or (iv) a corporationor other entity in which any of the foregoing persons is an executive, principal or similar control person or in which such personhas a 5% or greater beneficial ownership interest.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.35pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Therewere no related party transactions that are required to be disclosed pursuant to Regulation S-K promulgated under the SecuritiesAct of 1933, as amended.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         DirectorIndependence        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theboard of directors has determined that Dr. Rogers and Messrs. Stuka, Berman and Kester, satisfy the requirement for independenceset out in Section 803 of the NYSE American rules and that each of these directors has no material relationship with us (otherthan being a director and/or a stockholder). In making its independence determinations, the board of directors sought to identifyand analyze all of the facts and circumstances relating to any relationship between a director, his immediate family or affiliatesand our company and our affiliates and did not rely on categorical standards other than those contained in the NYSE American rulereferenced above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_022">         </a>         Item14. Principal Accountant Fees and Services.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefees billed for professional services provided to us by Kesselman &amp; Kesselman, Certified Public Accountants (“Kesselman”),a member of PricewaterhouseCoopers International Limited, for the years ended December 31, 2020 and 2019 are described below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 77; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           77           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         AuditFees        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Kesselmanbilled us audit fees in the aggregate amount of $160,000 and $160,000 for the years ended December 31, 2020 and 2019, respectively.These fees relate to the audit of our annual financial statements and the review of our interim quarterly financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Audit-RelatedFees        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Kesselmanbilled us audit-related fees in the aggregate amount of $53,900 and $60,000 for the year ended December 31, 2020 and 2019, respectively.The fees for the year ended December 31, 2020 mostly related to registration statement on Form S-1 filed with the SEC in June2020 and to our prospectus supplements filed with the Securities and Exchange Commission in July 2020.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefees for the year ended December 31, 2019 mostly related to our prospectus supplements filed with the Securities and ExchangeCommission in April 2019 and to our registration statement on Form S-1 filed with the Securities and Exchange Commission in Augustand September of 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         TaxFees        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Kesselmanbilled us tax fees in the aggregate amount of $39,209 and $38,675 for the year ended December 31, 2020 and 2019, respectively.These fees relate to professional services rendered for tax compliance, tax advice and tax planning.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         AllOther Fees        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Kesselmandid not bill us for any other fees for the year ended December 31, 2020 and 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ouraudit committee pre-approves all auditing services, internal control-related services and permitted non-audit services (includingthe fees and terms thereof) to be performed for us by our independent auditor, except for de minimis non-audit services that areapproved by the audit committee prior to the completion of the audit. The audit committee may form and delegate authority to subcommitteesconsisting of one or more members when appropriate, including the authority to grant pre-approvals of audit and permitted non-auditservices, provided that decisions of such subcommittee to grant pre-approvals is presented to the full audit committee at itsnext scheduled meeting. The Audit Committee pre-approved all of the fees set forth above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_023">         </a>         PARTIV        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="a_024">         </a>         Item15. Exhibits and Financial Statement Schedules.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Documentsfiled as part of report:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        1.        <u>         Financial Statements        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing financial statements are included herein:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_001">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Report of Kesselman &amp; Kesselman, Independent Registered Public Accounting Firm           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_002">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Balance Sheets as of December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_003">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_005">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Changes in Equity for the Years Ended December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_006">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="#v_007">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Notes to Consolidated Financial Statements           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        2.        <u>         Financial Statement Schedules        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        3.        <u>         Exhibits        </u>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        SeeIndex to Exhibits       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 78; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           78           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Item16. Form 10-K Summary        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Indexto Exhibits        </b>        [Subject to additional analysis/review]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Exhibit    No.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Description           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577415003178/s102096_ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.2          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511000623/e608284_ex3-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.3          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420413056913/v358171_ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Designation, Preferences and Rights of Series A Preferred Stock (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2013)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.4          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416005628/s103343_ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.5          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315216012131/ex3-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the Quarterly Report on Form 10-Q filed on August 9, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.6          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315216013705/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.7          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217002455/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.8          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217013917/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.9          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217014147/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Designation of Preferences, Rights and Limitation of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 4, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.10          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217014515/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.11          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217015011/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 22, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.12          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218001617/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.13          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218002799/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 1, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.14          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218004660/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 3, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.15          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218009721/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on July 5, 2018)           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="margin-top: 0; margin-bottom: 0">      </p>      <!-- Field: Page; Sequence: 79; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           79           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.16          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219004101/ex3-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated March 27, 2019 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420413012900/v328423_ex4-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 3 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 5, 2013)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.2          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420413056916/v358212_ex1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Rights Agreement dated as of October 22, 2013 between InspireMD, Inc. and Action Stock transfer Corporation, as Rights Agent, including exhibits thereto (incorporated by reference to an exhibit to the Registration Statement on Form 8-A filed with Securities and Exchange Commission on October 25, 2013)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.3          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217002157/ex4-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Series B Warrant Agent Agreement and Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to Amendment No.3 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.4          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220003630/ex4-4.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Description of Securities (incorporated by reference to Exhibit 4.4 to our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2020)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.1+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511002138/e609038_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amended and Restated 2011 Umbrella Option Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.2+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511000675/e608253_ex10-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Stock Option Award Agreement (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.3+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511000675/e608253_ex10-21.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Employment Agreement, by and between InspireMD Ltd. and Craig Shore, dated as of November 28, 2010 (incorporated by reference to Exhibit 10.21 to Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.4+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511001650/e608811_ex10-22.htm" style="-sec-extract: exhibit">            Form of Indemnity Agreement between InspireMD, Inc. and each of the directors and executive officers thereof (incorporated by reference to Exhibit 10.22 to Amendment No. 1 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 26, 2011)           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.5          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511001650/e608811_ex10-26.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Agreement by and between InspireMD Ltd. and MeKo Laser Material Processing, dated as of April 15, 2010 (incorporated by reference to Exhibit 10.26 to Amendment No. 1 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 26, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.6          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511001650/e608811_ex10-27.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Agreement by and between InspireMD Ltd. and Natec Medical Ltd, dated as of September 23, 2009 (incorporated by reference to Exhibit 10.27 to Amendment No. 1 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 26, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.7+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420413068386/v363531_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on December 20, 2013)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.8+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414028324/v375932_ex10-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amended and Restated Employment Agreement, dated May 5, 2014, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.9+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414028324/v375932_ex10-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            First Amendment to the InspireMD, Inc. Amended and Restated 2011 UMBRELLA Option Plan (incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.10+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Incentive Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.2 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.11+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Nonqualified Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.3 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 80; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           80           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.12+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-4.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Restricted Stock Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.4 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.13+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Restricted Stock Unit Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.5 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.13+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-6.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Section 3(i) Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (Israeli) (incorporated by reference to Exhibit 99.6 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.14+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-7.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Section 102 Capital Gain Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (Israeli) (incorporated by reference to Exhibit 99.7 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.15+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-8.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Section 102 Capital Gain Restricted Stock Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (Israeli) (incorporated by reference to Exhibit 99.8 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.16+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-9.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (European) (incorporated by reference to Exhibit 99.9 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.17+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-10.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Restricted Stock Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (European) (incorporated by reference to Exhibit 99.10 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.18+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414035898/v380351_ex99-11.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Stock Option Award Agreement outside the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.11 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.19+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420414043665/v384128_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Employment Agreement, dated July 14, 2014, by and between InspireMD, Inc. and James J. Barry, Ph.D. (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on July 18, 2014)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.20+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420415000755/v398154_ex10-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amendment to Employment Agreement, dated January 5, 2015, by and between InspireMD, Inc. and James J. Barry, PhD (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2015)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.21+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420415000755/v398154_ex10-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            First Amendment to Amended and Restated Employment Agreement, dated January 5, 2015, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2015)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.22+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000114420415011886/v402598_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amendment Number Two to Employment Agreement, dated February 22, 2015, by and between InspireMD, Inc. and James J. Barry, PhD (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2015)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.23+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577415002506/s101800_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            First Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 9, 2015)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.24+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416004660/s102738_ex10-66.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Third Amendment to Employment Agreement, dated March 28, 2016, by and between InspireMD, Inc. and James J. Barry, PhD (incorporated by reference to Exhibit 10.66 to the Annual Report on Form 10-K filed on March 28, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.25          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416004502/s102813_ex10-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of $25,812.50 Underwritten Warrant (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2016)           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 81; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           81           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.26          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416004502/s102813_ex10-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of $32,265.63 Underwriter Warrant (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.27          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416004502/s102813_ex10-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of $25,812.50 Private Placement Warrant (incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.28          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416004502/s102813_ex10-7.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of $32,265.63 Placement Agent Warrant (incorporated by reference to Exhibit 10.7 to Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.29+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416005628/s103343_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Second Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May 25, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.30+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416005801/s103433_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Fourth Amendment to Employment Agreement, dated June 6, 2016, by and between InspireMD, Inc. and James Barry, Ph.D. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 7, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.31          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577416005876/s103470_ex10-6.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Warrant Agreement, dated June 13, 2016, by and between InspireMD, Inc. and Hercules Capital, Inc. (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed on June 14, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.32          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315216012131/ex10-12.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Placement Agent Unit Purchase Option, dated June 7, 2016, issued to Dawson James Securities, Inc. (incorporated by reference to Exhibit 10.12 to the Quarterly Report on Form 10-Q filed on August 9, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.33          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315216011751/ex1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Warrant Agent Agreement and Form of Warrant, dated as of July 7, 2016, between InspireMD, Inc. and Action Stock Transfer Corporation, as Warrant Agent (incorporated by reference to an exhibit to the Registration Statement on Form 8-A filed with Securities and Exchange Commission on July 26, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.34+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315216011836/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Second Amendment to Amended and Restated Employment Agreement, dated July 25, 2016, by and between InspireMD, Inc. and Craig Shore agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on July 29, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.35+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315216013705/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Third Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 29, 2016)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.36+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director    Offer Letter, between InspireMD, Inc. and Thomas J. Kester, dated September 6, 2016          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.37+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217010304/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Fifth Amendment to Employment Agreement, dated September 5, 2017, by and between InspireMD, Inc. and James Barry, Ph.D. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 7, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.38          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315217013917/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 29, 2017)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.39          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218002471/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amendment to Securities Purchase Agreement, dated February 21, 2018 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 21, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.40          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218002622/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Waiver Agreement, dated February 26, 2018 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 26, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.41          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218002799/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant, dated March 1, 2018 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 1, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.42          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218004128/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Waiver Agreement, dated March 28, 2018 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 29, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.43          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218004660/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant, dated April 2, 2018 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 3, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.44          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218009386/ex10-67.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Letter Agreement, dated June 28, 2018, by and between InspireMD, Inc. and Sabby Healthcare Master Fund, Ltd. (incorporated by reference to Exhibit 10.67 to the Registration Statement on Form S-1, Amendment No. 2, filed with the SEC on June 26, 2018 (File No. 333-225680))           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 82; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           82           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.45          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218009230/ex4-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Series D Warrant (incorporated by reference to Exhibit A to Exhibit 4.3 to the Company’s Registration Statement on Form S-1, Amendment No. 2, filed with the SEC on June 26, 2018 (File No. 333-225680))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.46          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218009230/ex4-4.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-1, Amendment No. 2, filed with the SEC on June 26, 2018 (File No. 333-225680))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.47          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218009230/ex4-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 2, filed with the SEC on June 26, 2018 (File No. 333-225680))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.48+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315218014895/ex10_1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Fourth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 26, 2018)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.49+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219001456/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amended and Restated Employment Agreement, dated February 4, 2019, by and between InspireMD, Inc. and James J. Barry, Ph.D. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 6, 2019)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.50+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000161577419004318/s116868_ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Fifth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 21, 2019)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.51+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219004101/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Third Amendment to Amended and Restated Employment Agreement, dated March 25, 2019, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 28, 2019)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.52          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219005020/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant, dated April 8, 2019 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 8, 2019)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.53          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219014111/ex4-3.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Series E Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on September 13, 2019 (File No. 333-233432)).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.54          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219014111/ex4-4.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on September 13, 2019 (File No. 333-233432)).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.55          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;  unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219014111/ex4-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on September 13, 2019 (File No. 333-233432)).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.56+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219018960/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            General Release and Severance Agreement, dated December 9, 2019, by and between the Company and James J. Barry, Ph.D. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on December 10, 2019)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.57+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315219018960/ex10-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Employment Agreement, dated December 9, 2019, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on December 10, 2019).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.58+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220000179/ex10-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            First Amendment to General Release and Severance Agreement, dated December 31, 2019, by and between the Company and James J. Barry, Ph.D. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 6, 2020).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.59+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220000179/ex10-2.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            First Amendment to Employment Agreement, dated December 31, 2019, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 6, 2020).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.60+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220003630/ex10-60.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nonqualified Stock Option Agreement, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.60 to the Annual Report on Form 10-K filed on March 10, 2020)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.61+          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220003630/ex10-61.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Restricted Stock Unit Award agreement, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.61 to the Annual Report on Form 10-K filed on March 10, 2020)           </font>          </a>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 83; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           83           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.62          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220010280/ex4-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Series F Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on June 1, 2020 (File No. 333-238247)).           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.63          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220010280/ex4-4.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on June 1, 2020 (File No. 333-238247))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.64          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220010280/ex1-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant (incorporated by reference to Exhibit 1.1 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on June 1, 2020 (File No. 333-238247))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.65          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315220014100/ex1-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Sales Agreement, dated July 28, 2020 (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 28, 2020)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.66          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315221002128/ex4-5.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Series G Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on February 3, 2021 (File No. 333-238247))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.67          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000149315221002128/ex4-6.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Form of Underwriter Warrant (incorporated by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on February 3, 2021 (File No. 333-238247))           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           21.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <a href="https://www.sec.gov/Archives/edgar/data/1433607/000119380511000675/e608253_ex21-1.htm" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2011)           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           23.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex23-1.htm">            Consent of Kesselman &amp; Kesselman, Certified Public Accountants           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           31.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex31-1.htm">            Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           31.2*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex31-2.htm">            Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           32.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex32-1.htm">            Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           32.2*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex32-2.htm">            Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following materials from the Company’s Annual Report on Form 10-K for the twelve months ended December 31, 2019, formatted    in XBRL (eXtensible Business Reporting Language), (i) Consolidated Balance Sheets, (ii)Consolidated Statements of Income,    (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Cash Flows, (v) Consolidated Statement    of Stockholders’ Equity (Capital Deficiency) and (vi) Notes to Consolidated Financial Statements          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        *Filed herewith.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        +Management contract or compensatory plan or arrangement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 84; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           -           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           84           <!-- Field: /Sequence -->           -          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         SIGNATURES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this reportto be signed on its behalf by the undersigned, thereunto duly authorized.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           INSPIREMD,    INC.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Date:    March 8, 2021          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           By:          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Marvin Slosman           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Marvin    Slosman          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           President    and Chief Executive Officer          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalfof the registrant and in the capacities and on the dates indicated.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Signature           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Title           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Date           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Marvin Slosman           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           President,    Chief Executive Officer and Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Marvin    Slosman          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (principal    executive officer)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Craig Shore           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chief    Financial Officer, Chief Administrative Officer,           <br/>           Secretary and Treasurer          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Craig    Shore          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (principal    financial and accounting officer)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Paul Stuka           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chairman    of the Board of Directors          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Paul    Stuka          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Michael Berman           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Michael    Berman          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Thomas J. Kester           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Thomas    J. Kester          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Campbell Rogers, M.D.           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Campbell    Rogers, M.D.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Gary Roubin           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           March    8,          </font>          <font style="font: 10pt Times New Roman, Times, Serif">           2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Gary    Roubin          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left;  unicode-bidi: embed">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 85 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">      </p>      <!-- Field: Rule-Page -->      <div style="margin-left: auto; margin-right: auto; width: 100%">       <div style="font-size: 1pt; border-top: Black 1.5pt solid">       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        CONSOLIDATEDFINANCIAL STATEMENTS       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ASOF AND FOR THE YEAR ENDED DECEMBER 31, 2020       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 1; Options: NewSection -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           1           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        CONSOLIDATEDFINANCIAL STATEMENTS       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ASOF AND FOR THE YEAR ENDED DECEMBER 31, 2020       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">        TABLEOF CONTENTS       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Page           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <a href="#v_001">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-3          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            CONSOLIDATED    FINANCIAL STATEMENTS:           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif">          <a href="#v_002">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Balance Sheets           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-4          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif">          <a href="#v_003">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Operations           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-5          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif">          <a href="#v_005">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Changes in Equity           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-6    - F-7          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">         <td style="font: 10pt Times New Roman, Times, Serif">          <a href="#v_006">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Statements of Cash Flows           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-8          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">         <td style="font: 10pt Times New Roman, Times, Serif">          <a href="#v_007">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Notes to the Consolidated Financial Statements           </font>          </a>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-9    - F-29          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           2           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <img alt="" src="form10-k_001.jpg" style="height: 53px; width: 68px"/>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <a name="v_001">       </a>       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Reportof Independent Registered Public Accounting Firm        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Tothe board of directors and shareholders of InspireMD Inc.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Opinionon the Financial Statements         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave audited the accompanying consolidated balance sheets of InspireMD Inc. and its subsidiaries (the “Company”) asof December 31, 2020 and 2019, and the related consolidated statements of operations, changes in equity and cash flows for theyears then ended , including the related notes (collectively referred to as the “consolidated financial statements”).In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of theCompany as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformitywith accounting principles generally accepted in the United States of America.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.55pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Changein Accounting Principle        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.55pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asdiscussed in Note 2(g) to the consolidated financial statements, the Company changed the manner in which it accounts for leasesin 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Basisfor Opinion         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theseconsolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express anopinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registeredwith the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect tothe Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities andExchange Commission and the PCAOB.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standardsrequire that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statementsare free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged toperform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understandingof internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’sinternal control over financial reporting. Accordingly, we express no such opinion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ouraudits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whetherdue to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating theaccounting principles used and significant estimates made by management, as well as evaluating the overall presentation of theconsolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CriticalAudit Matters         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Criticalaudit matters are matters arising from the current period audit of the consolidated financial statements that were communicatedor required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to theconsolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. We determinedthere are no critical audit matters.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          /s/Kesselman&amp;Kesselman         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CertifiedPublic Accountants (Isr.)        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Amember of PricewaterhouseCoopers International Limited        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Tel-Aviv,Israel       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        March8, 2021       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave served as the Company’s auditor since 2010.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 3 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           3           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <a name="v_002">       </a>       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CONSOLIDATEDBALANCE SHEETS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (U.S.dollars in thousands)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="font-weight: bold; text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold">          ASSETS         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left">          CURRENT ASSETS:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; width: 68%; text-align: left">          Cash and cash equivalents         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          12,645         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          5,514         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Accounts receivable:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Trade, net         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          476         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          823         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt">          Other         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          146         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          150         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Prepaid expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          334         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          87         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt">          Inventory         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,415         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,236         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; padding-bottom: 1.5pt">          Receivable for sale of Shares         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          323         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          TOTAL CURRENT ASSETS         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          15,339         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          7,810         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left">          NON-CURRENT ASSETS:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Property, plant and equipment, net         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          448         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          547         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Operating lease right of use assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,265         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          937         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Fund in respect of employee rights upon retirement         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          725         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          586         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          TOTAL NON-CURRENT ASSETS         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          2,438         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          2,070         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">          TOTAL ASSETS         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          17,777         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          9,880         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="margin: 0">      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          <b>          </b>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center">          <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">           <b>            December 31,           </b>          </p>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          <b>          </b>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: center">          <p style="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">           <b>            2020           </b>          </p>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: center">          <p style="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">           <b>            2019           </b>          </p>         </td>         <td style="padding-bottom: 1.5pt; text-align: center">          <b>          </b>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: center">          LIABILITIES AND EQUITY         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          CURRENT LIABILITIES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Accounts payable and accruals:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; width: 68%">          Trade         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          236         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          646         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt; padding-left: 20pt">          Other         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          3,469         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          2,469         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          TOTAL CURRENT LIABILITIES         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          3,705         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          3,115         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          LONG-TERM LIABILITIES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Operating lease liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          999         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          653         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Liability for employee rights upon retirement         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          910         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          729         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          TOTAL LONG-TERM LIABILITIES         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1,909         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1,382         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          COMMITMENTS AND CONTINGENT LIABILITIES (Note 6)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          TOTAL LIABILITIES         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,614         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          4,497         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold">          EQUITY:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2020 and 2019; 49,264,830 and 3,916,134 shares issued and outstanding at December 31, 2020 and 2019, respectively         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt">          Preferred B shares, par value $0.0001 per share;          <br/>          500,000 shares authorized at December 31, 2020 and 2019; 17,303 shares issued and outstanding at December 31, 2020 and 2019, respectively         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Preferred C shares, par value $0.0001 per share;          <br/>          1,172,000 shares authorized at December 31, 2020 and 2019; 2,343 and 34,370 shares issued and outstanding at December 31, 2020 and 2019, respectively         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Additional paid-in capital         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          180,334         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          163,015         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Accumulated deficit         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (168,176         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (157,632         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Total equity         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          12,163         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,383         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">          Total liabilities and equity         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          17,777         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          9,880         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Theaccompanying notes are an integral part of the consolidated financial statements.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 4 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           4           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <a name="v_003">       </a>       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CONSOLIDATEDSTATEMENTS OF OPERATIONS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (U.S.dollars in thousands, except per share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year Ended December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; font-weight: bold; text-align: left">          REVENUES (2020 - net of settlement payment of $580, see note 6)         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          2,485         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          3,721         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; padding-bottom: 1.5pt">          COST OF REVENUES         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          2,402         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          2,965         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          GROSS PROFIT         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          83         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          756         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left">          OPERATING EXPENSES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Research and development         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,233         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,954         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Selling and marketing         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,103         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,396         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          General and administrative         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          6,127         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,222         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Total operating expenses         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          10,463         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          10,572         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          LOSS FROM OPERATIONS         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (10,380         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (9,816         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          FINANCIAL EXPENSES         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (160         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (200         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          LOSS BEFORE TAX EXPENSES         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (10,540         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (10,016         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          TAX EXPENSES         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          4         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          24         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          NET LOSS         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (10,544         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (10,040         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">          NET LOSS PER SHARE - basic and diluted         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (0.46         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (4.80         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">          WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          22,686,590         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,089,964         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Theaccompanying notes are an integral part of the consolidated financial statements.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 5 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           5           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <a name="v_005">       </a>       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CONSOLIDATEDSTATEMENTS OF CHANGES IN EQUITY        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (U.S.dollars in thousands, except share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Common stock         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Series B            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Convertible            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Preferred Stock            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Series C            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Convertible            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Preferred Stock            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          Additional paid-in         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          Accumulated         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          Total         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Amount         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Amount         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Amount         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          capital         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          deficit         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          equity         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 28%; font-weight: bold">          BALANCE as of December 31, 2018         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          768,615         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 4%; text-align: right">          *         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          17,303         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 4%; text-align: right">          *         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          61,423         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 4%; text-align: right">          *         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          $         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          156,355         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          $         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          (147,592         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          )         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          $         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          8,763         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Net loss         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          (10,040         </td>         <td style="font-weight: bold; text-align: left">          )         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          (10,040         </td>         <td style="font-weight: bold; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of $1,177 issuance costs         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          3,039,161         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          6,335         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          6,335         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Conversion of Series C Convertible Preferred Stock to common shares         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          38,614         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          (27,053         </td>         <td style="font-weight: bold; text-align: left">          )         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">          Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of 838 shares         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          69,744         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          325         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          325         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; padding-bottom: 2.5pt">          BALANCE as of December 31, 2019         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          3,916,134         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          17,303         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          34,370         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          163,015         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          (157,632         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">          )         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          5,383         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         *        </b>        Represents an amount less than $1       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 6 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           6           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CONSOLIDATEDSTATEMENTS OF CHANGES IN EQUITY        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (U.S.dollars in thousands, except share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Common stock         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Series B          <br/>          Convertible          <br/>          Preferred Stock         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Series C          <br/>          Convertible          <br/>          Preferred Stock         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          Additional paid-in         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          Accumulated         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">          Total         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Amount         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Amount         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Amount         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          capital         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          deficit         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          equity         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 28%; font-weight: bold">          BALANCE as of December 31, 2019         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          3,916,134         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          17,303         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          34,370         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          $         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          163,015         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          $         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          (157,632         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          )         </td>         <td style="width: 2%; font-weight: bold">         </td>         <td style="width: 1%; font-weight: bold; text-align: left">          $         </td>         <td style="width: 4%; font-weight: bold; text-align: right">          5,383         </td>         <td style="width: 1%; font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Net loss         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          (10,544         </td>         <td style="font-weight: bold; text-align: left">          )         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          (10,544         </td>         <td style="font-weight: bold; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold">          Exercise of pre-funded warrants         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          14,856,400         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          16         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          18         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Settlement of restricted stock units in shares of common stock         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          165,000         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Issuance of common shares, including at the market offering net of $1,110 issuance costs         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          24,108,771         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          3         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          15,197         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          15,200         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold">          Exercise of Warrants F         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          2,866,600         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          1,418         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          1,418         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; font-weight: bold">          Exercise of Unit Purchase Option         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          253,587         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          82         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          82         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; font-weight: bold; text-align: left">          Conversion of Series C Convertible Preferred Stock to common shares         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          372,173         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          (32,027         </td>         <td style="font-weight: bold; text-align: left">          )         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 55,755 shares         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          2,726,165         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          606         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">          606         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; padding-bottom: 2.5pt">          BALANCE as of December 31, 2020         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          49,264,830         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          5         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          17,303         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          2,343         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            *           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          180,334         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          (168,176         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">          )         </td>         <td style="font-weight: bold; padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">          12,163         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         *        </b>        Represents an amount less than $1       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 7 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           7           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <a name="v_006">       </a>       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CONSOLIDATEDSTATEMENTS OF CASH FLOWS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (U.S.dollars in thousands)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          CASH FLOWS FROM OPERATING ACTIVITIES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; width: 68%; text-align: left">          Net loss         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          (10,544         </td>         <td style="width: 1%; text-align: left">          )         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          (10,040         </td>         <td style="width: 1%; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Adjustments required to reconcile net loss to net cash used in operating activities:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Depreciation and amortization         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          151         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          158         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Loss from sale of property, plant and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          14         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Change in liability for employees rights upon retirement         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          181         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          124         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Non cash financial expense (income)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (4         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Net change in operating lease assets and liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          56         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          78         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Share-based compensation expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          606         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          325         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Gains on amounts funded in respect of employee rights upon retirement, net         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (18         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (35         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Changes in operating asset and liability items:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 30pt; text-align: left">          Increase in prepaid expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (247         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (6         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 30pt; text-align: left">          Decrease (increase) in trade receivables         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          347         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (107         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 30pt; text-align: left">          Decrease (increase) in other receivables         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (46         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 30pt; text-align: left">          Increase in inventory         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (179         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (102         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 30pt; text-align: left">          Decrease in trade payables         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (410         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (283         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">          Increase in other payables         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          962         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          116         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Net cash used in operating activities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (9,081         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (9,810         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          CASH FLOWS FROM INVESTING ACTIVITIES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Purchase of property, plant and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (88         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (284         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Proceeds from sale of property, plant and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          22         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Amounts withdrawn in respect of employee rights upon retirement, net         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (121         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (103         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Net cash used in investing activities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (187         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (387         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left">          CASH FLOWS FROM FINANCING ACTIVITIES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">          Proceeds from issuance of shares and warrants and exercise of Pre-Funded    Warrants and unit purchase option, net of $1,110 and $1,177 issuance costs, respectively         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          16,395         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          6,335         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Net cash provided by financing activities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          16,395         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          6,335         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          4         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (8         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left">          INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7,131         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (3,870         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">          BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,514         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          9,384         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">          BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          12,645         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          5,514         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-weight: bold; text-align: left">          SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Acquisition of right-of-use assets by means of lease liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          619         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          67         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt">          Receivable for Shares         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          323         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Theaccompanying notes are an integral part of the consolidated financial statements.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 8 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           8           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <a name="v_007">       </a>       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE1 - DESCRIPTION OF BUSINESS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            a.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            General           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           InspireMD,    Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing    on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of    complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection    in stenting procedures.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device    to treat carotid artery disease.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company’s coronary product combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) is marketed for use in    patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary    interventions (bypass surgery).          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company markets its products through distributors in international markets, mainly in Europe.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           As    of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations    for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations    until its products (primarily CGuard™ EPS) reach commercial profitability. Therefore, in order to fund the Company’s    operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            b.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            COVID-19    Pandemic           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During                                         the year ended December 31, 2020, in an effort to contain and mitigate the spread of                                         COVID-19, many countries have imposed unprecedented restrictions on travel, quarantines                                         and other public health safety measures. As of the beginning of the second quarter of                                         2020, we began to experience a significant COVID-19 related impact on our financial condition                                         and results of operations, which we primarily attribute to the postponement of CGuard                                         EPS procedures (non-emergency procedures), as hospitals shifted resources to patients                                         affected by COVID-19. To the best of our knowledge, most European countries in which                                         we operate are reinstating elective procedures, but we do not know when the hospitals                                         will resume to normal pre-pandemic levels with such procedures in light of recent increases                                         in COVID-19 cases in the territories we sell into. We anticipate that the continuation                                         of the pandemic and related restrictions and safety measures would likely result in a                                         continued fluctuations in sales of our products for the upcoming periods.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>            </b>           </font>          </p>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 9 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           9           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE2 - SIGNIFICANT ACCOUNTING POLICIES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            a.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Use    of estimates           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that    affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial    statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those    estimates.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           As    applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory    valuations, assessing the likelihood of exercise of options to extend the lease term and legal contingencies.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            b.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Functional    currency           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is    the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries    is the U.S. dollar.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their    original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for    non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income    or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange    rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary    items are based on historical exchange rates.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            c.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Principles    of consolidation           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and    balances have been eliminated upon consolidation.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            d.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Cash    and cash equivalents           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit),    that are not restricted as to withdrawal or use, to be cash equivalents.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 10 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           10           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE2 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            e.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Concentration    of credit risk and allowance for doubtful accounts           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Financial    instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents,    which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable.    The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company    performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers.    The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful    accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance    for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection    experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial    obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management    reasonably believes will be collected, which is netted against “Accounts receivable - Trade”.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            f.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Inventory           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <p style="margin-top: 0; margin-bottom: 0">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.           </font>          </p>          <p style="margin-top: 0; margin-bottom: 0">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           The fair value of the Company’s financial instrumentsapproximates their carrying values.”          </p>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            g.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Leases           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           In    February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees    to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes    a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases    will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition    in the statement of operations. We adopted the new standard on January 1, 2019 using the modified retrospective transition    method and we did not restate comparative periods. The new standard provides a number of optional practical expedients in    transition. We have elected the ‘package of practical expedients’, which permit it not to reassess under the new    standard its prior conclusions about lease identification, lease classification and initial direct costs for leases entered    into prior to adoption of Topic 842.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Additionally,    the Company did not separate lease and non-lease components for all of our leases. The Company elected the short-term lease    recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize    ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term    leases of those assets in transition. Instead, we will continue to recognize the lease payments for those leases in profit    or loss on a straight-line basis over the lease term.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate    to (1) the recognition of new operating lease ROU assets and operating lease liabilities on its balance sheet for real estate    operating leases; and (2) providing significant new disclosures about its leasing activities.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Upon    adoption, we recognized additional operating lease liabilities, of approximately $1.2 million based on the present value of    the remaining lease payments under current leasing standards for existing operating leases. The Company also recognized    corresponding ROU assets of approximately $1.2 million. Lease terms may include options to extend or terminate the lease when    the Company is reasonably certain that the extension option will be exercised or termination option will not be exercised.    For Operating Lease expense is recognized on a straight-line basis over the lease term. Our leases may include variable    payments based on measures that include changes in price index which are expensed as incurred   and presented as    operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed    lease payments.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    new standard also provides practical expedients for an entity’s ongoing accounting. See Note 5.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            h.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Property,    plant and equipment           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Property,    plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using    the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic    equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years).    Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated    life of the improvements.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            i.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Impairment    in value of long-lived assets           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication    of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets    is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to    their estimated fair values, based on expected future discounted cash flows.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 11 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           11           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE2 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            j.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Revenue    recognition           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           A    contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their    respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to    be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or    services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the    consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.    Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance    Obligations upon transfer of control to the customer, excluding sales taxes.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Revenue    from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once    the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are    obtained by the customer. This occurs when products are shipped.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets    that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses.    Disaggregated revenue is disclosed in Note 10.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company recognizes revenue net of value added tax (VAT).          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            k.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Research    and development costs           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Research    and development costs are charged to the statement of operations as incurred.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            l.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Share-based    compensation           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock    and restricted stock units (“RSUs”). Employee equity awards are classified as equity awards and accounted for    using the grant-date fair value method. The Company determines compensation expense associated with Restricted Stock and RSUs    based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes    valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules    using the accelerated multiple option approach.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            m.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Uncertain    tax positions           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the    tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not    that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not    of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that    is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the    liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include    interest related to unrecognized tax benefits within “Financial expenses - net”.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            n.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Deferred    income taxes           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Deferred    taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences    between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated    to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred    income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred    income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered    to be realizable.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such    additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements    as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing    dividends only in connection with a specific tax opportunity that may arise.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Taxes    that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing    the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 12 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           12           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE2 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            o.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Advertising           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Costs    related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses    were approximately $163,000 and $262,000 for the years ended December 31, 2020 and 2019, respectively.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            p.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Net    loss per share           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Basic                                         and diluted net loss per share is computed by dividing the net loss for the period attributable                                         to common stock by the weighted average number of shares of common stock outstanding                                         during the period, including 922,720 and 151,884 weighted average shares of common stock                                         issuable to holders of Series B Convertible Preferred Stock for the years                                         ended December 31, 2020 and 2019, respectively, (since they are convertible based on                                         passage of time) and 72,493 weighted average shares of common stock issuable to holders                                         of unexercised Pre-Funded Warrants for the year ended December 31, 2019.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The        total number of shares of common stock related to outstanding options, warrants, restricted stock, restricted stock units,        Series C Convertible Preferred Stock and placement agent units excluded from the calculations of diluted loss per share        were 32,493,268 and 4,707,230 for the years ended December 31, 2020 and 2019, respectively.           </font>          </p>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            q.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Segment    reporting           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company has one operating and reportable segment.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            r.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Fair    value measurement           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based    on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market    participants at the measurement date.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure    fair value into three broad levels, which are described below:          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Level    1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The    fair value hierarchy gives the highest priority to Level 1 inputs.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Level    2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Level    3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority    to Level 3 inputs.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           In    determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize    the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 13 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           13           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE2 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            s.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Issued    accounting pronouncements effective in future periods           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Financial    Instruments - Credit Losses          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           In    June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial    Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition    and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit    losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions    and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit    Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”).    The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger    public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies    (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will    have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.    All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal    periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and    is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through    a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently    evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not believe the adoption    of this standard will have a material impact on its consolidated financial statements.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 14 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           14           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE3 - PROPERTY, PLANT AND EQUIPMENT        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -19.85pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            a.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Composition    of assets, grouped by major classifications, is as follows:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold">         </td>         <td colspan="6" style="font-weight: bold; text-align: center">          ($ in thousands)         </td>         <td style="font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Cost:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; width: 60%; text-align: left">          Computer equipment         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          289         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          287         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Office furniture and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          95         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          95         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Machinery and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,427         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,414         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Leasehold improvements         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          211         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          206         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,022         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,002         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Less - accumulated depreciation and amortization         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,574         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,455         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Net carrying amount         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          448         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          547         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            b.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Depreciation    and amortization expenses totaled approximately $151,000 and $158,000 for the years ended December 31, 2020 and 2019, respectively.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE4 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Israelilabor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certainother circumstances.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto section 14 of the Israeli Severance Compensation Act, 1963, some of the Company’s employees are entitled to have monthlydeposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance withsection 14 relieve the Company from any future severance payments to these employees.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theseverance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability,is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurancepolicies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously depositedfor savings in connection with the payment of severance. The severance pay expenses were approximately $276,000 and $197,000for the years ended December 31, 2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Definedcontribution plan expenses were approximately $339,000 and $294,000 for the years ended December 31, 2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany expects contribution plan expenses in 2021 to be approximately $346,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 15 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           15           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE5 – LEASE AGREEMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 96px; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company’s Israeli subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with    an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement.    The company exercised the Option Period as estimated. In addition, the Company amended the agreement mentioned above which    include a new option period for two additional years until December 31, 2024 under the terms stipulated in the agreement,    the Option Period was taken in consideration when calculating the operating lease right of use assets and liabilities.    In addition, the Company entered into another amendment to the lease agreement for a lease of additional space in the facility,    the additional space amendment was taken in consideration when calculating the operating lease right of use assets and    liabilities.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Company leases its motor vehicles under operating lease agreements.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Operating    lease cost for the year ended December 31, 2020 was comprised of the following:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Twelve months ended            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             December 31            </b>           </font>          </p>         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Twelve months ended            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             December 31            </b>           </font>          </p>         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: justify">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: justify">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($ in            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             thousands)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($ in            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             thousands)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: justify">          Operating lease expense         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          370         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          358         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify; padding-bottom: 1.5pt">          Short-term lease expense         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          8         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           370          </p>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          366         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementalinformation related to leases are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold">         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          December 31         </td>         <td style="font-weight: bold">         </td>         <td style="font-weight: bold">         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          December 31         </td>         <td style="font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($ in            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             thousands)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ($ in            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             thousands)            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">          Operating lease right-of-use assets         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          1,265         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          937         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Current Operating lease liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (400         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (362         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Non-current operating lease liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (999         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (653         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Otherinformation:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-indent: 35.4pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in">       <tbody>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">          Operating cash flows from operating leases (cash paid in thousands)         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          (387         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">          (366         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Weighted Average Remaining Lease Term         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1.73         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1.33         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Weighted Average Discount Rate         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          8.38         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          %         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          9.07         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Maturitiesof lease liabilities are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-indent: 35.4pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="margin-left: 1.25in; border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: left">         </td>         <td style="font-weight: bold">         </td>         <td colspan="2" style="font-weight: bold; text-align: center">          Amount         </td>         <td style="font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: left">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 76%; text-align: left">          2021         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 20%; text-align: right">          421         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          2022         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          389         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          2023         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          400         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          2024         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          419         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Total lease payments         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,629         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Less imputed interest         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (230         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Total         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,399         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 16 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           16           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE6 - COMMITMENTS AND CONTINGENT LIABILITIES        </b>        :       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Litigation:           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1.1pt">       In July 2016,a service provider filed a suit seeking damages from the Company’s subsidiary amounting to $1,967,822. The Company’ssubsidiary and the plaintiff have entered into a confidential settlement agreement in the amount of $600,000, and on April 24,2019, the parties filed a stipulation of dismissal, dismissing all claims in this action. On April 25, 2019, the court denied asmoot all pending motions. The related increase in provision of $354,000 was recorded to “Research and development expense”within the Consolidated Statements of Operations for the year months ended December 31, 2019.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1.1pt">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1.1pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJuly 2019, a former distributor filed a suit seeking damages from the Company’s subsidiary for pre-paid goods subject tothe voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively€1,024,000 (which is approximately $1.1 million). In January 2021, we executed a Mediation Agreement with the formerdistributor, pursuant to which the former distributor agreed to release the Company from all claims stated in the Complaint inexchange for a payment of $580,000. Accordingly, the amount of $580,000 was recorded as a debit to revenue.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 28, 2020, we entered into a settlement agreement and release with the prior underwriter, under which it provided us a final,unconditional release from any further obligations arising out of or related to the engagement agreements, underwriting agreementsand placement agency agreements which we had been party to with it and with respect to any services which it had provided to us.We, in turn, provided the prior underwriter a final, unconditional release from any further obligations arising out of or relatedto the prior agreements and services.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asconsideration for the final release provided to us, we paid to the prior underwriter $400,000 in cash and reduced, to $0.495,the exercise price per share of warrants to purchase 274,029 shares of our common stock that had been issued by us to the priorunderwriter in various offerings that took place between March 2018 and September 2019. That reduced exercise price representsthe exercise price for the Series F Warrants that we issued in our June 2020 public offering. The warrants that were repricedhad existing exercise prices per share ranging from $187.50 to $2.25 and a weighted average exercise price per share of $7.32.All other terms of those warrants will remain unchanged. The related increase in expenses of $400,000 was recorded to “Generaland Administrative expense” within the Consolidated Statements of Operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJuly 2020, a former senior employee of InspireMD GmbH filed a statement of claim at the Munich Labor Court, seeking confirmationof the court that the notice of termination is not effective. On November 10, 2020, we entered into a settlement agreement. Asconsideration for the final release, we paid the former senior employee 25,000 Eur (approximately $30,000) which was recordedto “Selling and marketing expense” within the Consolidated Statements of Operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE7 - EQUITY        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            a.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Share    capital           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany’s common stock are listed on the NYSE American.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 27, 2019, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amendedand Restated Certificate of Incorporation to effect a one-for-fifty reverse stock split of its common stock, par value $0.0001per share, effective as of March 29, 2019, which decreased the number of issued and outstanding shares of common stock and restrictedstock as of December 31, 2018 from   38.4 million shares to 769 thousand shares.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Allrelated share and per share data have been retroactively applied to the financial statements and their related notes for all periodspresented.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 17 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           17           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE7 – EQUITY        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         PublicOffering        </i>        s       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnApril 8, 2019, the Company closed an underwritten public offering of 486,957 shares of the Company’s common stock at theoffering price to the public of $5.00 per share. The Company received net proceeds of approximately $2 million from the offering,after deducting underwriter discounts and commissions and other fees and expenses payable by the Company. In connection with thispublic offering, on April 12, 2019, the underwriter partially exercised its over-allotment option and purchased an additional12,393 shares of our common stock at a price to the public of $5.00 per share. The Company received net proceeds of approximately$47,000 from the exercise of the over-allotment option.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inconnection with the offering, the Company issued to the underwriter warrants to purchase up to 34,955 shares of common stock,or 7% of the shares sold in the offering, including the shares issued pursuant to the over-allotment option (the “April2019 Underwriter Warrants”). The April 2019 Underwriter Warrants are exercisable at any time and from time to time, in wholeor in part, following the date of issuance and ending on April 4, 2024, at an exercise price of $6.25 per share (125% of the offeringprice to the public per share).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Uponexecution of the underwriting agreement, the respective conversion price of the outstanding shares of Series B Convertible PreferredStock and Series C Convertible Preferred Stock was reduced to $5.00 pursuant to the anti-dilution adjustment provisions of theSeries B Convertible Preferred Stock and of the Series C Convertible Preferred Stock, and the number of shares of common stockissuable upon conversion of the Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock had increasedas follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 96px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    aggregate of 133,233 additional shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock,    including the payment of the cumulative dividends accrued thereunder in common stock, based on 17,303 shares of Series B Convertible    Preferred Stock outstanding as of April 4, 2019.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    aggregate of 50,708 additional shares of common stock issuable upon conversion of the Series C Convertible Preferred Stock,    based on 59,423 shares of Series C Convertible Preferred Stock outstanding as of April 4, 2019.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         September 19, 2019, the Company entered into an underwriting agreement relating to an                                         underwritten public offering (the “September 2019 Offering”) of (i) 539,000                                         common units (“2019 Common Units”), with each 2019 Common Unit being comprised                                         of one share of the Company’s common stock and one Series E warrant (collectively,                                         the “Series E Warrants”) to purchase one share of common stock and (ii) 2,238,777                                         pre-funded units (“2019 Pre-Funded Units”), with each 2019 Pre-Funded Unit                                         being comprised of one pre-funded warrant (collectively, the “2019 Pre-Funded Warrants”)                                         to purchase one share of common stock and one Series E Warrant, which closed on September                                         24, 2019. The offering price to the public was $1.80 per 2019 Common Unit and $1.79 per                                         2019 Pre-Funded Unit. In connection with this public offering, on September 24, 2019,                                         the underwriter partially exercised its over-allotment option and purchased an additional                                         Series E Warrants to purchase 194,444 shares of common stock at a purchase price of $0.01                                         per Series E Warrant.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The        Series E Warrants included in the 2019 Common Units and the 2019 Pre-Funded Units are immediately exercisable at a price        of $1.80 per share of common stock, subject to adjustment in certain circumstances, and expire five years from the date        of issuance.           </font>          </p>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Each                                         2019 Pre-Funded Warrant contained in a 2019 Pre-Funded Unit is exercisable for one share                                         of our common stock at an exercise price of $0.01 per share. The 2019 Pre-Funded Warrants                                         are immediately exercisable and may be exercised at any time until all of the 2019 Pre-Funded                                         Warrants are exercised in full.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.9pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In        connection with the offering, the Company issued to the underwriter warrants to purchase up to 194,444 shares of common        stock, or 7% of the shares sold in the offering, including the number of shares of common stock issuable upon exercise        of the 2019 Pre-Funded Warrants sold in the offering (the “September 2019 Underwriter Warrants”). The September        2019 Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, following the date of        issuance and ending on September 19, 2024, at an exercise price of $2.25 per share (125% of the offering price to the        public per 2019 Common Unit).           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.9pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pursuant        to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s        Series B Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the        Series B Convertible Preferred Stock and the Series C Preferred Stock was reduced to $1.80 per share, effective as of        the date of the underwriting agreement entered for the September 2019 Offering, and the number of shares of common stock        issuable upon conversion of the Series B Preferred Stock and the Series C Preferred Stock had increased as follows:           </font>          </p>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 96px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    aggregate of 355,288 additional shares of common stock upon conversion of the Series B Preferred Stock and as payment of the    dividends thereunder in common stock, based on 17,303 shares of Series B Preferred Stock outstanding as of September 19, 2019.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    aggregate of 84,253 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 37,025 shares    of Series C Preferred Stock outstanding as of September 19, 2019.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 18 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           18           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE7 – EQUITY        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The                                         Company received gross proceeds of $5.0 million from the offering, before deducting underwriter                                         discounts and commissions and other fees and expenses payable by the Company.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On        June 5, 2020, the Company closed an underwritten public offering of (i) 7,635,800 units (“Units”), with each        Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share, and one Series F warrant        (a “Series F Warrant”) to purchase one share of common stock, and (ii) 14,586,400 pre-funded units (the “Pre-Funded        Units”), with each Pre-Funded Unit being comprised of one pre-funded warrant (a “Pre-Funded Warrant”)        to purchase one share of common stock and one Series F Warrant. In connection with this public offering, the underwriter        exercised its over-allotment option in full and purchased an additional 3,333,300 shares of common stock and 3,333,300        Series F Warrants. The offering price to the public was $0.45 per Unit and $0.449 per Pre-Funded Unit. The net proceeds        to the Company from the offering and the exercise of the underwriter’s over-allotment option were approximately        $10.7 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated        with the offering, but excluding the proceeds, if any, from the exercise of Series F Warrants and the Pre-Funded Warrants        sold in the offering. The pre-funded warrants exercisable at a price of $0.001 per share of common stock.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The        Series F Warrants included in the Common Units and the Pre-Funded Units are immediately exercisable at a price of $0.495        per share of common stock, subject to adjustment in certain circumstances, and expire June 2, 2025. The shares of common        stock, or Pre-Funded Warrants in the case of the Pre-Funded Units, and the Series F Warrants were offered together, but        the securities contained in the Common Units and the Pre-Funded Units were issued separately.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During        the year ended December 31, 2020, 2,866,600 Series F Warrants were converted into 2,866,600 shares of common stock. The        net proceeds to the Company from exercise of the Series F Warrants were approximately $1.4 million.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pursuantto the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s SeriesB Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B ConvertiblePreferred Stock and the Series C Preferred Stock was reduced to $0.45 per share, effective as of the date of the underwritingagreement entered for the June 2020 Offering, and the number of shares of common stock issuable upon conversion of the SeriesB Preferred Stock and the Series C Preferred Stock had increased as follows:           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●        An aggregate of 1,665,414 additional shares of common stock upon conversion of the Series B Preferred Stock and as payment        of the dividends thereunder in common stock, based on 17,303 shares of Series B Preferred Stock outstanding as of June        2, 2020.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●        An aggregate of 283,285 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 26,558        shares of Series C Preferred Stock outstanding as of June 2, 2020.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            for        the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise        of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined        by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. The Company        has also concluded that the series F warrants are classified as equity, since the warrants meet all criteria for equity        classification.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During        the year ended December 31, 2020, the Company issued a total of 14,586,400 shares of common stock in connection with the        exercise of all outstanding Pre-Funded Warrants issued in June 2020. In addition, the Company issued a total of 270,000        shares of its common stock in connection with the exercise of 270,000 Pre-Funded Warrants issued in September 2019. As        of December 31, 2020, there are no outstanding Pre-Funded Warrants.           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During        the year ended December 31, 2019, the Company issued a total of 2,000,811 shares of its common stock in connection with        the exercise of an aggregate of 2,000,811 Pre-Funded Warrants and 2019 Pre-Funded Warrants. The Company received aggregate        cash proceeds equal to approximately $35,705 in connection with such exercises.           </font>          </p>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 19 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           19           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ATMOffering        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe year ended December 31, 2020, the Company sold 12,917,448 shares of its common stock pursuant to its at-the-market (ATM) issuancesales agreement with A.G.P./Alliance Global Partners. These sales resulted in net proceeds to the Company of approximately $4,447thousand.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s SeriesB Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B ConvertiblePreferred Stock and the Series C Preferred Stock was reduced to $0.321 per share, triggered by the ATM Facility, effective asof December 14, 2020 , and the number of shares of common stock issuable upon conversion of the Series B Preferred Stock and theSeries C Preferred Stock had increased as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 96px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    aggregate of 892,371 additional shares of common stock upon conversion of the Series B Preferred Stock and as payment of the    dividends thereunder in common stock, based on 17,303 shares of Series B Preferred Stock outstanding as of December 14, 2020.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           an    aggregate of 13,392 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 2,343 shares    of Series C Preferred Stock outstanding as of December 14, 2020.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, the Number of Preferred shares the amount each class is convertible into is below:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1in">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Number    of Preferred Stock          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Number    of underlying Common stock          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Series    B Convertible Preferred Stock*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           17,303          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3,112,923          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           **          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Series    C Convertible Preferred Stock          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2,343          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           46,714          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ***          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Total          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3,159,637          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        *See “Note 11 - Subsequent events” regarding conversion of all remaining Series B Convertible Preferred Stock intocommon stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        **On July 7, 2016, we issued 442,424 shares of Series B Preferred Stock in a public offering. Our Series B Preferred Stock has astated value of $33.00 which currently converted into 3,112,923 reflecting a conversion price equal to $ 0.321. The holders ofSeries B Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the statedvalue for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversionprice adjustment, if any.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ***On March 14, 2017, we issued 1,069,822 shares of Series C Preferred Stock in a public offering. Our Series C Preferred Stock hasa stated value of $6.40 which currently converted into 46,714 reflecting a conversion price equal to $ 0.321.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, the Company has outstanding warrants to purchase an aggregate of 26,705,502 shares of common stock as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 12pt Times New Roman, Times, Serif; margin-left: 1.25in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">          Number of          <br/>          underlying          <br/>          Common stock         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt">         </td>         <td style="font-size: 10pt; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">          Weighted          <br/>          average          <br/>          exercise price         </td>         <td style="padding-bottom: 1.5pt; font-size: 10pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; font-size: 10pt; text-align: justify">          Series A Warrants         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          1,107         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>         <td style="width: 2%; font-size: 10pt">         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">          $         </td>         <td style="width: 16%; font-size: 10pt; text-align: right">          8,750.00         </td>         <td style="width: 1%; font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: justify">          Series B Warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          2,448         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          3,500.00         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify">          Series D Warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          766,698         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          15.00         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: justify">          Series E Warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          2,972,221         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          1.80         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify">          Series F Warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          22,688,900         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          0.50         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="font-size: 10pt; text-align: justify">          Underwriter Warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          274,029         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          0.50         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify">          Other warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          99         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          21,993.00         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="font-size: 10pt; text-align: justify">          Total Warrants         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt; text-align: right">          26,705,502         </td>         <td style="font-size: 10pt; text-align: left">         </td>         <td style="font-size: 10pt">         </td>         <td style="font-size: 10pt; text-align: left">          $         </td>         <td style="font-size: 10pt; text-align: right">          1.82         </td>         <td style="font-size: 10pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, the Company has 155,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 150,000,000are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe event of our liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock and Series C ConvertiblePreferred Stock are entitled to receive the amount of cash, securities or other property to which such holder would be entitledto receive with respect to such shares of Preferred Stock if such shares had been converted to common stock immediately priorto such event.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 20 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           20           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE7 – EQUITY        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            b.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Share-Based    Compensation           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Pursuant    to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options may be granted    through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). As a result of an    election made by the Company under Section 102 of the Income Tax Ordinance, the Company will not be allowed to claim as an    expense for tax purposes in Israel the amounts credited to the employee as capital gains to the grantees, although it will    generally be entitled to do so in respect of the salary income component (if any) of such awards when the related tax is paid    by the employee.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           During    the year ended December 31, 2020, the Company granted stock options to the CEO, employees and directors to purchase a total    of 1,379,856 shares of the Company’s common stock. The options have exercise prices ranging from $0.33-$1.10 per share,    respectively, which were the fair market value of the company’s common stock on the date of each respective grant. As    of December 31, 2020, the fair value of the above options, using the Black-Scholes pricing models, was approximately $509,000.    The options are subject to a three-year vesting period with one-third of such awards vesting each year.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           During    the years ended December 31, 2020 and 2019, the Company granted to the then CEO, employees and directors 2,781,920 and 70,582    restricted stock, respectively. The fair value of these restricted stock was approximately $1,051,604 and $668,000, respectively.    The restricted stock are subject to a three-year vesting period, with one-third of such awards vesting each year.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           During    the years ended December 31, 2020 and 2019, the Company granted CEO and former CEO 1,357,668 and 165,000 Restricted Stock    Units, respectively. The fair value of these restricted stock units was approximately $658,981 and $141,900, respectively.    The restricted stock units granted during the years ended December 31, 2020 are subject to a three-year vesting period, with    one-third of such awards vesting each year. The restricted stock units granted during the year ended December 31, 2019 were    fully vested upon grant.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 96px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           5)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table summarizes information about stock options granted to employees:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of options         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Weighted            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             average            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             exercise price            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of options         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Weighted            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             average            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             exercise price            </b>           </font>          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 40%">          Outstanding - beginning of period         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 11%; text-align: right">          160         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 11%; text-align: right">          189,161.99         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 11%; text-align: right">          164         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 11%; text-align: right">          184,656         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Granted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,379,856         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.41         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           -          </p>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Forfeited         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (4,751         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          343.51         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (4         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,423         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">          Outstanding -end of period         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,375,265         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          21.24         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          160         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          189,162         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Exercisable at the end of the period         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          115         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          249,006         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          160         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          189,162         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 21 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           21           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE7 – EQUITY        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           6)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table summarizes information about stock options granted to non-employees:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of options         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Weighted average exercise price         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of options         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Weighted average exercise price         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 40%">          Outstanding - beginning of period         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 11%; text-align: right">          16         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 11%; text-align: right">          1,711,975         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 11%; text-align: right">          20         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 11%; text-align: right">          1,693,174         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Granted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Forfeited         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,156,208         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (4         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,617,338         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Exercised         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Outstanding - end of period         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          15         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,682,385         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          16         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,711,975         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Exercisable at the end of the period         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          15         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,682,385         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          16         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,711,975         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           7)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table summarizes information about restricted stock granted to employees:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of restricted stock         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Outstanding - beginning of period         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          69,631         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          19         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Reverse Split Adjustments         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           -          </p>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (127         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Granted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,781,920         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          70,582         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Forfeited         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (55,755         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (838         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Vested         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (9,915         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (5         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">          Outstanding - end of period         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,785,881         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          69,631         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           8)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table summarizes information about Restricted Stock Unit granted to employees:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Number of restricted stock         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Outstanding - beginning of period         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          165,000         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Granted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,357,668         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          165,000         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Forfeited         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           -          </p>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           -          </p>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Vested         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (165,000         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           -          </p>         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Outstanding - end of period         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,357,668         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          165,000         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           9)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table provides additional information about all options outstanding and exercisable:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Outstanding as of December 31, 2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Exercise            </b>           </font>          </p>          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             price            </b>           </font>          </p>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Options outstanding         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Weighted average remaining contractual life (years)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Options          <br/>          exercisable         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 52%; text-align: left">          $0.175         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          2         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          1.39         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          2         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          $0.33-0.39         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,314,356         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9.69         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          $1.10         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          60,794         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9.01         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           -          </p>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          $175 and above         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          128         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          4.71         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          128         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: right; padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,375,280         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          9.66         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          130         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theweighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2020 was 4.66 years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaggregate intrinsic value of the total exercisable options as of December 31, 2020 was approximately $1.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 22 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           22           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.65pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE7 – EQUITY        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theweighted average fair value of options granted was $0.37 for the year ended December 31, 2020. The weighted average fair valueof options granted was estimated using the Black-Scholes option-pricing model.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table sets forth the assumptions that were used in determining the fair value of options granted to employees for    the year December 31, 2020:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Expected life         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5.5-6.5 years         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Risk-free interest rates         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0.32%-0.42          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Volatility         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           124.53%-136.66          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 76%; text-align: left">          Dividend yield         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 20%; text-align: right">          0         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takesinto consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equalto the option’s contractual life).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theannual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as boththe exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historicaldata.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           11)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           As    of December 31, 2020, the total unrecognized compensation cost on employee and non-employee stock options and restricted stock,    related to unvested stock-based compensation, amounted to approximately $1.7 million. This cost is expected to be recognized    over a weighted-average period of approximately 0.95 years. This expected cost does not include the impact of any future stock-based    compensation awards.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           12)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations:          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="margin-left: 1in; border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Cost of revenues         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          22         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          14         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Research and development         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          29         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Sales and marketing         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          32         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          29         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          General and administrative         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          523         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          272         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          606         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          325         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 23 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           23           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE8 - TAXES ON INCOME:        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            a.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Tax    laws applicable to the Company and its subsidiaries           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Taxationin the United States        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InspireMD,Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2020 is 21%. State tax may also apply   .       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Taxationin Israel        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecorporate tax rate was 23% in 2020 and will be 23% thereafter.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Taxationin Germany        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InspireMDGmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% andtrade tax rate of 17.15%.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            b.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Tax    benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”):           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InspireMDLtd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof,which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profitsattributable to the specific program of investment to which the status was granted.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themain benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the abovelaw, is a two-year exemption and five to eight years of a reduced tax rate of 10% to 23% from tax on income derived from beneficiaryactivities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all taxoffsetting losses. The tax benefit period is twelve years from the year of election, which means that after a year of election,the two-year exemption and eight years of reduced tax rate can only be used within the next twelve years. The Company electedthe year 2011 as a year of election.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 24 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           24           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE8 - TAXES ON INCOME        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe event of a distribution of tax-exempt income attributable to “Beneficiary Enterprises” as a cash dividend, theCompany will be required to pay tax at a rate of 10% to 23% on the amount distributed, subject to certain conditions. In addition,dividends originating from income attributable to the “Beneficiary Enterprises” will be subject to a 20% withholdingtax.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ShouldInspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits,such income shall be taxable at the regular corporate tax rate.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Conditions    for entitlement to the benefits          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theentitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulationspublished thereunder and the instruments of approval for the specific investments in approved assets. In the event of failureto comply with these conditions, the benefits may be cancelled, and InspireMD Ltd. may be required to refund the amount of thebenefits, in whole or in part, with the addition of interest and linkage.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany opted not to apply for Preferred Enterprise status (as defined in the Amendment of the Law for the Encouragement of CapitalInvestments, 1959).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.24in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            c.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Carry    forward tax losses           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, the Company had a net carry forward tax loss of approximately $44 million, of which approximately $35 million(arising before January 1, 2018), expires until 2037, and approximately $9 million, which does not expire, but is limited to offset80% of the net income in the year it is utilized.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated intax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue tohave a two-year carryback and twenty-year carryforward period.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Furtherto COVID-19 CARES act of the U.S. Treasury, the business tax provision temporarily removes the current law taxable income 80%limitation to allow an NOL to fully offset income in tax years 2018, 2019 and 2020. The provision also allows an NOL fromtax years beginning in 2018, 2019, or 2020 to be carried back for five years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 31, 2020, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $98 million. UnderIsraeli tax laws, the carry forward tax losses can be utilized indefinitely.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 87.9pt; text-indent: -19.85pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.24in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            d.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Loss    before income taxes           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecomponents of loss before income taxes are as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table align="RIGHT" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="font-weight: bold">         </td>         <td colspan="6" style="font-weight: bold; text-align: center">          ($ in thousands)         </td>         <td style="font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Loss before taxes on income:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 60%; text-align: left">          InspireMD, Inc.         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          (3,897         </td>         <td style="width: 1%; text-align: left">          )         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          (3,687         </td>         <td style="width: 1%; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Subsidiaries         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (6,643         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (6,329         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (10,540         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (10,016         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 25 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           25           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE8 - TAXES ON INCOME        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            e.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Current    taxes on income           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themain reconciling items between the statutory tax rate of the Company and the effective tax rate are the change in subsidiary taxrates and the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of therealization of such tax benefits and changes in tax rates following the 2017 Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thechanges in the valuation allowance for the year ended December 31, 2020 and 2019 were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          Balance at the beginning of the year         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          31,181         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          27,640         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Changes during the year:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-left: 10pt">          Losses during the year (including foreign exchange rate effect)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,964         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,541         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Balance at the end of the year         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          35,145         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          31,181         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            f.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Accounting    for Uncertain Tax position           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Followingis a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2020and 2019 were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: right">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Balance at beginning of period         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          44         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          28         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Increase in uncertain tax positions because of tax positions taken during the year         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          16         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Balance at end of period         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          52         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          44         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asummary of open tax years by major jurisdiction is presented below:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom; background-color: White">         <td style="border-bottom: Black 1.5pt solid; width: 80%; font-weight: bold; text-align: center">          Jurisdiction         </td>         <td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; width: 18%; font-weight: bold; text-align: center">          Years         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          U.S.         </td>         <td>         </td>         <td style="text-align: right">          2017-2020         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Israel         </td>         <td>         </td>         <td style="text-align: right">          2015-2020         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Germany         </td>         <td>         </td>         <td style="text-align: right">          2017-2020         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          United Kingdom         </td>         <td>         </td>         <td style="text-align: right">          2014-2015         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 26 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           26           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE8 - TAXES ON INCOME        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            g.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Deferred    income tax:           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="6" style="text-align: right">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Long-term:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 60%; text-align: left">          Allowance for bonus         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          2         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          57         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Provision for vacation and recreation pay         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          63         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          35         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          R&amp;D expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          578         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          589         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Operating lease right of use assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (291         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (215         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Operating lease liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          322         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          233         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Share-based compensation         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,669         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,596         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Carry forward tax losses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          31,759         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          27,854         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Accrued severance pay, net         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          43         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          32         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          35,145         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          31,181         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Less-valuation allowance         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (35,145         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (31,181         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 51.05pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Balancesheets:        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 51.05pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Inventory:           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          Finished goods         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          350         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          173         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Work in process         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          376         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          81         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Raw materials and supplies         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          689         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          982         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,415         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,236         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 27 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           27           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INSPIREMD,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION        </b>        (continued):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 57px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 39px">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            a.           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Accounts    payable and accruals-other:           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          Employees and employee institutions         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          1,236         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          1,238         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Accrued vacation and recreation pay         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          278         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          188         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Accrued expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          886         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          604         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Accrual for settlement payment (see note 6)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           580          </p>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Current Operating lease liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          400         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          362         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Other         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          89         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          77         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3,469         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,469         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE10 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES        </b>        :       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Revenuesare attributed to geographic areas based on the location of the customers. The following is a summary of revenues:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          ($ in thousands)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Germany         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          708         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          727         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Italy         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          596         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          686         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Poland         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          219         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          370         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Other (2020 - net of settlement payment of $580, see note 6)         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          962         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1,938         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,485         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3,721         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Byproduct:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold">         </td>         <td colspan="6" style="font-weight: bold; text-align: center">          ($ in thousands)         </td>         <td style="font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          CGuard™ EPS         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          2,764         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          3,265         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          MGuard Prime™ EPS (2020 - net of settlement payment of $580, see note 6)         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (279         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          456         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,485         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3,721         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Byprincipal customers (2020 - before of settlement payment of $580 see note 6):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Year ended December 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          Customer A         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          21         </td>         <td style="width: 1%; text-align: left">          %         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          18         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Customer B         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          11         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Customer C         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Customer D         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10         </td>         <td style="text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Alltangible long lived assets are located in Israel.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTE11 - SUBSEQUENT EVENTS:        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">        Subsequent to December 31, 2020 the Company had several stock transactionsas follows (U.S. dollars in thousands, except share data):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Common Stock         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Gross amount         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          BALANCE as of December 31, 2020         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          49,264,830         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Issuance of shares to Chinese distributor         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,341,682         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          900         </td>         <td style="text-align: left">          (a)         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          ATM sales         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          12,277,844         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,659         </td>         <td style="text-align: left">          (b)         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt">          February 2021 public offering         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          33,387,096         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          20,700         </td>         <td style="text-align: left">          (c)         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Series F and Series G warrants exercise         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          18,381,177         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9,469         </td>         <td style="text-align: left">          (d)         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Conversion of Series B Convertible Preferred Stock to common shares         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,112,923         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           -          </font>         </td>         <td style="text-align: left">          (e)         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        a.On February 3, 2021, the Company entered into a Distribution Agreement with three China-based partners, pursuant to which theChinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’sproducts in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with theterm of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-basedpartners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failureto meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, and on the same day, the Company entered into an investment transaction with one of the Chinese parties to the DistributionAgreement, , which included (i) a Securities Purchase Agreement, or the SPA, pursuant to which investor agreed to invest $900,000in exchange for shares of the Company’s common stock at a purchase price of $0.6708 per share.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 28 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           28           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <p style="margin: 0pt">       </p>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       b. Subsequent to year-end, the Company sold an aggregate of 12,277,844shares of common stock for aggregate gross proceeds of $5,659,000 under the ATM Sales Agreement. In addition, in January 2021 wereceived $323,000 for shares of common stock sold on December 2020 and recorded to "Receivable for sale of Shares" incurrent assets of the Consolidated Balance Sheet as of December 31, 2020.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        c.On February 3, 2021, the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, relating to an underwrittenpublic offering (the “Offering”) of 29,032,258 units (“Units”), with each Unit being comprised of oneshare of the Company’s common stock, par value $0.0001 per share, and one Series G warrant to purchase one-half of one shareof Common Stock. The offering price to the public was $0.62 per Unit. The Series G Warrants are immediately exercisable at a priceof $0.682 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance. The Offeringclosed on February 8, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany granted the Underwriter a 45-day option to purchase up to an additional 4,354,838 Units consisting of 4,354,838 sharesof Common Stock and Series G Warrants to purchase 2,177,419 shares of common stock in the Offering, which the Underwriter exercisedin full on February 4, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany granted the Underwriter a compensation warrant to purchase up to 1,669,355 shares of Common Stock. The Underwriter Warrantshave an exercise price of $0.682 per share and are exercisable immediately and for five years from the date of effectiveness ofthe registration statement in connection with the Offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thenet proceeds to the Company from the Offering, after giving effect to the exercise of the Underwriter’s over-allotment option,were approximately $18.9 million, after deducting underwriting discounts and commissions and payment of other estimated expensesassociated with the Offering, but excluding the proceeds, if any, from the exercise of Series G Warrants sold in the Offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-size: 10pt">        d. Subsequentto year-end,       </font>       <font style="font-size: 11pt; background-color: white">        Series F and Series G       </font>       <font style="font-size: 10pt">        warrantsto purchase shares of common stock were exercised by investors at an exercise price of $0.495 and $0.682 per share, resulting inthe issuance of 18,381,177 shares of common stock for proceeds of approximately $9,469,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        e.On February 3, 2021, 17,303 shares of Series B Convertible Preferred Stock were converted into 3,112,923 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 29; Options: Last -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           29           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>     </text>    </filename>   </sequence>  </type> </document></body>